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Strengthening And stretching for Rheumatoid Arthritis of
the Hand (SARAH). A randomised controlled trial and
economic evaluation
Mark A Williams,1* Esther M Williamson,1 Peter J Heine,1
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4University College London, London, UK
5Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences,
University of Oxford, Oxford, UK
*Corresponding author Mark.williams@ndorms.ox.ac.uk
Background: The effectiveness of exercise for improving hand and wrist function in people with
rheumatoid arthritis (RA) is uncertain.
Objectives: The study aims were (1) to estimate the clinical effectiveness and cost-effectiveness of adding
an optimised exercise programme for hands and upper limbs to standard care for patients with RA; and
(2) to qualitatively describe the experience of participants in the trial with a particular emphasis on
acceptability of the intervention, exercise behaviours and reasons for adherence/non-adherence.
Design: A pragmatic, multicentred, individually randomised controlled trial with an embedded qualitative
study. Outcome assessors were blind to group assignment and independent of treatment delivery.
Setting: Seventeen NHS trusts in England comprising 21 rheumatology and therapy departments.
Participants: Adults with RA who had pain and dysfunction of the hands and/or wrists and had been on
stable medication for at least 3 months. Patients were excluded if they were under 18 years old, had
undergone upper limb surgery/fracture in the last 6 months, were on a waiting list for upper limb surgery
or were pregnant.
Interventions: Usual care or usual care plus an individualised exercise programme. Usual care consisted
of joint protection education, general exercise advice and functional splinting if required. The exercise
programme consisted of six sessions of strengthening and stretching exercises with a hand therapist, daily
home exercises and strategies to maximise adherence.
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Main outcome measures: The primary outcome was the Michigan Hand Outcome Questionnaire
(MHQ) overall hand function subscale score at 12 months. Secondary outcome measures included the full
MHQ, pain, health-related quality of life (Short Form questionnaire-12 items), impairment (grip strength,
dexterity and range of motion) and self-efficacy. European Quality of Life-5 Dimensions, medication and
health-care use were collected for the health economics evaluation. Follow-up was at 4 and 12 months
post randomisation. Analysis was performed on an intention-to-treat basis.
Results: We randomised 490 patients (244 to usual care, 246 to exercise programme). Compliance
with the treatments was very good (93% of usual care participants and 75% of exercise programme
participants completed treatment). Outcomes were obtained for 89% of participants at 12 months
(222 for usual care, 216 for exercise programme). There was a statistically significant difference in favour
of the exercise programme for the primary outcome at 4 and 12 months [mean difference 4.6 points,
95% confidence interval (CI) 2.2 to 7.0 points; and mean difference 4.4 points, 95% CI 1.6 to 7.1 points,
respectively]. There were no significant differences in pain scores or adverse events. The estimated
difference in mean quality-adjusted life-years (QALYs) accrued over 12 months was 0.01 greater (95% CI
–0.03 to 0.05) in the exercise programme group. Imputed analysis produced incremental cost-effectiveness
ratio estimates of £17,941 (0.59 probability of cost-effectiveness at willingness-to-pay threshold of
£30,000 per QALY). The qualitative study found the exercise programme to be acceptable and highlighted
the importance of the therapist in enabling patients to establish a routine and incorporate the exercises
into their lives.
Conclusions: The results of the Strengthening And stretching for Rheumatoid Arthritis of the Hand trial
suggest that the addition of an exercise programme for RA hands/wrists to usual care is clinically effective
and cost-effective when compared with usual care alone. No adverse effects were associated with the
exercise programme. The economic analysis suggests that the intervention is likely to be cost-effective.
Study registration: Current Controlled Trials ISRCTN 89936343.
Funding details: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 19, No. 19. See the NIHR Journals Library website for further project information. This report has been
developed in association with the NIHR Collaboration for Leadership in Applied Health Research and Care
Oxford and the NIHR Biomedical Research Unit Funding Scheme. This project benefited from facilities
funded through Birmingham Science City Translational Medicine Clinical Research and Infrastructure Trials
Platform, with support from Advantage West Midlands.
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Plain English summary
Rheumatoid arthritis (RA) causes inflammation in the joints and often affects people’s hands. Commonsymptoms are pain and swelling which cause reduced strength and movement of the hands. This can
make carrying out day-to-day activities difficult. It is not known if exercises are helpful for people with
hand RA. This study investigated if a hand and wrist exercise programme improved hand function in
people with RA. We also studied the cost to deliver this treatment in the NHS.
We randomly allocated 490 adults who attended rheumatology clinics in 17 NHS trusts with RA of the
hand to standard care or standard care plus an exercise programme delivered by a hand therapist.
Standard care was one to three sessions and included education about protecting their joints, general
exercise advice and splints if needed. The exercise programme consisted of six sessions of strengthening
and stretching hand and wrist exercises, daily home exercises and strategies to help participants to do their
exercises regularly.
Participants attended an assessment with a researcher before treatment and then 4 and 12 months later.
Information was collected about hand function, pain, quality of life, measures of strength and movement
and medication and health-care use. The exercise programme resulted in increased hand function at 4 and
12 months’ follow-up compared with standard care. It did not cause an increase in pain or side effects
and was likely to be cost-effective to the deliver in the NHS. We interviewed 14 participants who found
the exercise programme to be acceptable.
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Scientific summary
Background
Rheumatoid arthritis (RA) is the most common inflammatory arthritis, affecting approximately 1% of the
UK adult population. In the majority of people with this condition, hands and wrists are affected by pain,
swelling, weakness and restricted mobility resulting in loss of function and social participation. Clinical
guidelines recommend strengthening and stretching exercises for the hands and wrists to maximise
strength, mobility and ultimately patient’s function but there is a distinct lack of research evidence to
support these treatments.
Objectives
1. To estimate the clinical effectiveness of adding an optimised exercise programme for hands and upper
limbs in addition to usual care in the reduction of hand dysfunction and pain for patients with RA.
2. To estimate the cost-effectiveness of adding this programme to usual care.
3. To qualitatively describe the experience of participants in the trial with a particular emphasis on
acceptability of the intervention, exercise behaviours and reasons for adherence/non-adherence.
Methods
Design
A pragmatic, multicentre randomised controlled trial (RCT). Participants were individually randomised to
usual care or usual care plus an individualised exercise programme consisting of strengthening and
stretching exercises for the hands and upper limbs. An economic evaluation and qualitative study were
run in parallel with the trial.
Setting
Seventeen NHS trusts in England comprising 21 rheumatology/therapy departments.
Participants
All adult patients with RA who had pain and dysfunction of hands and/or wrists and had been stable
on medication for at least 3 months were screened in rheumatology and hand therapy clinics. Patients
who had upper limb surgery or fracture in the previous 6 months or were pregnant were excluded.
Interventions
The control intervention was best practice usual care with an occupational therapist or physiotherapist
consisting of joint protection education, advice on simple mobility exercises for the whole body and,
if appropriate, functional splinting.
The experimental intervention was usual care plus an optimised exercise programme with an occupational
therapist or physiotherapist consisting of strengthening and stretching exercises for the hand, wrist and
upper limb delivered over six sessions. These sessions were supported by a home exercise programme
facilitated by strategies to maximise adherence.
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Follow-up
We collected follow-up data at 4 and 12 months post randomisation. The primary method of data capture
was face-to-face research clinic appointments. This was supplemented with postal and telephone data
collection for individuals who were unable to attend appointments but who consented to provide
information. We also conducted an extended follow-up by postal questionnaire at approximately 2 years
post randomisation following completion of the main study.
Clinical outcomes and analysis
The primary outcome measure was the Michigan Hand Outcome Questionnaire (MHQ) overall hand
function subscale score at 12 months. Secondary outcome measures included the full MHQ, pain
(troublesomeness), impairment (grip strength, dexterity, hand and wrist range of motion and joint
alignment), self-efficacy, disease activity, health-related quality of life (Short Form Questionnaire-12 items)
and adverse events.
The planned sample size was 480 participants assuming 25% of participants would be lost to follow-up
at 12 months. The difference between the intervention groups in mean MHQ overall hand function score
from baseline to 4 and 12 months was analysed by a linear model, adjusted for baseline, with further
analyses adjusting for covariates including current drug regime. The primary analysis used an
intention-to-treat approach.
Economic analysis
The cost–utility of the treatments was evaluated from a UK NHS perspective, using a within-trial
intention-to-treat analysis. Quality-adjusted life-years (QALYs) were estimated from European Quality of
Life-5 Dimensions-3 Levels (EQ-5D-3L) data at baseline and 4 and 12 months. For comparison, we also
estimated QALYs using the Short Form questionnaire-6 dimensions utility index. Costs were estimated for
each participant over 12 months of follow-up, based on patient-reported use of a list of health services
potentially influenced by hand function, RA status or side effects of treatment. Discounting was not applied.
Results
We recruited 490 patients between October 2009 and May 2011; 244 were randomised to usual care and
246 were randomised to the exercise programme arm. The percentage of female participants was 76%,
median age was 63 years and on average participants had been diagnosed with RA for 10 years. The two
groups of participants were well matched in terms of demographic data, primary outcome measure and
clinical assessment findings. Outcome data were obtained for 89% (438) of participants at 12 months.
At the extended follow-up time point (median 26 months) 326 (67%) participants provided data.
Clinical results
The exercise programme resulted in improvements in hand function in comparison with usual care at
4 and 12 months [difference in MHQ hand function 4.6, 95% confidence interval (CI) 2.2 to 7.0; and 4.4,
95% CI 1.6 to 7.1, respectively]. This statistically significant difference was mirrored for the full MHQ
score. Between-group differences in secondary outcomes were consistent with the exercise programme
providing improvement in physical function of the hand, physical roles including activities of daily living
and work, and confidence in managing the condition. There was no significant difference in pain scores or
adverse events between groups. At the extended follow-up time point participants in the exercise group
had, on average, better hand function scores than the control group but the difference was no longer
statistically significant. There were no longer any statistically significant differences between the groups for
the secondary outcome measures.
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Economic results
The estimated mean health-care costs with the exercise programme were approximately £100 higher than
with usual care alone (mean difference £102.90, 95% CI –£622 to £828). The estimated difference in
mean QALYs accrued over 12 months was 0.01 greater (95% CI –0.03 to 0.05) in the exercise programme
group than in the usual care group. The best estimate of the incremental cost-effectiveness ratio (ICER)
was £17,941 (EQ-5D-3L based, with multiple imputation for missing data). The estimated probability that
the ICER lies below £30,000 per QALY was 59–78% (depending on the method of analysis).
Qualitative study
We explored trial participants’ perspectives on the experiences of taking part in the Strengthening And
stretching for Rheumatoid Arthritis of the Hand exercise programme, including their satisfaction and how
they gauged its effectiveness. We also explored how acceptable the intervention was and, in particular,
the use of the adherence strategies embedded within it. We purposively sampled participants randomised
to the experimental intervention who reported benefiting and not benefiting from the treatments at their
4-month follow-up. Semistructured interviews were conducted with 14 participants (10 benefit reporters
and four non-benefit reporters). Participants were interviewed following their 4- and 12-month
follow-up appointments.
All interviewees said they were satisfied with the programme and would recommend it to others and
they seemed confident in the delivery and use of the exercises. This study has highlighted the importance
of the therapist in enabling patients to establish a routine and incorporate the exercises into their lives.
Establishing a routine was easy for some interviewees, but others required support and encouragement.
Interviewees found some elements of the programme challenging, for example the strengthening
exercises, which needed the most adaptation to ensure they were completed.
Conclusions
Implications for health care
The results of this large, definitive RCT suggest that the addition of an optimised exercise programme
for RA hands and wrists is clinically effective and cost-effective when compared with best-practice usual
care alone over a 12-month period. The exercise programme is feasible and acceptable to patients with
stable RA. Improvements in physical hand function, self-efficacy and impairment measures are maintained
over 12 months. A post-hoc extended follow-up study shows that these improvements are reduced at
approximately 2 years, which is probably associated with a reduction in performance of the specific
exercises. From a NHS perspective, although the exercise programme is approximately £100 per patient
more expensive than usual care, it is likely to be cost-effective at current levels of willingness to pay over a
1-year time horizon.
Recommendations for research
With the findings of the extended follow-up indicating participants found it hard to maintain the exercise
programme beyond 1 year, it would be beneficial to explore the effects of different motivational
techniques such as top-up contacts on adherence to the programme. Investigation of clinical effectiveness
and cost-effectiveness of the programme in a population of people with earlier RA is also needed.
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Chapter 1 Introduction
Background
Epidemiology of rheumatoid arthritis
Rheumatoid arthritis (RA) is the most common inflammatory polyarthritis.1 It is a chronic unpredictable
disorder that can cause persistent joint pain, joint damage and long-term disability (especially in the hands
and feet). The prevalence of RA is 1.16% in women and 0.44% in men, increasing with age to 5% in
those aged over 55 years.1 It affects approximately 1% of the UK adult population. Five years after
diagnosis, 40% of people with RA have relatively normal function (13% in remission), 44% have mild to
moderate disability and 16% have marked functional disability.2 The cause of the disease is unknown
but both environmental and genetic factors are believed to contribute.
Rheumatoid arthritis is a whole-body disorder with greater mortality and multisystemic effects. The
condition usually starts in the small joints of the hands and feet and later spreads to involve the larger
joints. T-cells infiltrate the synovium, resulting in hypertrophy and inflammation of the local area and
supporting ligaments. Deformities arise as a result of joint cartilage being eroded, which can then extend
into the bone cortex. There are common forms of deformities at the wrist (dorsal ulnar head subluxation),3
metacarpophalangeal (MCP) joints (volar subluxation of proximal phalanges and ulnar drift of fingers),
fingers (swan-neck and boutonnière deformities) and thumb [instability at the MCP and interphalangeal
(IP) joints]. Tendon rupture can occur as a result of weakening by synovial invasion or abrasion over an
irregular bony prominence.
Alongside this process of inflammation and deformity, other common associated problems for the hands
and wrists are pain, weakness and restricted mobility resulting in loss of function and social participation.4–6
RA patients report hand function to be important in their daily lives,5 with at least 70% of patients
reporting hand and wrist dysfunction.7
Pharmacological management of rheumatoid arthritis
Although there are increasingly effective drug treatments,8,9 the condition has no known cure. Thus, the
goals of management are to prevent or control joint damage, loss of function and decrease pain.10 In order
to achieve these goals, combinations of pharmacological, non-pharmacological and surgical treatments
are used.
The chief categories of drugs used are analgesics, non-steroidal anti-inflammatory drugs (NSAIDs),
disease-modifying anti-rheumatic drugs (DMARDs) (non-biological and biological) and corticosteroids.
NSAIDs offer a purely symptomatic treatment, commonly used when the disease flares up. There are a
multitude of DMARDs licensed for use and it is now agreed that these should be used early on in the
disease process for improved control.11 They are commonly used in combinations to achieve greater
benefit but with no extra harm. Corticosteroids offer a fast-acting solution and are frequently used
between changes in DMARD regimes. They can be used in oral, intravenous (IV) and intra-articular forms,
depending on how widespread the scope of the problem. The side effects limit the long-term use of these
drugs. Biological DMARDs, or biologics, are a relatively recent development in the management of RA.
Owing to their greater financial cost, their use is restricted by National Institute for Health and Care
Excellence (NICE) guidelines to patients whose disease is not controlled by conventional DMARDs.12 The
main classes of biologics in common use at present are tumour necrosis factor (TNF) inhibitors or ‘anti-TNF’
(including infliximab, etanercept, adalimumab and certolizumab pegol) and rituximab, which works by
depleting B lymphocytes. Newer biologics such as abatacept and tocilizumab are used where anti-TNF and
rituximab do not work or cause adverse effects.
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Non-pharmacological management of rheumatoid arthritis
Current UK clinical guidelines for the management of RA recommend the use of physiotherapy and
occupational therapy as adjuncts to drug treatment.13,14 The three most common components of
physiotherapy/occupational therapy for RA hands are exercise therapy, joint protection (JP) advice and
provision of functional splinting and assistive devices,15 although we are not aware of any research
describing current clinical practice in the NHS.
The use of exercise treatment for RA primarily aims to increase strength, stability and range of motion by
tackling rheumatoid cachexia (loss of body cell mass and muscle architecture), disuse atrophy and joint/soft
tissue restriction.16 Additional benefits may include reducing pain and increasing sensory–motor function.17
A systematic review18 of six randomised controlled trials (RCTs) of the effectiveness of dynamic general
exercise programmes in RA concluded that dynamic exercise was effective in improving muscular
endurance and strength, without having detrimental effects on disease activity or pain. The number of
RCTs that have specifically investigated the effects of exercise on RA hands and wrists is limited to five
small studies with short-term follow-up limited to a few months (n= 44, 50, 52, 44 and 67 individuals).19–23
Each of these studies demonstrated small improvements in hand impairment and/or function with no
increase in joint swelling, pain or disease activity.
Adherence to any exercise programme is crucial, as it is suggested that there is a dose–response
relationship in both healthy and RA populations for strength and pain.24 Adherence with short-term
supervised exercise programmes is generally high.25 However longer-term and home-based exercise
programmes do not have the same response,26 although data are sparse. There is some evidence to show
that a programme incorporating a behaviour-change framework based on the Health Belief Model27 is
effective in maintaining long-term adherence in RA patients.28
Joint protection advice includes pain management advice, planning and pacing activities, regular rest,
altering patterns of joint movement and assistive device use in order to minimise pain and fatigue and
make tasks easier. This advice may be provided in the form of information leaflets (e.g. Looking After Your
Joints When You Have Arthritis29), one-to-one sessions, group interventions or a combination of these.
Evidence suggests that, provided appropriate education methods are applied, JP improves function and
reduces pain in the short and long term.28,30
Provision of splinting is widespread in UK clinical practice,31 with the objectives of reducing hand and wrist
pain, improving hand function and reduction or prevention of deformity and soft tissue contractures,
although evidence of efficacy is unclear.32 Types of splinting may be categorised into resting or functional
depending on the exact requirements of the patient.
Costs of rheumatoid arthritis
The economic cost of RA is substantial for both the individual patient and society as a whole.33 Patients with
poor and declining function from their diagnosis of RA experience much higher costs of care overall.34 A report
by the National Rheumatoid Arthritis Society in 2010 found that the overall cost of RA to the UK economy
was almost £8B per annum, with NHS expenditure totalling approximately £700M.35 To date, no studies
evaluating exercise in hand and wrist RA have detailed costs involved or included a cost-effectiveness analysis.
Rationale for Strengthening And stretching for Rheumatoid Arthritis of the
Hand trial
Wrist and hand dysfunction as a result of pain, loss of movement and weakness is a common problem
in RA. To address this, exercises are currently recommended as part of clinical management of people living
with RA with an increasing shift towards more active treatments at an earlier stage. These recommendations
are not supported by high-quality evidence.
INTRODUCTION
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With previous small-scale studies showing some promise over the short term, there is a clear need for
long-term evaluation of an optimised hand exercise programme in a large group of people living with RA.
As part of this evaluation, it is important that strategies to maximise programme adherence are
incorporated and evaluated. A mixed-methods approach provides rich data that should facilitate
understanding of why such a programme does or does not work.
In the Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH) trial we evaluate a
hand exercise programme that will be acceptable to NHS physiotherapists and occupational therapists
based on current available evidence. Such a programme is over and above what is currently provided in
the UK NHS. A parallel economic evaluation will enable conclusions to be made about cost-effectiveness.
Research objectives
1. To estimate the clinical effectiveness of adding an optimised exercise programme for hands and upper
limbs in addition to usual care in the reduction of hand dysfunction and pain for patients with RA.
2. To estimate the cost-effectiveness of adding this programme to usual care.
3. To describe, qualitatively, the experience of participants in the trial with a particular emphasis on
acceptability of the intervention, exercise behaviours and reasons for adherence/non-adherence.
The null hypotheses of the study were that there would be no difference in either the clinical and cost
outcomes between the two treatment arms.
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Chapter 2 Methods
Trial design
The SARAH trial was a pragmatic, multicentre RCT. The control arm (usual care) consisted of JP education,
advice on simple mobility exercises for the whole body and, if appropriate, functional splinting. This was
compared with an experimental intervention consisting of the same regimen supplemented with an
optimised exercise programme. This programme consisted of strengthening and stretching exercises for the
hand, wrist and upper limb delivered over six sessions with a therapist over a 12-week period.
Participants
Inclusion criteria
l RA meeting the American College of Rheumatology (ACR) clinical and immunological criteria (Box 1).10
l Pain and dysfunction of the hands and/or wrist joints.
l No treatment with a DMARD or having been on a stable DMARD regimen for 3 months or more.
Exclusion criteria
l Age less than 18 years.
l Upper limb joint surgery, or fracture, in the previous 6 months.
l Being on a waiting list for upper limb orthopaedic surgery.
l Pregnancy.
Screening and recruitment
Patients were approached primarily by clinical staff during routine clinic visits. They were provided with
a patient information sheet (see Appendix 1) and asked if they would consider participating. If they
agreed, a research clinician (physiotherapist, occupational therapist or nurse) then contacted them to book
an appointment at a research clinic. At this appointment, the trial information was discussed, the patient
had an opportunity to ask questions, eligibility was rechecked and, if appropriate, patients were consented
(see Appendix 2). Patients were asked to give written informed consent according to principles of Good
BOX 1 Summary of ACR clinical and immunological criteria
Patients must meet four of the following seven criteria:
l morning stiffness in and around joints lasting at least 1 houra
l swelling in three or more jointsa
l swelling in hand or wrist jointsa
l symmetrical joint swellinga
l erosions or decalcification on radiographs of hand and/or wrist
l rheumatoid nodules
l abnormal serum rheumatoid factor.
a Must be present for at least 6 weeks.
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Clinical Practice and the Declaration of Helsinki.36 At the time of consent, outcome assessors collected
baseline measures.
In addition, patients on rheumatology consultant or therapy review lists without planned clinic
appointments were approached using postal questionnaires. They were sent an information sheet and a
brief questionnaire to return with a pre-paid envelope by the research team. The questionnaire asked
whether or not they were currently experiencing problems with their hands and/or wrists and about other
eligibility criteria. Patients who returned the questionnaire were contacted by the research clinician and,
if appropriate, had a research clinic appointment made.
Settings and locations
The trial was run in the hospitals of 17 NHS trusts (names at time of participation):
l Basingstoke and North Hampshire Hospitals NHS Foundation Trust (North Hampshire Hospital)
l Derby Hospitals NHS Foundation Trust (Royal Derby Hospital)
l Dorset Primary Care Trust (Victoria Hospital)
l George Eliot Hospital NHS Trust (George Eliot Hospital)
l Heart of England NHS Foundation Trust (Solihull Hospital)
l Nuffield Orthopaedic Centre NHS Trust (Nuffield Orthopaedic Centre)
l Poole Hospital NHS Foundation Trust (Poole General Hospital)
l Portsmouth Hospitals NHS Trust (Queen Alexandra Hospital)
l Royal Bournemouth NHS Foundation Trust (Christchurch Hospital)
l Royal National Hospital for Rheumatic Diseases NHS Foundation Trust (Bath Royal National Hospital for
Rheumatic Diseases)
l South Warwickshire General Hospitals NHS Trust (Warwick Hospital and Stratford-Upon-Avon Hospital)
l Sussex Community NHS Trust (Bognor Regis War Memorial Hospital)
l Winchester and Eastleigh Health Care Trust (Royal Hampshire County Hospital)
l Worcestershire Acute Hospitals NHS Trust (Worcestershire Royal Hospital; Alexandra Hospital, Redditch;
Kidderminster Hospital and Treatment Centre)
l Wrightington, Wigan and Leigh NHS Foundation Trust (Wrightington Hospital)
l University Hospitals Coventry and Warwickshire [University Hospital (Walsgrave site) and Rugby
St Cross Hospital]
l University Hospitals of Leicester NHS Trust (Leicester Royal Infirmary and Leicester General Hospital).
Interventions
Full details of the interventions are provided in Chapter 3, but the interventions are described briefly here
for continuity.
All interventions were delivered by physiotherapists or occupational therapists experienced in the treatment
of hand and rheumatology conditions. They were independent of the recruitment and randomisation
procedures, attended a training session delivered by the trial team and received ongoing support
and guidance regarding the intervention to ensure quality standards were met. Therapists were trained
to deliver both the experimental and control interventions. Contamination was minimised through a variety
of quality control measures that included monitoring the treatment logs completed at each session, visiting
therapists at the beginning of their time delivering interventions on the trial for quality assurance purposes
and providing additional materials sufficient to cover only participants randomised to the experimental arm
of the study. The rationale and protocol for the interventions were described in a training and reference
manual. Both control and experimental interventions were developed using focus group meetings with
stakeholder clinicians from across the UK.
METHODS
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Participants randomised to the control intervention (usual care) had, depending on the clinical need,
between one and three sessions of outpatient therapy with a maximum total contact time of 1.5 hours.
Treatments in these sessions consisted of JP advice, general mobility exercises and, if appropriate,
functional splinting. Participants were provided with information sheets 29,37,38 and were encouraged to
remain active. The participant was not reviewed again by the treating therapist after the 1.5 hours unless
there were additional splinting requirements.
Participants randomised to the exercise programme received the usual care package plus an additional five
sessions with a therapist over a 12-week period. The aim was to increase hand function using exercises
to stretch and strengthen the muscles and tendons, as well as mobilise the joints of the hand and wrist
and improve dexterity. This was supported by a home exercise programme (reinforced by a behaviour change
approach and exercise diary) to be performed daily.
Monitoring the intervention delivery
Attendance rates and content of treatment appointments were recorded by the therapist using treatment
logs. Logs were completed for each session for all participants and returned to the study co-ordinating
centre. Close contact was maintained between the clinical research fellow and the therapy departments
to address any problems that were highlighted by the treatment logs.
All sites were visited to ensure smooth implementation of the interventions within the trial. This quality
control process involved the same clinical research fellow auditing treatment logs and notes and observing
experimental arm intervention sessions.
Outcomes
Follow-up data collection was by face-to-face clinical assessments at 4 and 12 months following
randomisation. Where face-to-face assessment was not possible, postal and telephone data collection
methods were used to obtain core data. The outcome measures are detailed in Table 1 and Appendix 3.
The primary outcome measure was the overall hand function subscale of the Michigan Hand Outcome
Questionnaire (MHQ), which has shown to be a reliable, valid and responsive measure for a RA
population.39–41 The overall MHQ contains six domains:
1. overall hand function
2. activities of daily living (ADLs)
3. pain
4. work performance
5. aesthetics
6. patient satisfaction with hand function.
Scores range from 0 to 100, with higher scores indicating better performance, except for the pain scale.
For the pain scale, a higher score indicates more pain.
In the initial version of the protocol, the Arthritis Impact Measurement Scale 2 (AIMS2) finger and hand
function subscale was documented as the primary outcome measure. However, prior to the full trial
commencing, we conducted a pilot study involving 16 participants, and as part of this evaluated both
the AIMS2 and MHQ. Based on this the MHQ was substituted as the primary outcome measure. This
substantial amendment was approved by the Multicentre Research Ethics Committee and full trial protocol
subsequently published.42
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TABLE 1 Outcome measures
Domain Data source
Measures: instrument (scale/units – high value
is better score unless specified)
Time points
(months)
Function Research clinic questionnaire
(participant reported)
MHQ – overall hand function score (0–100)
MHQ – overall score (0–100)
0, 4, 12
Pain Research clinic questionnaire Pain sub-scale of MHQ (0–100; high score is worse)
‘Troublesomeness’ rating (0–20; high score is worse)
0, 4, 12
Impairment Research clinic examination
(performed by outcome
assessor)
Joint deformity (MCP joint only) – goniometer
(degrees; high score is worse)
Wrist range of motion (flexion/extension) – goniometer
(degrees)
Finger range of motion (combined flexion and combined
extension) – ruler (mm; high score is worse for combined
flexion)
Thumb opposition range of motion – observation (0–10)
Dexterity – timed nine-hole peg test (seconds; high score
is worse)
Grip and pinch strength – dynamometer (N)
0, 4, 12
Disease
Activity
Medical records
Research clinic examination
ESR (mm/hour) and/or CRP (mg/l) blood test
Hand and wrist joint tenderness and swelling
count – examination (0–22; high score is worse)
0, 4, 12
HRQoL Research clinic questionnaire SF-12 (0–100)
EQ-5D-3L (health utility) (0–1)
0, 4, 12
Self-efficacy Research clinic questionnaire Confidence to manage their condition
(seven item questionnaire)
0, 4, 12
Satisfaction Research clinic questionnaire Treatment satisfaction item
Satisfaction subscale of MHQ (0–100)
4, 12
Global
Change
Research clinic questionnaire Participant-rated improvement in their condition question
(7-point Likert scale)
Perceived benefit/harm from trial treatments
(5-point Likert scale)
4, 12
Adherence Research clinic questionnaire Adherence with treatment (5-item questionnaire)
Patient reported current exercise behaviour
0, 4, 12
Economics Research clinic questionnaire Resource use questionnaire 4, 12
CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; EQ-5D-3L, European Quality of Life-5 Dimensions-3 Levels;
HRQoL, health-related quality of life; MHQ, Michigan Hand Outcomes Questionnaire; SF-12, Short Form questionnaire-
12 items.
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Secondary outcome measures consisted of measures of pain troublesomeness,43 self-efficacy,44 the
European Quality of Life-5 Dimensions-3 Levels (EQ-5D-3L),45 the Short Form questionnaire-12 items
(SF-12),46 socioeconomic questions (employment status, sick days in past month due to RA in wrists/hands,
benefits, highest educational qualification, household income), treatment preference and healthcare use
and costs. Blood test results [C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum
rheumatoid factor] and current medication (prescribed and as required in last 7 days) were taken from
hospital and prescription records. The outcome assessor was present to answer any questions regarding
the measures but was trained not to influence the participant’s responses. Following completion of the
case report form, a physical assessment was performed in a standardised order and standardised positions.
This included the measurement of joint deformity (MCP ulnar/radial deviation in maximum pronation,
where ulnar deviation is recorded as a positive value) and active range of motion (wrist flexion and
extension from the neutral position with a goniometer,47 combined finger flexion according to Ellis and
Bruton,48 combined finger extension and thumb opposition according to Kapandji).49 A modified swollen
and tender joint count (22 joints of hand and wrist)50 was taken, along with a test of upper limb dexterity
(nine-hole peg test according to Mathiowetz et al.).51 Finally, two forms of grip strength (full-hand and
tripod pinch) were measured using the MIE Digital Grip Analyser (MIE Medical Research Ltd, Leeds, UK).52
The standard test position recommended by the American Society of Hand Therapists was used.53 Patients
were sat in a straight-backed chair without arm rests, feet flat on floor, the shoulder of the assessed limb
relaxed by the side, the elbow flexed to 90°, the wrist extended and in ulnar deviation between 0° and
15° and the forearm rotated to neutral pronation/supination. The mean of three maximal 3-second grips
was calculated for each hand, with 60-second rests between repetitions.
Harms/adverse events and reasons for withdrawals are tabulated in Chapter 4.
While aware of the Outcome Measures in Rheumatology (OMERACT) core set of disease activity measures,
we prioritised outcomes that were likely to be sufficiently sensitive to detect any effect resulting from
the interventions.
Sample size
A standardised mean difference of 0.3 is reported to represent a clinically important difference in hand
function in this group.54 A previous small study using a similar intervention found a mean benefit of 0.7 in
the AIMS2 with a standard deviation of 1.81 and a standardised effect size of 0.39.23 This suggested that
in this larger, more pragmatic, multicentre trial, a standardised effect size of 0.3 in the similar function
score using the MHQ would be realistic and meaningful. To show this difference with 80% power at the
5% significance level, we required data on at least 352 participants [using Statistical Analysis Software
(V9.2, SAS Institute Inc., Cary, NC, USA) procedure GLMPOWER]. Assuming a 25% loss to follow-up
would require at least 469 participants. Over 15 months we expected 1200 people with hand RA to be
referred at our participating centres. If half of these were assessed for study entry and 80% of them joined
the study, we would have 480 participants (1200 × 0.5 × 0.8). This was our target sample size. The
assumptions underlying the sample size calculation were monitored by the Data Monitoring and Ethics
Committee (DMEC) throughout the study.
Randomisation
Randomisation to the exercise programme or usual care was via a central telephone randomisation service
at Warwick Clinical Trials Unit, University of Warwick.
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Sequence generation
The variable block randomisation schedule was prepared by the trial statistician (CM). Randomisation
was stratified by centre to control for any confounding factors evident at local recruitment sites, such as
therapist effects or local contamination of intervention.
Allocation concealment
The research clinician telephoned the randomisation service, and only once the participant was registered
in the trial was the random allocation generated. Hence allocation was concealed. Allocation was faxed
or emailed direct to the therapist, and the participant was told either when their first appointment was
made or at the appointment itself.
Blinding
The outcome assessor was blind to the group allocation of the participant and was independent of
intervention delivery. Participants were requested not to disclose group allocation to the outcome assessor.
If an outcome assessor was unblinded, this was recorded. If they remained unblinded, the assessors were
asked to guess which allocation they thought the participant was given. The participants and therapists
could not be blinded to the group allocation.
Statistical methods
Participants were analysed according to the treatment group to which they were randomised, regardless
of the treatment that they actually received (intention-to-treat analysis).55 Analyses were guided by an
analysis plan prepared before data were available. Demographic, clinical characteristics and baseline
measurements are presented to evaluate the comparability of intervention groups and generalisability to
clinical settings (see Chapter 4, Baseline data). A Consolidated Standards of Reporting Trials (CONSORT)
diagram was produced (see Figure 4).56
The difference between the intervention groups in mean score of MHQ overall hand function score from
baseline to 4 and 12 months was analysed by a linear model, adjusted for the baseline score. Means and
95% confidence intervals (CIs) are given.
The secondary outcome measures of change in pain, impairment measures, disease activity, quality of life,
self-efficacy, satisfaction and global change scores were analysed in a similar manner to the primary
outcome measure.
Analyses also took account of age, sex and current drug regimens by including baseline medication
covariates on outcome analyses. The therapy groups used were biologic DMARD, combination
non-biologic DMARDs, single non-biologic DMARD and no DMARD. Patient-rated improvement was
compared using the Wilcoxon test. Other ordinal testing for patient-rated benefit/harm and treatment
satisfaction used the Mantel–Haenszel chi-squared test for linear association and tests for differences in
other categorical data including medication and performing exercises used Pearson’s chi-squared.
Standardised mean differences are calculated as the unadjusted mean difference between treatments
divided by the pooled baseline standard deviation.
A pre-specified complier average causal effect (CACE) analysis was conducted to determine if the level
of compliance with the exercise programme affected participant outcome as measured by the overall
hand function subscale of the MHQ (primary outcome). The CACE estimates were calculated using the
instrumental variable method described in Dunn et al.57 The analysis was performed using a threshold
of six or more sessions (i.e. attended all sessions) as defining compliance. An additional analysis
investigated a threshold of three or more sessions.
METHODS
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The impact of therapist effects was evaluated by including a random therapist effect nested within centre
in the main outcome model. The effect of missing data was investigated using a Markov chain Monte
Carlo multiple imputation analysis.
In the original protocol, the primary analysis was stated as a repeated measures mixed model, but this was
changed to an adjusted linear model to make the results more interpretable by a wide audience. It was
also decided that survival analysis methods applied to surgical and serious adverse (SAE) event data were
not appropriate. These changes were approved by the DMEC and Multicentre Research Ethics Committee
(MREC) in the statistical analysis plan and Version 2 of the protocol which was subsequently published.42
Statistical analyses were performed using SAS V9.2 software.
Database and data processing
The database was held on Warwick Clinical Trial Unit’s Microsoft SQL Server system (Microsoft Inc.,
Bellevue, WA, USA) and imposed rules for data entry which include valid range for responses, linked dates
and patient identification numbers.
Data were single entered into the database by study personnel. The trial statistician carried out checks
of plausibility of values, missing data and form return rates to enable further queries to be resolved prior
to freezing data for scheduled DMEC reports and analysis.
For data quality assessment, 10% of all forms at all time points were randomly selected for data checking
on a 2-monthly basis. All disagreements found when checking were corrected and any systematic faults
found as a result of the checks were also corrected. The levels of accuracy specified were 1% for primary
end point data and 5% for secondary end point data. Five time periods were covered and disagreement
levels were always below 1% apart from one occasion when, in one 2-month period, a 2% level was
found for primary data. Corrections were made and the problem did not recur.
Scoring and missing items
Michigan Hand Outcome Questionnaire scales were scored as described by Chung et al.58 Individual item
scores are summed to give a raw score for each scale. These are converted to a score between 0 and 100
using the MHQ scoring algorithms. Averages of right and left hand are used for those scales where both
hands are measured. Scales were calculated if at least 50% of their items were completed. An overall
score can be obtained by averaging the score for all scales (with pain scale reversed). At least four scales
need to be completed to calculate the overall MHQ score.
The SF-12 was scored as described by Ware et al.59 We analysed mean component scores for the Mental
(Mental Component Score; MCS) and Physical (Physical Component Score; PCS) subscales. Missing
responses were dealt with using an imputation algorithm.60
European Quality of Life-5 Dimensions was used mainly for economic analyses evaluation; methods and
results for the economic analyses evaluations are described in Chapter 6.
Further details on the scoring used for impairment measures is given in Appendix 4.
Subgroup analyses
Statistical tests of interaction were used to perform pre-specified subgroup analysis on baseline drug
regimen (no DMARD, single DMARD, combination DMARD or biologic DMARD) and disease duration
(< 5 years or ≥ 5 years). Post hoc exploratory analyses were also conducted for baseline MHQ overall hand
function (< 52.5 points or ≥ 52.5 points), age (< 60 years or ≥ 60 years), type of referral (clinic or review
list mail out), gender, baseline ESR (< 16 mm/hour or ≥ 16mm/hour), baseline CRP (< 6mg/l or ≥ 6mg/l),
SF-12 PCS (< 34 points or ≥ 34 points) and SF-12 MCS (< 50 points or ≥ 50 points).
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Sensitivity analyses
Sensitivity analyses were planned to explore effects of results of adjustment for age, sex, site and any
imbalance in baseline characteristics. A repeated measures analysis was also performed.
Ethical approval and monitoring
Ethics committee approval
The SARAH trial was approved by the Oxford C Multicentre Research Ethics Committee in June 2008
(Research Ethics Committee reference 08/H0606/47) and by the research and development department
of each participating centre. The final approved study protocol has been published.42
Trial Steering Committee
A Trial Steering Committee (TSC) was responsible for monitoring and supervising the progress of the
SARAH trial. The TSC consisted of three independent experts, a lay member and leading members of
the Trial Management Group (TMG). Membership of the TSC is given in Acknowledgements.
Data Monitoring and Ethics Committee
The DMEC was independent of the trial and was tasked with monitoring ethical, safety and data
integrity. The trial statistician provided data and analyses requested by the DMEC at each of the meetings.
Membership of the DMEC is given in Acknowledgements.
Trial Management Group
A TMG was responsible for the day-to-day management of the trial, consisting of the chief investigator,
research fellows, statistician, trial co-ordinator, research nurse and data-entry clerk. The role of the group
was to monitor all aspects of the conduct and progress of the trial, to ensure that the protocol was
adhered to and to take appropriate action to safeguard participants and the quality of the trial itself.
METHODS
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Chapter 3 Intervention description and rationale
Introduction
The commissioning brief requested a large-scale pragmatic RCT to investigate the clinical effectiveness
and cost-effectiveness of an exercise programme for the management of RA of the hand. The brief
stipulated a trial of conventional care plus a defined package of hand exercise therapy incorporating the
following elements:
l a defined package of hand exercise therapy with instruction from an appropriate therapist
l the setting should be an out-patient clinic or therapy department
l the control group would receive ‘conventional care’ only.
A multifaceted approach was undertaken to design an intervention in response to these requirements.
This chapter explores the development of the interventions for the experimental and control arms of
the SARAH trial. Defining conventional or usual care within the NHS as well as designing an exercise
programme specifically for the hand constituted the major elements of the initial development stages.
Development of the Strengthening And stretching for
Rheumatoid Arthritis of the Hand intervention
The initial design of the SARAH intervention was based on a small study61 which was modified after
drawing together several strands of evidence including current guidelines, evidence from the literature,
expert and patient opinion, and physiological and theoretical considerations. Subsequent testing took
place during a pilot study at two hospitals in the West Midlands in which 16 subjects received a specific
hand exercise programme in addition to usual NHS care.
Clinical guidelines
Current UK guidelines for the management of RA62–64 recommend that access to physiotherapists and
occupational therapists should be offered to all people with RA to assess the impact and treat the
consequences of the condition. Specifically, the stated aims of therapy include:
l facilitating ADLs (e.g. washing, using the toilet, dressing, cooking, eating, working and leisure)
l improving general health-related fitness and encouraging regular exercise
l providing instruction on a range of strategies to reduce pain and stress on joints while carrying out
everyday activities
l providing instruction on specific exercises aimed at enhancing joint flexibility and muscle strength and
reducing other functional impairments
l providing information and advice about short-term pain relief provided by electrophysical interventions
(e.g. transcutaneous electrical nerve stimulation and wax baths).
Treatment provided by occupational therapists and/or physiotherapists can involve a variety of modalities
to achieve these aims. According to surveys of current practice, the three most common components of
therapy currently provided for people with RA of the hands are exercise therapy, JP advice and functional
splinting.15,65–67 Hence, current treatment is a balance between the provision of strategies to support
and protect joints (including symptomatic relief) and exercise to improve or maintain strength, flexibility and
functional ability. However, little guidance is available as to the specifics of any exercise programme.
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Evidence base
There is evidence suggesting that exercise improves general muscular endurance and strength without
detrimental effects on disease activity or pain in RA.68 However, few studies have investigated the effect
of exercises specifically for the rheumatoid hand. Some improvements in strength, mobility and/or function
with no negative effects have been reported,19,20,22,61,69,70 although the long-term effectiveness has not
been established.
A systematic review of the literature was performed to establish the evidence base for exercise in RA.
This encompassed general exercise programmes designed for the whole body as well as those specifically
addressing the hand and upper limb. In particular, exercise programmes from those studies that described
the actual intervention in detail were evaluated as part of designing the final SARAH intervention protocol.
General exercise
Several studies have investigated the effects of various types of exercise on different aspects of the patient
experience, the majority reporting beneficial responses.18 Almost all have involved general or ‘whole-body’
programmes focusing on aerobic fitness, strengthening and/or active range-of-movement (ROM) exercises.
In the past, issues of disease activity and potential irritation of symptoms led to a degree of caution in
exercise prescription for sufferers of RA. Current evidence suggests that exercise does not appear to have
a negative impact on the disease process and may in fact be beneficial,68 including for the small joints of
the hands and feet.71 It should be noted that these studies were not specific to the hands; rather the
hands were used during general upper limb exercise activity.
Specific hand exercise
Very few studies have specifically investigated the effect of hand exercises for patients with RA. A
systematic review in 200472 found nine studies of sufficient quality from which no definite conclusions
could be reached owing to the different designs, outcome measures and exercises utilised. These findings
were reinforced in a similar review73 which concluded that evidence was lacking as to the effectiveness
of shoulder- and hand-strengthening exercises.
An updated systematic review was undertaken by members of the SARAH trial team, including only
RCTs or controlled clinical trials that used quasi-randomised methods of treatment.74 Five studies were
included19–22,61 (Table 2). None of the studies described any significant detrimental effect resulting from
exercise – if anything there was a tendency for some measures of disease activity to improve even
with intensive exercise. Reported gains in strength following exercise were variable and of unknown
clinical significance.
TABLE 2 Studies investigating exercise for RA hands
Study
Number of subjects,
follow-up duration Exercise type
Outcomes
Strength ROM Function
Dellhag et al.,
199221
n= 52, 4 weeks Strength and/or ROM No change ↑ Some
measures
No change
Brighton et al.,
199319
n= 44, 4 years ROM and functional ↑ Gross grip and
pincer grip
↓ Loss of
ROM
Not measured
Hoeing et al.,
199322
n= 41, 12 weeks Strength or ROM or
combined ROM/strength
↑ Some measures No change Not measured
Buljina et al.,
200120
n= 100, 3 weeks Strength and ROM
(+ heat)
↑ Strength (all) ↑ ↑
O’Brien et al.,
200623
n= 67, 6 months Strength and/or ROM ↑ Some grip
strength measures
No change ↑
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Eight studies reported hand exercise programmes in sufficient detail to enable reproduction (Table 3).
They all used various combinations of strength and/or stretching exercises, with only two attempting to
differentiate between them in subsequent analyses.22,61 Three of the studies named the same source
for the exercise intervention used,76,77 while a fourth designed their programme following a survey of
hand therapists.61 None of the remaining studies provided any rationale for the exercises used.
TABLE 3 Reported hand exercise programmes in RA
Author Frequency Sets/reps Type Exercise
McLaughlin
and Reynolds,
197375
× 2/day for
4 weeks
Start 1 × 5;
progress
to 1 × 10
Flexion of PIP and DIP joints
Finger extension
Radial deviation of fingers against gravity
Flexion, extension and radial deviation of wrist
Pronation and supination
Flexion of thumb IP joint
Thumb opposition
Intrinsic muscle exercise
Dellhag et al.,
199221
× 3/week for
4 weeks
1 × 5 Flatt’s
programmea
Finger flexion, extension and radial deviation
Wrist flexion, extension and ulnar deviation
Thumb opposition and abduction
Shoulder rotation, flex and abduction
Brighton et al.,
199319
× 1/day for
4 years
1 × 5 1. Warm-up, fast flexion and extension of the fingers,
10 times
2. Place hands flat on table and try to lift (extend)
each finger off the table
3. Repeatedly flexing and extending the MCP joints by
placing the hands over the edge of a table at the
level of the MCP joints
4. In a similar fashion the PIP joints are also exercised
5. Grip a sheet of paper between thumb and each
finger in turn – try to pull it out
6. Roll and unroll a crepe bandage
7. Roll and unroll a bath towel
Hoenig et al.,
199322
× 2/day for
12 weeks
1 × 10 ROM Tendon gliding exercises
Strength Balanced resistive hand exercises including finger
abduction and adduction with MCP extended and
gross grip (with therapy putty – plasticity rating 85)
Buljina et al.,
200120
× 1/day for
3 weeks
1 × 5 Flatt’s
programmea
Finger flexion, extension and radial deviation
Wrist flexion, extension and ulnar deviation
Thumb opposition and abduction
Shoulder rotation, flexion and abduction
Strength Balanced resistive hand exercises including finger
abduction and adduction with MCP extended and
gross grip (with therapy putty – plasticity rating 85)
continued
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TABLE 3 Reported hand exercise programmes in RA (continued )
Author Frequency Sets/reps Type Exercise
O’Brien et al.,
200623
× 2/day for
6 months
Start 1 × 5;
progress
to 1 × 20
Strength
and ROM
1. Eight simple strengthening and mobilising ‘tendon
gliding’ exercises for fingers, thumb and wrist
2. Radial finger walking
3. Pinch grip exercises
4. Strengthening the intrinsic and thenar eminence
muscles (using a towel)
5. Wrist extensor muscle groups with a ‘Theratubes’
resistive band (Promedics, Glasgow, UK)
ROM only Stretches including:
l wrist flexion
l extension and circumduction
l pronation and supination
l radial deviation
l global flexion and abduction of all finger joints
l thumb opposition
l IP flexion
Rønningen
and Kjeken,
200869
× 5/week
minimum for
14 weeks
1 × 3 Conservative Gentle exercises performed against resistance of a
soft dough:
1. wrist ulnar deviation (fingers flexed)
2. flexing the fingers into a fist, extending the fingers
3. thumb opposition, rolling a ‘ball’ with the palm
on the table (fingers extended)
4. radial finger walking
5. thumb abduction with flexed IP joint
Exercises performed without resistance:
1. volar and dorsal flexion of the wrist
2. pronation and supination of the hand and forearm
3. opposition of the thumb
4. flexion of thumb IP joint
1 × 10 Intensive As above except: thumb opposition performed against
resistance; touching the tip of each finger with the
thumb and rolling a ‘ball’ with the palm on the table
were removed; each exercise repeated ×10 except
radial ‘finger walking’ (× 5); finger flexion and
extension exercises repeated three times during the
training session
Brorsson et al.,
200970
× 5/week 1 × 10 Gross grip, pinch grip, finger ‘clawing’ and rolling putty
with flat hand (with therapy putty – soft, medium or firm)
DIP, distal interphalangeal; PIP, proximal interphalangeal.
a According to Flatt.76
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Theoretical and physiological considerations
Strength
Weakness associated with RA is well documented, with reports of patients having an average of 40%
of normal power and pinch grip within 6 months of diagnosis.78 The mechanisms behind this are thought
to be due in part to ‘rheumatoid cachexia’ (loss of muscle cell mass and destruction of muscle architecture
because of the autoimmune, catabolic nature of the condition) as well as disuse atrophy of muscle.79
This loss of muscle tissue is of particular concern considering the importance of muscle strength and power
to provide movement as well as joint stability and protection.
Accepted principles of exercise physiology conclude that an increase in strength requires a sufficient
training stimulus, in the form of volume and intensity, in accordance with the principle of overload.
This can be altered by manipulation of frequency, load, number of sets and repetitions, and rest intervals.80
If the effects of muscle atrophy are to be countered, then muscles have to work at an appropriate intensity
and with sufficient volume79 to induce muscle hypertrophy. Other important aspects include duration of
programme, specificity of exercises and individualisation (i.e. adjusting the programme to suit each
participant). Depending on response and duration of the programme, progression is required to maintain
improvement and prevent plateauing or potential reversal of training effects.
Unfortunately, the literature provides little detail concerning exercise protocols, especially with regard to
strengthening. Of the studies examining exercise in rheumatoid hands, only five (see Table 3) described
the loads used, and no mention was made of how initial load was selected or progressed by these or any
other trial. The volume of exercise varied according to the different regimes, ranging from one set of three
repetitions up to a maximum of one set of 20 repetitions. These were performed anywhere between
three times a week and twice a day for periods lasting from 3 weeks to 4 years.
Mobility
Although deficits in upper limb ROM are commonly described as a consequence of RA, there is very little
quantitative information in the literature. One study reported mean reductions of up to 17% in hand ROM
in the early stages of the disease (i.e. within 7–12 months of diagnosis) compared with age- and
gender-matched healthy individuals.81 A cross-sectional study reported that 28% of RA patients had wrist
and finger ROM deficits in the dominant hand of greater than 15 degrees compared with healthy
volunteers after 2–4 years, rising to 35% and 49% for the wrist and fingers, respectively, after 8 years.6
Other upper limb joints have also been implicated, including the shoulder, making it difficult to place the
hand into positions for efficient function.82 Decreased finger ROM has been linked to reduced hand
function.17,83 In accordance with this limited evidence, we considered it important to maintain or improve
ROM in all the upper limb joints.
The tendon sheaths of RA patients have also been reported as prone to adhesions. Specific ‘tendon
gliding’ exercises for the hand have been developed that target combined movements of the fingers to
maintain full mobility of the flexor and extensor tendons.84
Evidence to support ROM exercises is mixed, with some studies finding no change22,61,69 while others have
reported some improvement or decline in the speed at which movement is lost.19,20 A study looking at
finger stretching exercises for sufferers of systemic sclerosis concluded that passive ROM was significantly
improved in each finger after 1 month and this was further improved or maintained after 1 year. This
involved one to three repetitions of each exercise with 10-second holds performed once a day.85
Given the importance of sufficient flexibility in satisfactory functioning of the hand and the lack of
evidence that ROM exercise causes harm, we included specific exercises in the experimental intervention
developed for the SARAH trial in an attempt to improve, or at least maintain, mobility of the upper limb.
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Expert opinion
A crucial part of the development programme was the advice received from clinicians and other experts,
including patient groups. Most notably, a consensus meeting was held with specialist hand therapists from
across England to gain further understanding of normal practice within typical NHS clinics and to assist
in the design of the exercise intervention. The result of this discussion was a standardised protocol for
usual care. Agreement was also reached as to what would constitute an effective and practical exercise
programme for the hand and upper limb. It needed to be feasible to perform within NHS hand therapy
clinics taking into account normal appointment duration and commonly available rehabilitation materials.
A list of upper limb exercises described in the literature, along with others proposed by various hand
therapists, was examined in detail and decisions made as to which of these exercises were the most
important to include in a programme specifically designed for RA. The selection was based on clinical
relevance, a desire to include all functionally relevant movements/muscle actions of the hand and wrist,
avoidance of replication and convenience/duration issues, especially with regard to the home exercise
component. Initial load and volume, as well as progression and regression strategies, were also agreed.
Pilot study
The acceptability and feasibility of trial procedures and the exercise intervention were tested in a pilot
study that ran from June 2009 to February 2010 and involved two senior therapists at two sites. The
therapists received a half-day training session and a manual describing the trial and interventions. Sixteen
participants were recruited and five were interviewed following their treatment to provide detailed
feedback. Patient materials, exercise instructions and some trial procedures were modified following
recommendations from therapists and patients as well as observations made by the trial team. Specifically,
the assessment form, the Borg scale of perceived exertion of exercises86 and other forms used to document
intervention delivery were altered along with instructions for the pinch grip and resisted wrist extension
exercises. Information provided to patients at discharge from treatment was also developed following
therapist recommendations.
The Strengthening And stretching for Rheumatoid Arthritis of
the Hand intervention
The intervention was delivered by UK-registered physiotherapists and/or occupational therapists with
expertise in rheumatology and hand rehabilitation. It occurred within individual sessions at typical NHS
therapy outpatient clinics. All therapists were NHS employees who treated trial participants alongside their
normal caseload. In most centres, therapists delivered both the usual care components and the exercise
programme to participants. Other centres split this role so that one therapist provided usual care while
another conducted the exercise sessions (Table 4).
TABLE 4 Division of treatment components between therapists
Treatment component Therapists, n (%) (N= 48)
Delivered both components 34 (71)
Delivered usual care component only To usual care arm participants only 1 (2)
To exercise arm participants only 2 (4)
To participants in both arms 5 (10)
Delivered exercise component only 6 (13)
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All sessions for both arms of the trial were to be completed within 12 weeks, after which time the patient
was discharged (Figure 1). Patients receiving the experimental intervention were encouraged to continue
with their programmes at home following discharge.
Control arm: usual care only
The design of the usual care intervention was based on evidence from the literature and discussions with
hand therapists. Clinical guidelines on the management of RA agree that the goals of management are
symptom control, prevention or control of joint damage, reduction of disability, and maintenance or
improvement of quality of life.10,63,64
According to a Cochrane review in 2004, therapy for RA can include a variety of interventions including
training of motor function, instruction on JP, advice and instruction in the use of assistive devices and
provision of splints.87 The most commonly provided treatments appear to be prescriptions of assistive
devices, orthoses, hand-training instructions and patient education.88 Evidence of effectiveness varies with
relatively strong support for exercise and self-management interventions and modest support for JP
programmes, orthoses and comprehensive care interventions.89
Research clinic appointment
Elibility confirmed, consent taken and baseline 
assessment performed
Randomisation
Within 
12 weeks
4-month follow-up research clinic assessment
12-month follow-up research clinic assessment
Usual care (control) Usual care and exercise
Exercise session 1
Exercise session 2
Exercise session 3
Exercise session 4
Exercise session 5
discharge
Follow-up session 1
(if required)
Follow-up session 2
(if required)
Assessment and advice
session
Assessment and advice
session
FIGURE 1 Strengthening And stretching for Rheumatoid Arthritis of the Hand intervention flow chart.
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The control arm treatment for the SARAH trial consisted of an initial assessment and advice session
with the option of a further two follow-up sessions as necessary. Treatment included the provision of JP
information, functional splinting, assistive devices and other general advice as required. In order to
evaluate the effects of exercise, participants in the control arm were not prescribed any specific exercises
for the upper limb. Apart from this, the content of the control arm was consistent with what is
considered usual care according to discussions with specialist hand therapists, unpublished surveys of
current practice and clinical guidelines.31,66,67,87
Joint protection education
Joint protection is a self-management technique widely taught to people living with RA. The aim of JP
in RA is to reduce pain, inflammation, joint stress and deformity through using assistive devices and
alternative movement patterns of affected joints to perform everyday activities. Conventional JP strategies
include pain management advice, planning and pacing activities, regular rest, altering patterns of joint
movement and assistive device use. 28,90
Commonly available booklets from Arthritis Research UK were provided to reinforce information.29,37,38
These included Rheumatoid Arthritis,38 a booklet providing general information about the disease and
its management; Looking After Your Joints When You Have Arthritis,29 describing various self-management
techniques and JP advice; and Keep Moving – How a few Simple Exercises can Make You Feel Better
About Yourself and Your Arthritis,37 a booklet providing general exercise information along with
suggestions as to specific exercises that could be performed for all parts of the body.
In 2004, Hammond and Freeman28 reported that an educational, behaviourally based patient education
programme providing JP advice of 8–12 hours’ duration has a small positive effect in improving function.
It is unclear how widespread this approach is in the UK, therefore the SARAH trial used more conventional
forms of advice provision which involved individual advice provided within a normal treatment session
with reinforcement at subsequent sessions if required.
Splinting
A survey of members of the British Association of Hand Therapists found that 100% of respondents
reported regularly prescribing orthotics in the management of RA, usually in an effort to decrease hand
and wrist pain and improve hand function.66 There are two approaches to splinting. Resting wrist splints
are prescribed mainly to reduce pain and other signs of inflammation and, to a lesser extent, to preserve
function, although the evidence for their effectiveness is limited.91 Functional wrist splints are used
intermittently during functional activities in which resistance, weight or protracted positioning are likely
to stress the hand and wrist. This type of ‘intermittent support’ splinting has more evidence of
effectiveness than the ‘immobilisation’ resting splint approach.92,93
The provision of functional wrist splints is common practice in the UK15 and, therefore, was not restricted
in the SARAH trial as we expected their use to be similar in both arms of the study. In contrast, resting
splints were not included as a treatment modality owing to some evidence suggesting little benefit from
their use.
Summary
The control arm can be summarised as follows:
l individual appointment(s) with a therapist (number of sessions dependent on clinical need up to a
maximum of three sessions or 1.5 hours in total)
l JP advice
l provision of Arthritis Research Campaign (ARC) booklets containing further advice and
exercise information
l functional splinting as deemed necessary by the therapist
l assistive devices as required
INTERVENTION DESCRIPTION AND RATIONALE
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l no resting splints provided
l no explicit exercise prescription
l no manual therapy (i.e. joint mobilisations) or electrotherapy
l assessment and treatment documented using a standardised log.
Experimental arm: hand exercise plus usual care
The experimental arm consisted of the usual care described above plus a hand and upper limb exercise
programme (Figure 2), which included seven mobility exercises and four strength exercises against
resistance (i.e. therapy putty, Theraband or hand exerciser balls).
FIGURE 2 Strengthening And stretching for Rheumatoid Arthritis of the Hand exercises.
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The experimental intervention involved a total of six sessions, of which the last five were exercise sessions
(Figure 3). Participants were provided with an exercise booklet with pictures and instructions describing the
programme as well as the resistance materials required. They were asked to perform the programme daily
at home between clinic sessions for a period of approximately 12 weeks.
A modified Borg scale was used to set the load (resistance) for the strength exercises based on
self-perception of effort. This 10-point version of the original Rate of Perceived Exertion scale86 has been
validated for use in regulating the intensity of resistance exercise.94 For each strength exercise, the level of
resistance was determined by the subjects’ rating of perceived effort using the weaker hand in order to
avoid overloading the more affected side. The load was purposefully set at a moderate level initially
(3–4 on the scale) to permit subsequent progression, enhance motivation and adherence and reduce the
possibility of increasing patient symptoms.
Usual care only (control)
Usual care and exercise (experimental)
Assessment and advice
•  Subjective history taking including problems
    with ADLs/work, etc.
•  Assessment of impairment/function/disease
    activity
•  Provision of ARC booklets
•  Provision/review of JP advice
•  Provision/review of functional splinting
    (if required)
•  Provision of assistive devices (if required)
•  Other advice including exercise (if required)
Adherence measures
•  Exercise diary completed and discussed       
•  Patient goals and action plan recorded
 – – –
 – – –
 – – –
–
–
–
–
–
–
–
–
 – – – – –
 – – – – –










    
   
   




–
–
– – – – –
–
–
–
   –
– –
– – –
– – –
– – –
– – –
– –
–
–
–
–
  
– – –  
  
– – –  
1 2 3 4 5 6
1 2 3 4 5 6
Session
Specific exercise programme
•  Load selected for resistance exercises       
•  Performed exercise programme as per
    protocol
•  Progression/regression of exercises as per
    protocol
Assessment and advice
•  Subjective history taking including problems
    with ADLs/work, etc.
•  Assessment of impairment/function/disease
    activity
•  Provision of ARC booklets
•  Provision/review of JP advice
•  Provision/review of functional splinting
    (if required)
•  Provision of assistive devices (if required)
•  Other advice including exercise (if required)
FIGURE 3 Content of SARAH interventions.
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Although initial guidelines as to sets and repetitions (volume) of exercise were provided (Table 5), the
programme was tailored to the abilities of the participant by progressing the load and volume of each
exercise according to each patient’s capabilities. If necessary, the manner of executing a particular exercise
could also be modified. For example, joint restrictions may prevent the degree of movement described in
a particular exercise, in which case the participant achieved as much movement as possible within their
available ROM. The overriding goal was for the participant to get as close as possible to performing the
exercise in an ideal manner at a volume and load that was achievable while still providing a stimulus for
physiological change. A defined protocol for both strength and ROM exercise progression (or regression)
was provided for subsequent sessions according to both patient capability and therapist judgement
(see Table 5).
Adherence
Adherence to any exercise programme is vital to ensure that the dosage required to strengthen muscle and
improve flexibility is achieved. Previous studies have found a dose–response relationship between prescribed
exercise and improvement in strength and pain among patients with arthritis who adhere to the exercise
programe.24 It is especially important in the context of the SARAH trial as participants were required to
perform the programme at home between sessions in order to provide a sufficient dose for physiological
change to occur.
Unfortunately, patient adherence to home treatment programmes is typically low.26 We aimed to maximise
adherence to the prescribed exercise regimen by incorporating evidence-based strategies recommended
for routine use by health professionals to promote patient behaviour change.95 This involved a two-stage
mechanism aimed at increasing the intention to adhere to the exercise regimen, along with enabling the
translation of this behavioural intention into actual behaviour.
TABLE 5 Strengthening And stretching for Rheumatoid Arthritis of the Hand exercise programme
Exercise
type Exercise Frequency Sets Repetitions Initial hold Initial load Progression
Mobility MCP flexion Daily 1 × 5 5 seconds
(where
required)
– Step 1: increase
up to 10 repetitions
Step 2: increase
up to 10-second
holds
Tendon gliding
Finger radial
walking
Wrist circumduction
Finger abduction
Hand-behind-head
Hand-behind-back
Strength Eccentric wrist
extension
Daily 1 × 10 (minimum
8 repetitions;
maximum
12 repetitions)
– Between
3 and 4 on
modified
10-point
Borg scale
Step 1: 2 × 10
repetitions
Step 2: 4–5 on
Borg scale
Step 3: 5–6 on
Borg scale
Step 4: 3 × 10
repetitions
Gross grip
Finger adduction
Pinch grip
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In collaboration with the therapist, participants set a hand-related functional goal that they hoped to
achieve by carrying out the prescribed exercise regime, in accordance with SMART (specific, measurable,
attainable, realistic and timely) principles. Therapists then went on to assess the patient’s confidence in
successfully carrying out the exercise programme (self-efficacy) on a 10-point visual analogue scale (VAS)
(0= no confidence, 10= highly confident).95 A minimum level of self-efficacy for the exercise regimen was
set (7/10) and, if necessary, we developed collaborative activities to identify barriers to, and facilitators of,
exercise behaviour in order to boost confidence. The guiding philosophy was that behaviour is more likely
to be performed if people believe they are able to perform it, and if it is perceived as relating to a
personally relevant goal.96
The intention to perform a behaviour does not always result in the actual behaviour being carried out.97
In order to translate behavioural intention into action, Gollwitzer’s concept of implementation intentions98
was used. Implementation intentions link situational cues (i.e. good opportunities to act) with behavioural
responses (in this case performing the prescribed exercise programme) that are effective in attaining
desired outcomes (i.e. functional goal patient wishes to achieve). Participants were asked to specify when
and where (i.e. situation) they would perform the prescribed exercise regimen, and to put this in writing,
such that the implementation intention could be formed as ‘when situation Y is encountered, then I will
initiate behaviour Z in order to reach goal X’. In other words, when the participant is in the designated
place at the designated time, this will serve as a cue to perform the exercise programme in order to
achieve their pre-determined functional goal. Implementation intentions have been shown to be effective
in promoting the initiation of goal-related behaviour, and in sustaining such behaviour through the
shielding of ongoing goal pursuit from unwanted influences.99
Adherence was further supported through the use of exercise diaries, in which participants recorded their
performance of prescribed exercises. In addition to assisting therapists in deciding on the need to modify
the prescribed exercises, diaries promote important behaviour change techniques, including immediate
feedback and self-monitoring.100
Exercise diary
At each exercise session, participants were provided with a diary sheet (see Appendix 5) to record
completion of the exercise programme during the appointment and for subsequent days until the next
session. This served various purposes:
l a reminder to perform the exercise programme daily, especially as the participant was aware that the
therapist would review it at the next session
l a means of gauging adherence to the programme
l a method of initiating discussion regarding success (or lack of) in the performance of the programme
since the last appointment
l an aid in deciding on progression/regression of exercise programme.
There is evidence to suggest that the use of an exercise diary improves adherence to a home exercise
programme, especially when participants are aware that programme performance will be monitored.101
Goal setting and patient contract
At the end of the first exercise session, the goal-setting exercise was undertaken, with the participant
stating both what they aimed to achieve as well as how they planned to achieve it. The aim was to increase
compliance by attempting to strengthen the intention and motivation to perform the exercise programme
and using action plans to convert this into actual behaviour. Goals and action plans were recorded and
signed-off by both the therapist and participant. Both participant and therapist kept a copy of the form (see
Appendix 6) which was reviewed, along with the exercise diary (see Appendix 5), at each exercise session.
INTERVENTION DESCRIPTION AND RATIONALE
NIHR Journals Library www.journalslibrary.nihr.ac.uk
24
Summary
The experimental intervention can be summarised as follows:
l assessment and advice session plus five 30- to 45-minute exercise sessions spread over 12 weeks
l content of usual care arm treatment.
l an exercise programme aiming to improve strength, mobility and dexterity (including four strength
exercises for the hand and seven mobility exercises of all the upper limb joints)
l a home exercise plan with exercises performed daily
l a standardised protocol for progression or regression
l strategies to improve programme adherence including exercise diaries
l no resting splints
l no manual therapy or electrotherapy
l assessment and treatment documented using a standardised log.
Therapist training and support
The intervention and rationale were documented in a manual in accordance with the principles of the
Medical Research Council guidance for complex interventions.102
To standardise the treatment provided, all therapists attended a training session (maximum of 4 hours
depending on group size), including a practical element, at which they were instructed in how to treat
participants according to the trial protocol. Therapists were provided with the treatment manuals which
comprehensively described the interventions, including a session-by-session guide. None of the proposed
interventions were beyond the scope of normal therapy practice.
The SARAH team was in contact with the treating therapists throughout the duration of the trial. Three
update events were held during the intervention phase of the study to provide a forum for therapists to
discuss any problems that had arisen. These were attended by therapists from 15 out of 17 trusts that
were recruiting. The therapists unable to attend were visited to provide an update on the trial.
Monthly newsletters were also circulated among all involved therapists giving further advice and
information regarding the trial, as required.
Quality control
All treatments provided during each session were recorded in a detailed log by therapists and returned to
the trial centre once treatment had finished. These were reviewed, along with other trial paperwork, by
the research fellow responsible for the design of the intervention (PH). Any digressions from protocol or
queries about treatments provided were directed back to the therapists with advice, reinforcement or
reminders regarding treatment protocols, as necessary. Information from the treatment logs was entered
onto the trial database.
Quality control visits were performed to ensure adherence with intervention protocols. This involved the
research fellow (PH) observing each therapist delivering a treatment session with a trial participant to
ensure compliance with the protocols. Treatment logs and other paperwork associated with treatment of
the participants were also reviewed. As well as ensuring consistency between therapists across all centres,
it also served as an avenue for further support.
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Chapter 4 Results
Trial sites
Centre characteristics
Seventeen UK NHS trusts (21 individual departments) participated in the study (Table 6). The recruitment
period at each trust varied from 2 to 19 months with resulting variation in the number of participants
recruited at each site.
Participating therapists
Forty-eight therapists were involved in providing treatment for both arms of the study (Table 7). Almost
two-thirds were occupational therapists and the remainder physiotherapists. All were working in specialist
hand therapy departments. The number of therapists involved at each site varied from one to six (see Table 6).
The level of experience of each therapist (as determined by Agenda for Change pay banding103) is described
in Table 7. The vast majority of therapists were on either band 6 or 7 and the median level of experience
was 13 years.
TABLE 6 Characteristics of participating departments
Trust name Start date
Months of
recruitment
Number of
therapists
University Hospitals Coventry and Warwickshire NHS Trust October 2009 19 6
South Warwickshire NHS Foundation Trust October 2009 19 2
Basingstoke and North Hampshire Hospital NHS Foundation Trust December 2009 15 3
Wrightington, Wigan and Leigh NHS Trust December 2009 17 3
Royal National Hospital for Rheumatic Diseases NHS Foundation Trust January 2010 17 2
Winchester and Eastleigh Healthcare NHS Trust January 2010 16 3
Poole Hospital NHS Foundation Trust March 2010 14 3
Portsmouth Hospitals NHS Trust March 2010 14 4
Royal Bournemouth and Christchurch Hospitals NHS Trust March 2010 14 1
Dorset Primary Care Trust April 2010 3a 1
Worcestershire Acute Hospitals NHS Trust April 2010 13 5
Nuffield Orthopaedic Centre NHS Trust June 2010 11 5
George Eliot NHS Trust June 2010 11 2
Heart of England NHS Trust February 2011 3 1
Sussex Community NHS Trust March 2011 2 1
University Hospitals of Leicester NHS Trust March 2011 3 2
Derby Hospitals NHS Foundation Trust April 2011 2 4
a Finished early owing to therapist maternity leave.
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Participant flow
The overall flow of participants through the study is described in the CONSORT diagram (Figure 4). Further
detail for each stage is provided in following sections.
Recruitment
Screening
Screening and recruitment took place between October 2009 and May 2011. A total of 1606 patients
were screened in rheumatology clinics and on review lists (Table 8), of whom 512 (32%) were eligible and
willing to attend a research clinic appointment (Table 9), with a further 564 (35%) not eligible – Table 10
displays, where known, the reasons for ineligibility. Of those eligible but not willing, no reason was given
in the majority of cases (73%) (Table 11).
Recruitment
Of the 512 patients initially given appointments for baseline assessment, six were found to be
subsequently ineligible, six did not attend or cancelled and 10 declined to participate, resulting in
490 patients being randomised (see Figure 4). Although the recruitment target of 480 was achieved in
April 2011, a further 10 participants were recruited in early May 2011 as bookings made in the later
stages before the target was reached were all honoured. The final recruitment total was 490 patients
over a 20-month period. The proportion of participants in each arm was equivalent across all centres.
During the study, two participants recruited and allocated to the usual care arm withdrew from the study
and also withdrew consent for their data to be used. Therefore, totals for subsequent analysis use a
potential maximum of 488.
TABLE 7 Characteristics of participating therapists
Agenda for Change band Occupational therapists (n) Physiotherapists (n)
5 3 0
6 18 8
7 10 9
Totala 31 17
a Some therapists left and others joined during the trial.
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Following screening in rheumatology clinic or therapy
review list potentially eligible and approached
(n = 1042)
Excluded, n = 530
•  Declined to participate, n = 530
Excluded, n = 22
•  Not meeting inclusion criteria, n = 6
•  Declined to participate, n = 10
•  Did not attend appointment, n = 6
Allocated to usual care arm, n = 244
•  Received allocated intervention, n = 244
•  Did not receive allocated intervention, n = 0
•  Withdrew consent for data to be used, n = 2
Did not attend, n = 5
Completed intervention, n = 235
Discontinued intervention, n = 2
•  Reason unknown, n = 2
Allocated to exercise programme arm, n = 246
•  Received allocated intervention, n = 246
•  Did not receive allocated intervention, n = 0
Withdrew prior to treatment, n = 2
Did not attend, n = 6
Completed intervention, n = 184
Discontinued intervention, n = 54
•  Withdrew from treatment, n = 46
•  Withdrew from trial, n = 8
Responders, n = 224
•  Full, n = 197
•  Postal, n = 20
•  Telephone, n = 7
Lost to follow-up, n = 22
•  Unable to contact, n = 13
•  Withdrawal, n = 9
•  Death, n = 0
Responders, n = 16
•  Full, n = 174
•  Postal, n = 33
•  Telephone, n = 9
Lost to follow-up, n = 21
•  Unable to contact, n = 13
•  Withdrawal, n = 8
•  Death, n = 0
Responders, n = 228
•  Full, n = 211
•  Postal, n = 15
•  Telephone, n = 2
Lost to follow-up, n = 14
•  Unable to contact, n = 10
•  Withdrawal, n = 4
•  Death, n = 0
Responders, n = 222
•  Full, n = 190
•  Postal, n = 28
•  Telephone, n = 4
Lost to follow-up, n = 16
•  Unable to contact, n = 10
•  Withdrawal, n = 4
•  Death, n = 2
Assessed at research clinic
appointment
(n = 512)
Randomised
(n = 490)
Enrolment
Allocation
Treatment fidelity
4-month follow-up
12-month follow-up
Analysis
Due
(n = 246)
Due
(n = 242)
Due
(n = 237)
Due
(n = 238)
FIGURE 4 Consolidated Standards of Reporting Trials flow diagram.
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TABLE 8 Number of patients screened by centre
Trust name Screened Recruited
University Hospitals Coventry and Warwickshire NHS Trust 179 59
South Warwickshire NHS Foundation Trust 150 61
Basingstoke and North Hampshire Hospital NHS Foundation Trust 60 40
Wrightington, Wigan and Leigh NHS Trust 132 37
Royal National Hospital for Rheumatic Diseases NHS Foundation Trust 126 40
Winchester and Eastleigh Healthcare NHS Trust 239 37
Poole Hospital NHS Foundation Trust 202 37
Portsmouth Hospitals NHS Trust 114 31
Royal Bournemouth and Christchurch Hospitals NHS Trust 50 19
Dorset Primary Care Trust 10 5
Worcestershire Acute Hospitals NHS Trust 125 34
Nuffield Orthopaedic Centre NHS Trust 59 24
George Eliot NHS Trust 95 27
Heart of England NHS Trust 36 13
Sussex Community NHS Trust 10 7
University Hospitals of Leicester NHS Trust 11 11
Derby Hospitals NHS Foundation Trust 8 8
Total 1606 490
TABLE 9 Categories for screened patients
Category n (%)
Eligible, willing and research clinics appointment booked 512 (32)
Eligible but not willing 530 (33)
Not eligible (reason known) 292 (18)
Not eligible (reason unknown) 272 (17)
Total 1606
TABLE 10 Known reasons for ineligibility of screened patients
Reason n (%)
Not RA 49 (17)
Medicine change 129 (44)
No hand/wrist problems 34 (12)
Upper limb/surgery/waiting list 21 (7)
Other reason 59 (20)
Total 292
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Baseline data
Baseline characteristics of participants by trial arm
The baseline characteristics of patients recruited to the trial are summarised in Table 12. The randomisation
process appears to have been successful, with both study arms well matched in terms of demographic
data, primary outcome measure and clinical assessment findings. Baseline RA status was similar in both
groups with respect to disease activity (ESR and CRP levels) and disease duration (average ≈ 10 years), with
both markers indicating a population with ‘stable’ RA (see Table 12).
Over 80% of participants were recruited from direct clinic referrals, the majority of them white females
with a median age of 63 years (range 24–94 years).
Treatment preference was also well matched, with just over half stating no preference in both groups and
another 40% preferring the exercise arm.
As part of the initial session with the therapist, participants were asked whether or not they had ever
undergone surgery for the upper limb. Of the 430 responses, 144 (33%) replied ‘yes’, with similar
proportions in both arms of the trial.
TABLE 11 Reasons for unwillingness of eligible patients to participate
Reason n (%)
Lack of time 85 (16)
Travel 38 (7)
Feel well 23 (4)
No reason 384 (73)
Total 530
TABLE 12 Characteristics of participants by trial arm
Baseline characteristic Exercise programme Usual care
Referral source, n (%)
N 246 242
Clinic referral 198 (81) 199 (82)
Mail out from review list 48 (20) 43 (18)
Age (years)
N 246 242
Mean (SD) 61.3 (12) 63.5 (11)
Median (IQR) 63 (53–70) 64 (57–72)
Minimum, maximum 27, 94 24, 86
Sex, n (%)
N 246 242
Male 58 (24) 58 (24)
Female 188 (76) 186 (76)
continued
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TABLE 12 Characteristics of participants by trial arm (continued )
Baseline characteristic Exercise programme Usual care
Ethnic group, n (%)
N 246 240
White 238 (97) 235 (98)
Indian 3 (1) 2 (1)
Pakistani 0 (0) 1 (< 1)
Mixed 3 (1) 1 (< 1)
Other 2 (1) 1 (< 1)
Marital status, n (%)
N 246 241
Single 24 (10) 10 (4)
Married 157 (64) 155 (64)
Separated 4 (2) 5 (2)
Divorced 19 (8) 24 (10)
Widowed 28 (11) 36 (15)
Cohabiting 14 (6) 11 (5)
Employment status, n (%)
N 246 242
Full-time employed 29 (12) 22 (9)
Part-time employed 26 (11) 30 (12)
Self-employed 11 (5) 10 (4)
Unpaid work 3 (1) 2 (1)
Unemployed 12 (5) 6 (3)
Full-time student – 1 (< 1)
Looking after home 24 (10) 20 (8)
Retired/economically inactive 141 (57) 151 (62)
Receiving any state benefits, n (%)
N 243 240
No 110 (45) 111 (46)
Yes 133 (55) 129 (54)
Educational level, n (%)
N 239 237
Higher degree 26 (11) 26 (11)
NVQ4/NVQ5/degree or equivalent 18 (8) 14 (6)
Higher education below degree 23 (10) 25 (11)
NVQ3/GCE A-level equivalent 18 (8) 25 (11)
NVQ2/GCE O-level equivalent 41 (17) 39 (17)
NVQ1/CSE other grade equivalent 24 (10) 10 (4)
Foreign/other 9 (4) 11 (5)
No qualification 80 (34) 87 (37)
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TABLE 12 Characteristics of participants by trial arm (continued )
Baseline characteristic Exercise programme Usual care
Right/left hand dominant, n (%)
N 246 240
Right 226 (92) 215 (90)
Left 18 (7) 23 (9)
Not clearly one or the other 2 (1) 2 (1)
Gross annual household income, n (%)
N 218 221
< £10,000 59 (27) 45 (20)
£10,000 to < £20,000 62 (28) 82 (37)
£20,000 to < £30,0000 49 (23) 41 (19)
£30,000 to < £40,000 18 (8) 23 (10)
£40,000 to < £50,000 16 (7) 15 (7)
≥ £50,000 14 (6) 15 (7)
Patient treatment preference, n (%)
N 244 241
Usual care 11 (5) 6 (3)
Usual care plus exercise 100 (41) 95 (39)
No preference 133 (55) 140 (58)
Years since RA diagnosis, estimated by participant
N 218 218
Median (IQR) 10 (4–21) 10 (4–22)
Baseline ESR
N 188 185
Median (IQR) 15 (7–28) 16 (8–28)
Baseline CRP
N 219 210
Median (IQR) 5 (3–12) 6 (3–12)
Previous fracture or surgery for hand, wrist or upper limb
n/N (%) 75/212 (35) 69/218 (32)
A-level, Advanced level; CSE, Certificate of Secondary Education; GCE, General Certificate of Education; IQR, interquartile
range; NVQ1, National Vocational Qualification – level 1; NVQ2, National Vocational Qualification – level 2; NVQ3, National
Vocational Qualification – level 3; NVQ4, National Vocational Qualification – level 4; NVQ5, National Vocational
Qualification – level 5; O-level, Ordinary level; SD, standard deviation.
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Baseline medications
The most common medications prescribed at baseline were non-biologic DMARDs. Approximately 20% of
the cohort was on biologic DMARDs (Table 13). There was a small difference between arms regarding
non-biologic DMARDs – the proportion of participants on combinations was slightly higher in the exercise
programme arm than in the control arm while the proportion on single DMARDs was slightly lower
(29.3% vs. 21.9% and 41.9% vs. 48.8% respectively).
Non-biologic DMARDs are older, less expensive immunosuppressant agents, such as methotrexate, which
do not target individual cells or molecules specifically.
Baseline questionnaire scores
The scores for the questionnaires at baseline indicate that both arms of the study were similar (Table 14).
The mean overall hand function score of the MHQ (primary outcome) was 52 for both groups out of a
possible maximum of 100.
Baseline impairment measurements
Both study arms were well matched in terms of baseline impairment measures (Table 15). On average,
participants had moderate deformity, reduced ROM and strength in the wrist and hand with some swollen
and tender joints.
TABLE 13 Baseline medication
Prescribed current medications Exercise programme Usual care
Medication reported, N (%) 246 (100) 242 (100)
Treatment intensity medication group, n (%)
Biologic DMARDa 52 (21) 52 (22)
Combination non-biologic DMARDa 72 (29) 53 (22)
Single non-biologic DMARDa 103 (42) 118 (49)
No DMARD 19 (8) 19 (8)
Drug categories, n (%)b
Biologic DMARD 52 (21) 52 (22)
Single or combination non-biologic DMARD 216 (88) 208 (86)
Oral steroids 49 (20) 52 (22)
NSAIDs 105 (43) 100 (41)
Analgesics 89 (36) 84 (35)
Other prescribed medication 91 (37) 91 (38)
Additional ‘as required’ medication, n (%)
Extra NSAID(s) 9 (4) 15 (6)
Steroid tablet 2 (1) 5 (2)
Steroid injection into joint 1 (< 1) 0 (0)
Steroid injection into muscle 2 (1) 3 (1)
a Biologic DMARDs are newer, more expensive, agents that have been developed to target specific cells or molecules
within the immune system such as TNF or B lymphocytes. They include antiTNF agents and rituximab.
b Not mutually exclusive.
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TABLE 14 Baseline questionnaire scores
Scales/measures
Exercise programme Usual care
n Mean (SD) n Mean (SD)
MHQ (0–100; greater score =better function)
MHQ overall hand function both 246 52.1 (15.2) 242 52.1 (16.4)
MHQ ADLs both 244 54.5 (24.5) 242 54.1 (25.0)
MHQ work 246 48.2 (22.0) 241 48.4 (22.0)
MHQ pain 246 51.9 (21.9) 242 51.4 (19.9)
MHQ aesthetics both 245 56.9 (22.0) 242 58.6 (22.1)
MHQ satisfaction both 246 43.9 (19.7) 241 43.5 (22.3)
MHQ overall score 246 50.6 (16.4) 242 50.9 (16.9)
SF-12 (population mean = 50, higher score is better HRQoL)
SF-12 aggregate physical scale (PCS) 246 33.8 (9.8) 241 34.5 (9.5)
SF-12 aggregate mental scale (MCS) 246 48.1 (10.7) 242 48.9 (11.0)
SF-12 physical functioning 245 34.6 (30.2) 237 37.2 (30.4)
SF-12 role-physical 243 45.0 (27.0) 240 47.9 (24.7)
SF-12 bodily pain 246 49.5 (26.8) 242 50.6 (25.4)
SF-12 general health 246 45.0 (27.2) 242 46.4 (25.7)
SF-12 vitality 246 38.2 (24.7) 242 37.8 (26.1)
SF-12 social functioning 246 69.5 (28.6) 242 72.1 (27.4)
SF-12 role-emotional 243 67.4 (30.1) 240 70.5 (28.5)
SF-12 mental health 245 62.9 (20.9) 2239 64.2 (21.2)
EQ-5D-3L
Health state (full health= 1.0) 244 0.57 (0.29) 240 0.59 (0.26)
VAS (your health today) 246 66.1 (19.4) 242 67.3 (18.1)
Other scores
Pain troublesomeness overall score 246 46.0 (22.2) 242 48.5 (21.5)
Confidence in performing tasks overall score 245 67.0 (20.3) 242 68.7 (19.1)
HRQoL, health-related quality of life; SD, standard deviation.
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Follow-up
Across the two arms, 452 (92%) and 438 (89%) participants were followed up at 4 and 12 months
respectively (see Figure 4).
Table 16 displays the number of responses according to type of follow-up. The response rates were
generally well balanced between the arms, although full response rate (i.e. came into clinic for follow-up)
as were as total follow-up rate were slightly higher in the usual care arm than in the exercise programme
arm at both 4 and 12 months.
Follow-up was completed in the time frames intended, with the median time from randomisation to
follow-up being the same in the two groups at both 4 and 12 months (Table 17).
Withdrawals
In total, 25 participants (5%) withdrew from the trial during follow-up, with a greater proportion of these
in the experimental arm (n= 17 vs. n= 8 for usual care). Table 18 presents the timings of the withdrawals
from the trial by arm. In the exercise programme arm, the greatest proportion of participants withdrew
from the trial at the time of their treatment. There was no dominant reason for withdrawal in either arm
(Table 19). If participants withdrew from trial treatments, every effort was made to obtain follow-up data
from these participants (withdrawal from treatments and withdrawal from trial were differentiated on the
event notification form).
Comparisons of those retained compared with those lost to follow-up
There was no evidence of differences in sex or disease duration between those who did and did not
complete follow-up at 12 months. Those with 12 months’ follow-up were, on average, 5 years older than
those without and had higher baseline scores for MHQ hand function, SF-12 summary scores and
EQ-5D-3L health state. These differences were greater in the exercise programme arm. Table 20 shows
the characteristics of participants completing and not completing 12 months’ follow-up.
TABLE 15 Baseline impairment measurements
Scores/counts
Exercise programme Usual care
na Mean (SD) n Mean (SD)
MCP joint deformity in degreesb 245 6.8 (8.4) 238 7.4 (9.4)
Active wrist ROM score in degreesc 245 88.0 (29.6) 239 90.1 (31.7)
Combined finger flexion in mmb 245 13.0 (16.1) 238 12.8 (16.1)
Composite finger extension in mmb 244 21.3 (24.4) 231 20.2 (25.2)
Thumb opposition scoreb 246 8.2 (2.2) 241 8.0 (2.1)
Swollen joint countd 246 4.2 (4.8) 241 4.1 (4.8)
Tender joint countd 246 5.0 (5.4) 241 4.8 (5.1)
Dexterity: nine-hole peg test in secondsb 246 27.2 (8.2) 240 27.3 (9.4)
Grip handle width used in mm 245 22.3 (5.0) 240 22.6 (4.3)
Maximum full hand grip force in newtonsb 245 134.2 (83.3) 240 130.3 (73.1)
Maximum pinch grip force in newtonsb 243 40.2 (21.1) 237 39.1 (19.6)
SD, standard deviation.
a Baseline measures not available for some participants owing to inability to complete measures due to deformity or pain.
b Mean score of dominant and non-dominant sides.
c Mean combined score of flexion and extension for dominant and non-dominant sides.
d Sum of dominant and non-dominant sides.
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TABLE 16 Response rates by arm and type of response
Type of
questionnaire
response
Baseline 4-month follow-up 12-month follow-up
Exercise
programme,
n (%)
Usual care,
n (%)
Exercise
programme,
n (%)
Usual care,
n (%)
Exercise
programme,
n (%)
Usual care,
n (%)
Questionnaires
Full response 246 (100) 242 (100) 197 (80.1) 211 (87.2) 174 (70.7) 190 (78.5)
Postal response – – 20 (8.1) 15 (6.2) 33 (13.4) 28 (11.6)
Telephone
response
– – 7 (2.8) 2 (0.8) 9 (3.6) 4 (1.7)
Total 246 (100) 242 (100) 224 (91.1) 228 (94.2) 216 (87.8) 222 (91.7)
Non-responder – – 13 (5.3) 10 (4.1) 13 (5.3) 10 (4.1)
Died – – – – – 2 (0.8)
Research clinic assessment formsa
Assessed 246 (100) 242 (100) 197 (80.1) 210 (86.8) 174 (70.7) 187 (77.3)
Medication detailsb – – 15 (6.1) 13 (5.4) 37 (15.0) 29 (12.0)
Total 246 (100) 242 (100) 212 (86.2) 223 (92.1) 211 (85.8) 216 (89.3)
Withdrawn – – 9 (3.7) 4 (1.7) 8 (3.3) 4 (1.7)
a Research clinic assessment forms only potentially available for participants that were full responders (i.e. attended
face-to-face clinic appointment).
b Research clinic assessment not attended but medication details are present.
TABLE 17 Median time (in months) from randomisation to follow-up completion
Time period Exercise programme, median (IQR) Usual care, median (IQR)
Time to 4-month follow-up 127 days (121–146 days) 127 days (122–143 days)
Time to 12-month follow-up 371 days (361–390 days) 371 days (364–386 days)
IQR, interquartile range.
TABLE 18 Timings of withdrawal by arm
Time of withdrawal from trial Exercise programme, n (%) Usual care, n (%) Total, n (%)
Prior to treatment 2 (0.8) 1 (0.4) 3 (0.6)
During treatment 8 (3.3) 2 (0.8) 10 (2.0)
After treatment, before 4-month follow-up 0 (0) 1 (0.4) 1 (0.2)
Between 4-month and 12-month follow-upa 7 (2.8) 4 (1.6) 11 (2.3)
Total 17 (6.9) 8 (3.3) 25 (5.1)
a Includes participants with 4-month follow-up who are non-responders at 12-months.
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TABLE 19 Reasons for withdrawals
Reason Exercise programme, n (%) Usual care, n (%) Total, n (%)
Travelling/time 4 (24) 2 (25) 6 (24)
Poor health 4 (24) 2 (25) 6 (24)
Unable to attend 2 (12) 1 (13) 3 (12)
Does not want to/not committed 3 (18) 1 (13) 4 (16)
Not in intervention arm – 2 (25) 2 (8)
Reason not given 4 (24) – 4 (16)
Total 17 8 25
TABLE 20 Characteristics of participants completing and not completing 12-month follow-up by arm
Characteristic by arm
Participants completing
12-month follow-up
Participants not completing
12-month follow-up
p-value for
difference
Exercise programme
Age at randomisation (years), mean (SD) 62.0 (11.9) 56.1 (14.6) 0.0175
Sex (percentage female) 76.9 73.3 0.6705
Disease duration (years), mean (SD) 13.1 (11.0) 13.2 (8.7) 0.5461
Baseline MHQ hand function, mean (SD) 52.7 (15.2) 47.3 (14.2) 0.0678
SF-12 PCS, mean (SD) 34.3 (9.5) 29.7 (10.4) 0.0147
SF-12 MCS, mean (SD) 48.8 (10.6) 43.0 (10.6) 0.0049
EQ-5D-3L health state, mean (SD) 0.6 (0.3) 0.4 (0.4) 0.0116
Usual care
Age (years), mean (SD) 63.8 (11.1) 60.5 (12.8) 0.2785
Sex (percentage female) 76.6 70.0 0.5093
Disease duration (years), mean (SD) 13.9 (11.9) 15.9 (13.3) 0.6105
Baseline MHQ hand function, mean (SD) 52.8 (16.1) 44.1 (18.0) 0.0226
SF-12 PCS, mean (SD) 34.4 (9.6) 35.2 (8.9) 0.7063
SF-12 MCS, mean (SD) 49.2 (10.9) 45.6 (12.1) 0.1561
EQ-5D-3L health state, mean (SD) 0.6 (0.3) 0.6 (0.3) 0.7110
Combined
Age, mean (SD) 62.9 (11.5) 57.8 (14.0) 0.0080
Sex (percentage female) 76.7 72.0 0.4583
Disease duration (years), mean (SD) 13.5 (11.5) 14.4 (10.8) 0.4280
Baseline MHQ hand function, mean (SD) 52.8 (15.7) 46.0 (15.7) 0.0042
SF-12 PCS, mean (SD) 34.4 (9.5) 31.9 (10.1) 0.0888
SF-12 MCS, mean (SD) 49.0 (10.7) 44.0 (11.2) 0.0020
EQ-5D-3L health state, mean (SD) 0.6 (0.3) 0.5 (0.4) 0.0197
SD, standard deviation.
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Blinding
Researchers measuring outcome were asked if they knew the allocation of participants or were able to
guess; we received 278 responses to this question at 12 months (Table 21). Of these, 173/278 (62%)
correctly identified the treatment received and 105/278 (38%) did not. The distribution was similar for usual
care and exercise therapy, i.e. the probability that patients would correctly identify the treatment received
was marginally higher than would be expected by chance (50%), but this probability was the same in both
arms. The knowledge of treatment allocation had no effect in a sensitivity analysis of the primary outcome
(p= 0.654 at 4 months, p= 0.407 at 12 months).
Missing data
The proportion of missing data from the self-report questionnaires across all time points was generally low,
with the rate exceeding 10% for only one item (diagnosis date at baseline). For the majority of measures,
data were missing in less than 5% of cases, and both arms were relatively well-matched across all time
points (Table 22).
The pattern of low levels of missing data was repeated for the Research Clinic Assessment forms
containing the impairment and disease activity measures (Table 23). Relatively higher levels of missing data
for both arms were recorded for the 4- and 12-month follow-ups as compared with the questionnaires,
which reflects the fact that these data were not collected for telephone or postal follow-ups.
TABLE 21 Comparison of actual participant allocation compared with research clinicians’ (assessor) opinion
Actual group allocation
Exercise programme Usual care
4 months, n (%) 12 months, n (%) 4 months, n (%) 12 months, n (%)
Clinician’s
opinion
Usual care 39 (25.5) 51 (38.3) 94 (63.9) 91 (62.8)
Exercise
programme
114 (74.5) 82 (61.7) 53 (36.1) 54 (37.2)
Total 153 133 147 145
Missing 59 78 76 46
TABLE 22 Missing items/scales from questionnaires
Missing items/scales
questionnaires
Baseline 4 month 12 month
Exercise
programme,
n (%)
(N= 246)
Usual care,
n (%)
(N= 242)
Exercise
programme,
n (%)
(N= 224)
Usual care,
n (%)
(N= 228)
Exercise
programme,
n (%)
(N= 216)
Usual care,
n (%)
(N= 222)
Date of birth 0 (0) 0 (0) NA NA NA NA
RA diagnosis date 28 (11.4) 24 (9.9) NA NA NA NA
Date of completion 0 (0) 0 (0) 2 (0.9) 0 (0) 2 (0.9) 0 (0)
Days off work 2 (0.8) 4 (1.7) 10 (4.5) 4 (1.8) 13 (6) 7 (3.2)
Benefit information 3 (1.2) 3 (1.2) 12 (5) 13 (6) 15 (7) 11 (5%)
continued
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TABLE 22 Missing items/scales from questionnaires (continued )
Missing items/scales
questionnaires
Baseline 4 month 12 month
Exercise
programme,
n (%)
(N= 246)
Usual care,
n (%)
(N= 242)
Exercise
programme,
n (%)
(N= 224)
Usual care,
n (%)
(N= 228)
Exercise
programme,
n (%)
(N= 216)
Usual care,
n (%)
(N= 222)
MHQ
MHQ: one or two
missing (out of 57)
14 (5.7) 21 (8.7) 10 (4.5) 20 (9) 13 (6.0) 12 (5)
MHQ: more than two
missing items
3 (1.2) 5 (2.1) 18 (8) 12 (5) 3 (1.4) 2 (0.9)
MHQ: overall hand
function botha
0 (0) 0 (0) 2 (0.9) 1 (0.4) 0 (0) 0 (0)
MHQ: overall score both 0 (0) 0 (0) 1 (0.4) 0 (0) 0 (0) 0 (0)
Secondary outcomes
Pain troublesomeness:
any missing
0 (0) 0 (0) 9 (4.0) 4 (1.8) 11 (5) 5 (2.3)
Confidence in tasks:
any missing
1 (0.4) 2 (0.8) 9 (4.0) 3 (1.3) 10 (5) 6 (2.7)
Self-reported efficacy 0 (0) 0 (0) 8 (3.6) 4 (1.8) 10 (5) 8 (3.6)
EQ-5D-3L any items 2 (0.8) 2 (0.8) 0 (0) 0 (0) 2 (0.9) 3 (1.4)
SF-12 missing one or
two items
7 (2.8) 8 (3.3) 9 (4.0) 5 (2.2) 8 (3.7) 4 (1.8)
SF-12 missing more than
two items
0 (0) 1 (0.4) 8 (3.6) 5 (2.2) 9 (4.2) 5 (2.3)
SF-12 aggregate scales 7 (2.8) 9 (3.7) 17 (8) 10 (4.4) 17 (8) 9 (4.1)
SF-12 aggregate scales
(with imputation)
0 (0) 1 (0.4) 6 (2.7) 2 (0.9) 9 (4.2) 5 (2.3)
Health resource usage sections
NHS services because
of RA
NA NA 5 (2.2) 5 (2.2) 11 (5) 10 (5)
Nights in NHS hospital
(RA)
NA NA 0 (0) 0 (0) 0 (0) 0 (0)
Nights in NHS hospital
(not RA)
NA NA 6 (2.7) 1 (0.4) 3 (1.4) 2 (0.9)
NHS day case NA NA 2 (0.9) 1 (0.4) 3 (1.4) 3 (1.4)
NHS tests (RA) NA NA 3 (1.3) 7 (3.1) 5 (2.3) 9 (4.1)
NHS devices NA NA 3 (1.3) 4 (1.8) 1 (0.5) 5 (2.3)
Private health care
(insurance)
NA NA 11 (5) 12 (5) 17 (8) 12 (5)
Private hospital nights NA NA 8 (3.6) 7 (3.1) 11 (5) 13 (6)
Private hospital as a
day case
NA NA 7 (3.1) 9 (3.9) 13 (6) 8 (3.6)
Private hospital tests (RA) NA NA 6 (2.7) 4 (1.8) 13 (6) 11 (5)
Medication bought (RA) NA NA 7 (3.1) 6 (2.6) 10 (5) 7 (3.2)
Medical devices bought NA NA 12 (5) 16 (7) 14 (6) 10 (5)
NA, not applicable.
a Primary outcome.
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Study treatments
Treatment attendance rates
Treatments were generally well attended, with 93% of participants completing the usual care treatment
and 93% of participants partially or entirely completing the exercise programme (75% completed all six
sessions). For the exercise programme, completion of treatment was defined as attendance at assessment
and all five treatment sessions, and partial completion was between two and five exercise sessions. For
usual care, completion of treatment was defined as attending all booked sessions (completion of treatment
in usual care arm may include only attending for assessment session). The proportion of participants not
attending any treatment sessions was roughly equal between the arms (Table 24). For the exercise
programme there was a gradual attrition of patients as the sessions went on (Table 25). A quality control
programme evaluated 38 of the 48 therapists, all of whom were following the protocol satisfactorily.
TABLE 23 Missing items/scales from research clinic assessment forms
Missing items/scales
clinical assessment
forms
Baseline 4-month follow-up 12-month follow-up
Exercise
programme,
n (%)
(N= 246)
Usual care,
n (%)
(N= 242)
Exercise
programme,
n (%)
(N= 212)
Usual care,
n (%)
(N= 223)
Exercise
programme,
n (%)
(N= 211)
Usual care,
n (%)
(N= 216)
CRP and ESR 10 (4%) 10 (4%) 25 (12%) 41 (18%) 51 (24%) 40 (19%)
MCP joint deformity 1 (< 1%) 4 (2%) 15 (7%) 18 (8%) 38 (18%) 32 (15%)
Active wrist
flexion/extension
1 (< 1%) 3 (1%) 16 (8%) 17 (8%) 38 (18%) 33 (15%)
Combined finger flexion 1 (< 1%) 4 (2%) 17 (8%) 17 (8%) 38 (18%) 31 (14%)
Composite finger
extension
3 (1%) 11 (5%) 16 (8%) 24 (11%) 39 (18%) 35 (16%)
Thumb opposition 5 (2%) 3 (1%) 16 (8%) 18 (8%) 39 (18%) 31 (14%)
Swollen/tender
joint count
– 1 (< 1%) 16 (8%) 15 (7%) 37 (18%) 29 (13%)
Timed dexterity – 2 (1%) 16 (8%) 16 (7%) 38 (18%) 31 (14%)
Full and pinch grip
strength
5 (2%) 6 (3%) 20 (9%) 23 (10%) 47 (22%) 38 (18%)
TABLE 24 Attendance rates of interventions
Type of attendance
Exercise programme
(maximum six sessions), n (%)
Usual care
(maximum three sessions), n (%)
Median number of sessions 6 1
Failed to attend any appointment 8 (3) 7 (3)
Attended for assessment only 8 (3) 135 (56)
Partial completion of treatment 46 (19) 10 (4)
Completed treatment 184 (75) 225 (93)
DOI: 10.3310/hta19190 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 19
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
41
Timing of delivery of interventions
Table 26 presents median times from randomisation to first and last appointment by arm. Interventions
were largely delivered within 3 weeks of randomisation and completed within 3 months and 1 month for
the experimental and control interventions respectively. Time to initial appointment was similar in both
groups with the differences in treatment arm protocols reflected in the time to their final session.
Type of treatment
Therapists completed treatment logs for each session detailing the types of treatment provided. Table 27
provides a summary of the treatment logs by arm and per session. Note that the usual care arm involved a
maximum of three sessions only, although most participants in this arm received only one session. The
figures indicate a high level of compliance with the treatment protocols with regard to provision of JP
advice, information and completion of exercise arm paperwork.
A similar level of splinting was provided for participants in both arms of the trial. The higher percentages
for subsequent sessions in the usual care arm reflect the fact that, for the majority of these participants,
follow-up appointments were made with the express purpose of either providing a splint when identified
as necessary in the initial session or reviewing and/or modifying those splints that were provided at the
first session.
Exercise programme progression
During the therapist training, emphasis was placed on the need to progress the exercise programmes as
much as possible during the 3 months of treatment. A treatment log was completed for each session
recording the details of the programme provided and allowing an estimation of treatment progression for
those completing all six sessions. In this case, progression was defined as an increase in repetitions, sets or
resistance between the first and last session. Maintained indicates no changes in exercise parameters
between the first and last sessions, whereas regressed is a decrease in repetitions, sets or resistance between
the first and last sessions. Table 28 describes the proportion of participants who were progressed,
maintained or regressed for each exercise. This illustrates that the vast majority of participants progressed in
at least one of the exercise variables (repetitions, sets, and/or resistance). Variation in the number of
participants prescribed each exercise is because of the individualised nature of the programme.
TABLE 25 Numbers of participants attending sessions by arm
Arm
Session 1,
n (%)
Session 2,
n (%)
Session 3,
n (%)
Session 4,
n (%)
Session 5,
n (%)
Session 6,
n (%)
Extra sessions,
n (%)
Exercise
programme
238 (97) 230 (94) 219 (89) 201 (82) 188 (76) 185 (75) 2 (1)
Usual care 236 (98) 99 (41) 27 (11) – – – 6 (3)
TABLE 26 Timing of delivery of interventions
Period Exercise programme, median (IQR) Usual care, median (IQR)
Time from randomisation to first
appointment attendance
20 days (13–33 days) 19 days (12–34 days)
Time from randomisation to last
appointment attendance
3.2 months (2.7–4.0 months) 1.1 months (0.5–1.7 months)
IQR, interquartile range.
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Outcomes and estimation
Numbers analysed
Data from a total of 488 participants were received at baseline (246 participants in exercise arm;
242 participants in usual care). At 4 months, this was reduced to 454 participants (222 participants in exercise
arm; 227 participants in usual care) and at 12 months to 438 participants (216 participants in exercise arm;
222 participants in usual care).
Primary outcome: overall hand function
The primary outcome was the overall hand function subscale of the MHQ at 12 months. On average,
both groups’ hand function scores improved over time although within group changes of the exercise
programme group were approximately twice those of the usual care group (Figure 5 and Tables 29
and 30).
TABLE 28 Treatment progression for intervention arm participants that attended all five exercise sessions
Exercise Prescribed Progressed, n (%) Maintained, n (%) Regressed, n (%) Unknown, n (%)
MCP flexion 180 146 (81.1) 26 (14.4) 2 (1.1) 6 (3.3)
Tendon gliding 180 136 (75.6) 31 (17.2) 6 (3.3) 7 (3.9)
Radial walking 177 145 (81.9) 23 (13.0) 3 (1.7) 6 (3.4)
Wrist circumduction 179 146 (81.6) 22 (12.3) 5 (2.8) 6 (3.4)
Finger abduction 179 149 (83.2) 22 (12.3) 2 (1.1) 6 (3.4)
Hand behind head 179 129 (72.1) 39 (21.8) 5 (2.8) 6 (3.4)
Hand behind back 179 128 (71.5) 41 (22.9) 3 (1.7) 7 (3.9)
Wrist extension 174 113 (64.9) 41 (23.6) 19 (10.9) 1 (0.6)
Gross grip 180 151 (83.9) 21 (11.7) 7 (3.9) 1 (0.6)
Finger adduction 177 114 (64.4) 44 (24.9) 18 (10.2) 1 (0.6)
Pinch grip 178 132 (74.2) 34 (19.1) 11 (6.2) 1 (0.6)
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FIGURE 5 Scores over time for MHQ overall hand function.
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With regard to between group differences, participants allocated to the exercise programme had
statistically significantly greater hand function compared with those receiving usual care at both 4 and
12 months. Adjustment for baseline differences between groups for centre, sex, age and medication usage
resulted in a small increase in the mean treatment difference at 4 months and a small decrease at
12 months (Table 30).
Other self-report outcomes
Other Michigan Hand Outcome Questionnaire scores
The findings for the primary outcome were replicated for the ADLs subscale and the overall score of the
MHQ at 4 and 12 months, and the work subscale at 12 months (Tables 31 and 32).
No statistically significant difference was found between groups for the rest of the MHQ subscales
including pain, although both groups’ pain improved over the follow-up time.
TABLE 29 Michigan Hand Outcome Questionnaire hand function subscale mean scores at baseline, 4 and
12 months
Questionnaire
Exercise programme, mean (SD) Usual care, mean (SD)
Baseline 4 months 12 months Baseline 4 months 12 months
MHQ overall hand function
(both hands)a
52.1 (15.2) 61.1 (16.0) 60.7 (18.1) 52.1 (16.4) 56.6 (15.6) 56.4 (18.6)
SD, standard deviation.
a Positive change score indicates improvement in function.
TABLE 30 Michigan Hand Outcome Questionnaire hand function subscale change scores and treatment effects at
4 and 12 months
MHQ overall
hand function
(both hands)a
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme Usual care
Exercise
programme Usual care
4 months
222 227 8.73
(6.83 to 10.64)
4.04
(2.17 to 5.91)
4.60
(2.22 to 6.97)
0.0002 0.30
(0.13 to 0.47)
Adjusted for centre, sex and age 4.91
(2.50 to 7.32)
0.0001 –
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 4.71
(2.32 to 7.11)
0.0001 –
12 months
216 222 7.93
(5.98 to 9.88)
3.56
(1.45 to 5.68)
4.35
(1.60 to 7.10)
0.0020 0.28
(0.09 to 0.46)
Adjusted for centre, sex and age 4.25
(1.46 to 7.03)
0.0030 –
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 4.28
(1.49 to 7.06)
0.0028 –
a Positive change score indicates improvement in function.
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TABLE 31 Michigan Hand Outcome Questionnaire subscale and overall mean scores at baseline, 4 and 12 months
Questionnaire
Exercise programme, mean (SD) Usual care, mean (SD)
Baseline 4 months 12 months Baseline 4 months 12 months
MHQ ADLs (both hands) 54.5 (24.5) 62.9 (24.1) 61.3 (25.6) 54.1 (25.0) 56.9 (25.5) 56.5 (27.5)
MHQ work 48.2 (22.0) 55.4 (24.3) 57.8 (25.0) 48.4 (22.0) 54.0 (24.1) 52.2 (24.9)
MHQ pain 51.9 (21.9) 43.3 (23.6) 41.6 (24.3) 51.4 (19.9) 46.1 (21.1) 45.3 (22.6)
MHQ aesthetics (both hands) 56.9 (22.0) 61.6 (23.1) 63.2 (24.1) 58.6 (22.1) 61.7 (22.6) 62.1 (22.7)
MHQ satisfaction (both hands) 43.9 (19.7) 54.1 (23.5) 55.5 (23.6) 43.5 (22.3) 50.0 (22.6) 50.9 (24.5)
MHQ overall score 50.6 (16.4) 58.6 (18.4) 59.5 (19.4) 50.9 (16.9) 55.4 (17.9) 55.5 (20.1)
SD, standard deviation.
TABLE 32 Michigan Hand Outcome Questionnaire subscale and overall change scores and treatment effects
MHQ
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
MHQ ADLs (both hands)
4 months 220 228 7.86
(5.44 to 10.28)
2.57
(–0.40 to 4.74)
5.46
(2.41 to 8.51)
0.0005a 0.21
(0.08 to 0.35)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 5.66
(2.64 to 8.69)
0.0003a –
12 months 214 222 5.89
(3.66 to 8.13)
2.27
(–0.04 to 4.59)
3.79
(0.64 to 6.93)
0.0187a 0.15
(0.02 to 0.28)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.48
(0.31 to 6.66)
0.0321a –
MHQ work
4 months 220 225 6.12
(3.68 to 8.56)
5.27
(2.62 to 7.92)
1.00
(–2.43 to 4.43)
0.5671 0.04
(–0.13 to 0.20)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.04
(–2.39 to 4.48)
0.5518 –
12 months 215 221 8.12
(5.36 to 10.87)
3.11
(0.23 to 5.98)
5.21
(1.44 to 8.99)
0.0071a 0.23
(0.05 to 0.41)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 4.62
(0.82 to 8.42)
0.0175a –
MHQ painb
4 months 219 226 –7.60
(–9.94 to –5.26)
–5.11
(–7.58 to –2.63)
–2.61
(–5.79 to 0.58)
0.1096 –0.12
(–0.28 to 0.04)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –3.30
(–6.50 to –0.11)
0.0433a –
12 months 215 222 –8.26
(–10.83 to –5.70)
–6.01
(–8.74 to –3.29)
–2.70
(–6.23 to 0.83)
0.1341 –0.11
(–0.29 to 0.07)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –2.40
(–5.92 to 1.12)
0.1814 –
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Health-related quality of life (Short Form Questionnaire-12 items and
European Quality of Life-5 Dimensions)
There were no significant differences between the groups for overall health-related quality of life (HRQoL)
scores as measured by the EQ-5D-3L and SF-12 (see Tables 33–36). There were significant differences in
the SF-12 subscales roles physical and emotional, and the EQ-5D-3L health thermometer at 12 months.
Effect sizes for these components were small.
Pain troublesomeness and self-efficacy
No statistically significant difference was reported between groups for pain troublesomeness at either
follow-up time point (Tables 37 and 38).
There was a small but statistically significant difference between groups for self-efficacy scores at both
4 and 12 months. The exercise programme group had a small but significant increase in self-efficacy
compared with the usual care group (Tables 39 and 40).
TABLE 32 Michigan Hand Outcome Questionnaire subscale and overall change scores and
treatment effects (continued )
MHQ
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
MHQ aesthetics (both hands)
4 months 218 224 3.52
(0.89 to 6.14)
2.84
(0.27 to 5.41)
0.40
(–2.96 to 3.76)
0.8152 0.03
(–0.14 to 0.20)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.39
(–2.96 to 3.74)
0.8209 –
12 months 215 222 4.70
(1.81 to 7.59)
3.37
(0.42 to 6.33)
1.29
(–2.43 to 5.01)
0.4967 0.06
(–0.13 to 0.25)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.01
(–2.70 to 4.72)
0.5933 –
MHQ satisfaction (both hands)
4 months 221 224 9.59
(6.86 to 12.32)
6.66
(4.01 to 9.31)
3.29
(–0.22 to 6.80)
0.0665 0.14
(–0.04 to 0.32)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.61
(0.12 to 7.09)
0.0430a –
12 months 216 220 10.36
(7.53 to 13.18)
7.06
(4.16 to 9.95)
3.76
(–0.02 to 7.54)
0.0517a 0.16
(–0.04 to 0.35)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.38
(–0.37 to 7.13)
0.0784 –
MHQ overall score
4 months 223 228 7.28
(5.65 to 8.91)
4.34
(2.67 to 6.00)
2.98
(0.73 to 5.24)
0.0098a 0.18
(0.04 to 0.32)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.17
(0.91 to 5.43)
0.0063a –
12 months 216 222 7.59
(5.75 to 9.43)
4.22
(2.23 to 6.21)
3.48
(0.82 to 6.15)
0.0108a 0.20
(0.04 to 0.37)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.21
(0.53 to 5.89)
0.0195a –
a Statistically significant (p< 0.05).
b Higher score=more pain.
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TABLE 33 Short Form Questionnaire-12 items mean scores at baseline, 4 and 12 months
Questionnaire Exercise programme, mean (SD) Usual care, mean (SD)
SF-12 aggregate physical scale 33.8 (9.8) 36.4 (10.5) 35.6 (10.3) 34.5 (9.5) 35.4 (9.9) 34.4 (10.2)
SF-12 aggregate mental scale 48.1 (10.7) 49.2 (10.4) 51.1 (10.2) 48.9 (11.0) 49.7 (10.4) 49.6 (9.9)
SF-12 physical functioning 34.6 (30.2) 42.3 (32.2) 39.7 (32.0) 37.2 (30.4) 39.8 (31.0) 37.9 (31.0)
SF-12 role-physical 45.0 (27.0) 51.6 (27.0) 53.3 (26.5) 47.9 (24.7) 50.5 (25.0) 48.5 (26.2)
SF-12 bodily pain 49.5 (26.8) 57.3 (26.6) 57.7 (27.6) 50.6 (25.4) 54.3 (25.8) 53.1 (26.4)
SF-12 general health 45.0 (27.2) 48.4 (27.1) 48.8 (27.8) 46.4 (25.7) 48.8 (26.6) 46.2 (25.5)
SF-12 vitality 38.2 (24.7) 40.2 (25.7) 40.5 (25.3) 37.8 (26.1) 39.7 (25.3) 37.3 (25.8)
SF-12 social functioning 69.5 (28.6) 72.8 (28.2) 74.9 (27.0) 72.1 (27.4) 71.7 (26.9) 71.8 (25.9)
SF-12 role-emotional 67.4 (30.1) 71.9 (29.0) 77.5 (27.0) 70.5 (28.5) 73.5 (27.5) 72.8 (27.1)
SF-12 mental health 62.9 (20.9) 66.3 (20.5) 68.5 (21.0) 64.2 (21.2) 66.9 (20.4) 66.4 (19.8)
SD, standard deviation.
TABLE 34 Short Form Questionnaire-12 items mean change scores and treatment effects
SF-12
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
SF-12 aggregate physical scale (PCS)
4 months 218 225 2.04
(1.01 to 3.08)
0.91
(0.03 to 1.80)
1.08
(–0.22 to 2.37)
0.1043 0.12
(–0.02 to 0.26)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.18
(–0.11 to 2.46)
0.0743 –
12 months 207 216 1.19
(0.23 to 2.14)
0.03
(–0.96 to 1.03)
1.14
(–0.19 to 2.46)
0.0931 0.12
(–0.02 to 0.26)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.93
(–0.35 to 2.22)
0.1555 –
SF-12 aggregate mental scale (MCS)
4 months 218 225 0.46
(–0.66 to 1.59)
0.58
(–0.56 to 1.73)
–0.26
(–1.70 to 1.18)
0.7215 –0.01
(–0.16 to 0.14)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.16
(–1.58 to 1.27)
0.8299 –
12 months 207 218 2.19
(0.75 to 3.63)
0.41
(–0.89 to 1.71)
1.63
(–0.01 to 3.26)
0.0516a 0.16
(–0.01 to 0.34)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.59
(–0.06 to 3.23)
0.0593 –
SF-12 physical functioning
4 months 214 219 5.96
(2.50 to 9.41)
2.28
(–0.33 to 4.90)
3.22
(–0.86 to 7.30)
0.1222 0.12
(–0.02 to 0.26)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.26
(–0.82 to 7.34)
0.1181 –
12 months 204 211 3.31
(0.16 to 6.46)
0.71
(–2.41 to 3.83)
2.40
(–1.81 to 6.61)
0.2643 0.09
(–0.06 to 0.23)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.58
(–2.61 to 5.76)
0.4611 –
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TABLE 34 Short Form Questionnaire-12 items mean change scores and treatment effects (continued )
SF-12
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
SF-12 role-physical
4 months 211 220 4.92
(2.07 to 7.76)
2.73
(–0.05 to 5.50)
1.80
(–1.86 to 5.45)
0.3360 0.08
(–0.07 to 0.24)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 2.22
(–1.38 to 5.82)
0.2268 –
12 months 202 215 6.68
(3.49 to 9.87)
0.47
(–2.71 to 3.64)
5.64
(1.55 to 9.73)
0.0072a 0.24
(0.07 to 0.41)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 5.43
(1.43 to 9.44)
0.0082a –
SF-12 bodily pain
4 months 218 226 6.31
(3.16 to 9.45)
3.65
(0.38 to 6.92)
2.82
(–1.23 to 6.86)
0.1732 0.10
(–0.07 to 0.28)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.80
(–0.21 to 7.81)
0.0637 –
12 months 206 218 6.07
(2.83 to 9.30)
2.64
(–0.42 to 5.70)
3.84
(–0.24 to 7.91)
0.0655 0.13
(–0.04 to 0.30)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.81
(–0.26 to 7.88)
0.0670 –
SF-12 general health
4 months 218 226 1.65
(–1.17 to 4.48)
1.66
(–1.16 to 4.47)
–0.14
(–3.83 to 3.54)
0.9404 0.00
(–0.15 to 0.15)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.37
(–3.98 to 3.25)
0.8419 –
12 months 207 217 1.91
(–1.12 to 4.94)
–0.65
(–3.95 to 2.66)
2.55
(–1.50 to 6.60)
0.2179 0.10
(–0.07 to 0.27)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.96
(–2.06 to 5.98)
0.3395 –
SF-12 vitality
4 months 216 224 0.93
(–2.07 to 3.92)
1.90
(–0.92 to 4.72)
–0.45
(–4.17 to 3.27)
0.8124 –0.04
(–0.20 to 0.12)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.13
(–3.48 to 3.73)
0.9454 –
12 months 207 217 1.45
(–1.71 to 4.61)
–0.58
(–3.78 to 2.63)
2.50
(–1.51 to 6.51)
0.2227 0.08
(–0.10 to 0.26)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.97
(–2.03 to 5.97)
0.3347 –
continued
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TABLE 34 Short Form Questionnaire-12 items mean change scores and treatment effects (continued )
SF-12
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
SF-12 social functioning
4 months 218 226 1.38
(–1.67 to 4.43)
–0.88
(–4.02 to 2.25)
1.85
(–2.10 to 5.80)
0.3593 0.08
(–0.08 to 0.24)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.94
(–2.02 to 5.90)
0.3369 –
12 months 207 218 2.42
(–1.37 to 6.20)
–1.03
(–4.63 to 2.56)
3.26
(–1.17 to 7.68)
0.1499 0.12
(–0.06 to 0.31)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 2.63
(–1.79 to 7.04)
0.2445 –
SF-12 role-emotional
4 months 213 220 3.11
(–0.40 to 6.62)
2.22
(–1.31 to 5.74)
–0.20
(–4.56 to 4.15)
0.9267 0.03
(–0.14 to 0.20)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.07
(–4.23 to 4.37)
0.9751 –
12 months 201 215 8.40
(4.45 to 12.34)
2.21
(–1.70 to 6.12)
5.25
(0.69 to 9.81)
0.0246a 0.21
(0.02 to 0.40)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 5.06
(0.50 to 9.61)
0.0301a –
SF-12 mental health
4 months 214 219 1.99
(–0.61 to 4.58)
2.45
(0.04 to 4.87)
–0.57
(–3.68 to 2.53)
0.7176 –0.02
(–0.19 to 0.15)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.22
(–3.27 to 2.83)
0.8877 –
12 months 206 214 4.13
(1.17 to 7.08)
1.64
(–0.97 to 4.24)
2.26
(–1.15 to 5.67)
0.1943 0.12
(–0.07 to 0.31)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 2.29
(–1.16 to 5.74)
0.1941 –
a Statistically significant (p< 0.05).
TABLE 35 European Quality of Life-5 Dimensions mean scores at baseline, 4 and 12 months
Questionnaire Exercise programme, mean (SD) Usual care, mean (SD)
EQ-5D-3L health state 0.57 (0.29) 0.62 (0.25) 0.62 (0.24) 0.59 (0.26) 0.60 (0.28) 0.62 (0.25)
EQ-5D-3L VAS (your health today) 66.1 (19.4) 69.5 (19.4) 69.5 (17.8) 67.3 (18.1) 67.7 (18.5) 66.5 (19.8)
SD, standard deviation.
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TABLE 37 Pain troublesomeness mean scores at baseline, 4 and 12 months
Questionnaire Exercise programme, mean (SD) Usual care, mean (SD)
Pain troublesomeness overall score 46.0 (22.2) 39.8 (21.2) 38.9 (23.3) 48.5 (21.5) 43.9 (21.3) 43.5 (21.8)
SD, standard deviation.
TABLE 36 European Quality of Life-5 Dimensions mean change scores and treatment effects
EQ-5D-3L
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
EQ-5D-3L health statea
4 months 222 226 0.04
(0.01 to 0.07)
0.01
(–0.03 to 0.04)
0.02
(–0.02 to 0.06)
0.3650 0.10
(–0.06 to 0.27)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.02
(–0.02 to 0.06)
0.3813 –
12 months 214 220 0.03
(0.00 to 0.06)
0.02
(–0.01 to 0.06)
0.00
(–0.03 to 0.04)
0.8547 0.02
(–0.14 to 0.18)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.00
(–0.03 to 0.04)
0.8714 –
EQ-5D-3L VAS (your health today)
4 months 224 228 2.53
(0.11 to 4.96)
–0.01
(–2.33 to 2.32)
2.19
(–0.77 to 5.15)
0.1483 0.14
(–0.04 to 0.31)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 2.22
(–0.72 to 5.17)
0.1402 –
12 months 214 220 2.14
(–0.09 to 4.37)
–1.10
(–3.68 to 1.48)
3.13
(0.10 to 6.15)
0.0432b 0.17
(–0.01 to 0.35)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 2.51
(–0.47 to 5.50)
0.0995 –
a Full health= 1.0.
b Statistically significant (p< 0.05).
TABLE 38 Pain troublesomeness mean change scores and treatment effects
Pain
troublesomeness
overall scorea
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
4 months 215 224 –5.44
(–7.91 to –2.97)
–4.64
(–7.23 to –2.05)
–2.16
(–5.36 to 1.04)
0.1856 –0.04
(–0.20 to 0.13)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –2.70
(–5.91 to 0.50)
0.0993 –
12 months 206 217 –4.32
(–7.15 to –1.49)
–4.54
(–7.35 to –1.73)
–1.84
(–5.47 to 1.80)
0.3226 0.01
(–0.17 to 0.19)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –1.61
(–5.21 to 1.99)
0.3810 –
a Higher score=more pain.
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Impairment measures
There were inconsistent findings for between-group comparisons of the impairment measures. Some
found no difference between the groups whereas others found small improvements in favour of the
exercise programme group.
Strength
Both groups had improvements in strength, with the exercise programme group showing greater
improvements. Statistically significant between-group differences in favour of the exercise programme
were apparent at 4 months for power grip and at 12 months for pinch grip (Tables 41 and 42).
Range of movement and dexterity
Apart from composite finger extension, there were no statistically significant between-group differences
for ROM measures (Tables 43 and 44).
Dexterity improved to a greater extent in the exercise programme group at 12 months and this difference
was statistically significant compared with the usual care group. There was no significant difference
between groups in the short term (Tables 45 and 46).
TABLE 39 Self-efficacy mean scores at baseline, 4 and 12 months
Questionnaire Exercise programme, mean (SD) Usual care, mean (SD)
Self-efficacy
(confidence to manage
their condition)
67.0 (20.3) 74.2 (18.5) 73.7 (18.6) 68.7 (19.1) 71.2 (20.2) 70.3 (22.3)
SD, standard deviation.
TABLE 40 Self-efficacy mean change scores and treatment effects
Self-efficacy
(confidence
to manage
their
condition)
Number of patients Mean change (95% CI)
Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
4 months 216 226 5.78
(3.40 to 8.17)
2.04
(–0.10 to 4.19)
3.41
(0.53 to 6.29)
0.0209a 0.19
(0.03 to 0.35)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.38
(0.45 to 6.30)
0.0244a –
12 months 205 217 5.19
(2.45 to 7.92)
1.11
(–1.44 to 3.66)
3.80
(0.41 to 7.19)
0.0286a 0.21
(0.02 to 0.40)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.21
(–0.19 to 6.62)
0.0651 –
a Statistically significant (p< 0.05).
TABLE 41 Strength measure mean scores at baseline and 4 and 12 months
Measure Exercise programme, mean (SD) Usual care, mean (SD)
Full hand grip force (N) 134.2 (83.3) 152.7 (87.1) 156.6 (88.9) 130.3 (73.1) 139.2 (79.3) 145.0 (81.8)
Pinch grip force (N) 40.2 (21.1) 45.1 (22.2) 47.2 (25.0) 39.1 (19.6) 42.6 (21.1) 42.7 (20.8)
SD, standard deviation.
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TABLE 42 Strength measure mean change scores and treatment effects
Strength
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
Full hand grip force (N, greater score =greater strength)
4 months 195 205 15.55
(10.17 to 20.93)
7.35
(2.43 to 12.28)
8.59
(1.39 to 15.80)
0.0198a 0.10
(0.01 to 0.20)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 9.29
(2.01 to 16.57)
0.0129a –
12 months 171 184 15.77
(10.11 to 21.42)
9.57
(3.66 to 15.48)
6.55
(–1.60 to 14.69)
0.1160 0.08
(–0.03 to 0.18)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 6.41
(–1.87 to 14.70)
0.1303 –
Pinch grip force (N, greater score =greater strength)
4 months 192 204 4.29
(2.74 to 5.84)
3.15
(1.60 to 4.70)
1.29
(–0.87 to 3.46)
0.2413 0.06
(–0.05 to 0.16)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.57
(–0.59 to 3.73)
0.1547 –
12 months 169 182 5.33
(2.99 to 7.68)
2.35
(0.63 to 4.06)
3.16
(0.32 to 6.00)
0.0301a 0.15
(0.00 to 0.29)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 3.01
(0.13 to 5.88)
0.0411a –
a Statistically significant (p< 0.05).
TABLE 43 Range of movement measure mean scores at baseline and at 4 and 12 months
Measure Exercise programme, mean (SD) Usual care, mean (SD)
Active wrist flexion/extension
(degrees)
88.0 (29.6) 94.6 (28.7) 94.9 (29.8) 90.1 (31.7) 92.4 (32.2) 95.5 (30.9)
Combined finger flexion (mm) 13.0 (16.1) 9.4 (14.6) 9.1 (14.8) 12.8 (16.1) 9.7 (14.0) 10.2 (14.1)
Composite finger extension (mm) 21.3 (24.4) 26.4 (21.0) 27.6 (20.6) 20.2 (25.2) 21.8 (26.0) 21.7 (26.4)
Thumb opposition score 8.1 (1.9) 8.4 (1.8) 8.5 (1.8) 8.0 (2.1) 8.2 (2.0) 8.1 (2.0)
SD, standard deviation.
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TABLE 44 Range of movement measure mean change scores and treatment effects
ROM
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
Active wrist flexion/extension score (degrees; greater score =greater movement)
4 months 196 205 4.84
(2.65 to 7.02)
2.75
(0.63 to 4.87)
2.08
(–0.87 to 5.02)
0.1671 0.07
(–0.03 to 0.17)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 1.58
(–1.25 to 4.41)
0.2750 –
12 months 173 183 4.56
(2.13 to 7.00)
4.21
(1.73 to 6.68)
0.21
(–3.13 to 3.55)
0.9040 0.01
(–0.10 to 0.12)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.27
(–2.72 to 3.26)
0.8587 –
Combined finger flexion (mm; lesser score =greater movement)
4 months 194 204 –4.45
(–5.82 to –3.07)
–3.39
(–4.54 to –2.25)
–0.90
(–2.44 to 0.64)
0.2543 –0.07
(–0.18 to 0.05)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.93
(–2.43 to 0.58)
0.2281 –
12 months 172 183 –3.92
(–5.48 to –2.36)
–3.20
(–4.51 to –1.89)
–0.89
(–2.67 to 0.89)
0.3290 –0.04
(–0.17 to 0.08)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.64
(–2.40 to 1.13)
0.4793 –
Composite finger extension (mm; greater score =greater movement)
4 months 194 196 4.04
(1.98 to 6.09)
1.45
(–0.17 to 3.07)
2.82
(0.34 to 5.30)
0.0262a 0.10
(0.00 to 0.21)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 2.55
(0.05 to 5.04)
0.0068a –
12 months 171 175 4.81
(2.77 to 6.84)
1.45
(–0.76 to 3.65)
3.61
(0.73 to 6.50)
0.0147a 0.14
(0.01 to 0.26)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 4.05
(1.13 to 6.96)
0.0068a –
Thumb opposition score (greater score =greater movement)
4 months 196 207 0.31
(0.13 to 0.50)
0.18
(0.00 to 0.35)
–0.15
(–0.39 to 0.09)
0.2133 0.07
(–0.05 to 0.20)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.13
(–0.10 to 0.37)
0.2725 –
12 months 173 186 0.16
(–0.04 to 0.37)
0.12
(–0.07 to 0.30)
–0.10
(–0.36 to 0.15)
0.4233 0.02
(–0.11 to 0.16)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.10
(–0.16 to 0.36)
0.4416 –
a Statistically significant (p< 0.05).
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Disease activity
Comparisons of swollen and tender joint counts found a small to moderate effect of the exercise
programme compared with the usual care groups in the short term only (Tables 47 and 48). On average,
both groups achieve a one-point improvement, however the exercise programme participants achieve this
in a shorter time frame (within 4 months) compared with the participants in the usual care group
(within 12 months). No significant changes were reported for CRP and ESR levels either within or between
groups at all time points indicating a relatively stable RA population that were then unchanged within
and between groups.
Participant-rated improvement, benefit and satisfaction
The exercise programme group rated themselves as having greater global improvement in their hands and
wrists than the usual care group at both 4 and 12 months (Wilcoxon test, p< 0.0001) (Table 49). They
also reported significantly more benefit [p< 0.0001 (both categorical and ordinal) for both time points]
and greater satisfaction from trial treatments (4 months: p< 0.0001 categorical, p= 0.0198 ordinal;
12 months: p< 0.0001 categorical, p= 0.347 ordinal) than the usual care group at both 4 and 12 months
(Tables 50 and 51).
TABLE 45 Dexterity mean scores at baseline and 4 and 12 months
Measure Exercise programme, mean (SD) Usual care, mean (SD)
Dexterity: nine-hole peg test (seconds) 27.2 (8.2) 25.6 (7.3) 25.1 (6.3) 27.3 (9.4) 26.5 (8.6) 26.7 (10.6)
SD, standard deviation.
TABLE 46 Dexterity mean change scores and treatment effects
Dexterity:
nine-hole peg
test (seconds;
lesser score=
greater
dexterity)
Number of patients Mean change (95% CI)
Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
4 months 196 207 –1.39
(–1.97 to –0.81)
–0.74
(–1.50 to 0.03)
–0.72
(–1.61 to 0.17)
0.1151 –0.07
(–0.18 to 0.03)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.64
(–1.53 to 0.26)
0.1151 –
12 months 173 185 –1.33
(–1.86 to –0.80)
–0.09
(–0.92 to 0.74)
–1.26
(–2.26 to –0.27)
0.0134a –0.14
(–0.25 to –0.03)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –1.19
(–2.15 to –0.23)
0.0156a –
a Statistically significant (p< 0.05).
TABLE 47 Disease activity measure mean scores at baseline and 4 and 12 months
Measure Exercise programme, mean (SD) Usual care, mean (SD)
MCP joint deformity (degrees) 6.8 (8.4) 5.4 (6.4) 5.8 (7.7) 7.4 (9.4) 6.6 (8.4) 6.9 (9.7)
Swollen joint count 4.2 (4.8) 3.2 (4.6) 3.4 (4.9) 4.1 (4.8) 4.0 (5.3) 3.3 (4.6)
Tender joint count 5.0 (5.4) 3.4 (4.5) 3.9 (5.3) 4.8 (5.1) 4.4 (5.0) 3.8 (5.1)
SD, standard deviation.
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TABLE 48 Disease activity measure mean change scores and treatment effects
Disease
activity
Number of patients Mean change (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
MCP joint deformity (degrees; greater score =greater deformity)
4 months 196 202 –0.92
(–1.57 to –0.27)
–0.59
(–1.32 to 0.15)
–0.59
(–1.48 to 0.30)
0.1933 –0.04
(–0.15 to 0.07)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.66
(–1.53 to 0.21)
0.1357 –
12 months 172 183 –0.70
(–1.41 to 0.01)
–0.32
(–1.01 to 0.36)
–0.46
(–1.43 to 0.51)
0.3539 –0.04
(–0.15 to 0.07)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.56
(–1.50 to 0.37)
0.2369 –
Swollen joint count (both hands; greater score =greater number of joints affected)
4 months 196 209 –1.05
(–1.58 to –0.53)
–0.12
(–0.73 to 0.48)
–0.90
(–1.65 to –0.16)
0.0173a –0.19
(–0.36 to –0.03)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.87
(–1.50 to –0.23)
0.0077a –
12 months 174 186 –1.13
(–1.69 to –0.56)
–1.02
(–1.71 to –0.34)
–0.06
(–0.83 to 0.71)
0.8854 –0.02
(–0.21 to 0.16)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.07
(–0.74 to 0.61)
0.8844 –
Tender joint count (both hands; greater score =greater number of joints affected)
4 months 197 208 –1.27
(–1.86 to –0.68)
–0.38
(–1.02 to 0.27)
–0.92
(–1.68 to –0.16)
0.0177a –0.17
(–0.34 to 0.00)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –1.03
(–1.77 to –0.29)
0.0069a –
12 months 174 186 –0.96
(–1.69 to –0.23)
–1.15
(–1.86 to –0.43)
0.14
(–0.76 to 1.03)
0.7651 0.04
(–0.16 to 0.23)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.12
(–0.77 to 1.00)
0.7955 –
ESR (log transformation)
4 months 138 138 –0.04
(–0.15 to 0.07)
–0.09
(–0.20 to 0.02)
0.01
(–0.14 to 0.16)
0.9763 0.05
(–0.12 to 0.21)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.06
(–0.23 to 0.11)
0.4864 –
12 months 119 133 –0.04
(–0.18 to 0.10
–0.10
(–0.23 to 0.03)
0.02
(–0.16 to 0.20)
0.8300 0.06
(–0.14 to 0.26)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) 0.02
(–0.18 to 0.15)
0.8323 –
CRP (log transformation)
4 months 163 159 –0.04
(–0.11 to 0.19)
–0.18
(–0.32 to 0.03)
0.18
(–0.01 to 0.38)
0.0645 0.21
(0.01 to 0.41)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.32
(0.08 to 0.55)
0.0093a –
12 months 142 149 –0.14
(–0.29 to 0.02)
–0.12
(–0.29 to 0.05)
–0.08
(–0.28 to 0.12)
0.4385 –0.02
(–0.24 to 0.21)
Adjusted for centre, sex, age and drug groups (DMARD and oral steroids) –0.03
(–0.24 to 0.19)
0.8185 –
a Statistically significant (p< 0.05).
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TABLE 49 Self-rated improvement at 4 and 12 months by arm
Response
4 months 12 months
Exercise programme,
n (%)
Usual care,
n (%)
Exercise programme,
n (%)
Usual care,
n (%)
Completely recovered 1 (1) 1 (< 1) 3 (2) 2 (1)
Much improved 40 (19) 20 (9) 42 (20) 16 (7)
Slightly improved 72 (33) 43 (19) 47 (23) 27 (13)
No change 61 (28) 89 (40) 61 (30) 89 (41)
Slightly worsened 30 (14) 60 (27) 35 (17) 61 (28)
Much worsened 10 (5) 10 (5) 15 (7) 17 (8)
Vastly worsened 2 (1) 1 (< 1) 3 (2) 4 (2)
Total 216 224 206 216
TABLE 50 Participant perceived benefit/harm from trial treatments at 4 and 12 months by arm
Response
4 months 12 months
Exercise programme,
n (%)
Usual care,
n (%)
Exercise programme,
n (%)
Usual care,
n (%)
Substantial benefit 62 (28.8) 27 (12.6) 64 (31.4) 31 (14.6)
Moderate benefit 111 (51.6) 103 (47.9) 101 (49.5) 104 (48.8)
No benefit 33 (15.4) 83 (38.6) 34 (16.7) 76 (35.7)
Moderate harm 9 (4.2) 1 (0.5) 3 (1.5) 2 (0.9)
Substantial harm – 1 (0.5) 2 (1.0) –
Total 215 215 204 213
TABLE 51 Treatment satisfaction at 4 and 12 months by arm
Response
4 months 12 months
Exercise programme,
n (%)
Usual care,
n (%)
Exercise programme,
n (%)
Usual care,
n (%)
Extremely dissatisfied 15 (6.9) 6 (2.8) 15 (7.4) 8 (3.8)
Very dissatisfied 10 (4.6) 13 (6.0) 17 (8.3) 13 (6.1)
Somewhat dissatisfied 1 (0.5) 7 (3.2) 2 (1.0) 13 (6.1)
Neither satisfied nor dissatisfied 14 (6.5) 38 (17.6) 22 (10.8) 50 (23.5)
Somewhat satisfied 23 (10.7) 39 (18.1) 21 (10.3) 38 (17.8)
Very satisfied 94 (43.5) 83 (38.4) 79 (38.7) 70 (32.9)
Extremely satisfied 59 (27.3) 30 (13.9) 48 (23.5) 21 (9.9)
Total 216 216 204 213
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Hand exercise performance
Participants were encouraged to maintain their exercise routine once the exercise programme had finished.
As would be expected, the proportion of participants who reported performing hand and wrist exercises
was significantly greater in the exercise programme group than in the usual care group at both 4 and
12 months (p< 0.0001 at 4 months and p= 0.0185 at 12 months) (Table 52).
Medication usage
There were no significant differences in medication usage between the two groups at the two follow-up
time points. There were small numbers of changes to medication over the 12 months (Tables 53–56).
Secondary analyses
Subgroup analyses
Analyses of various subgroups were conducted including age, sex, disease activity, medication and various
baseline outcome measures. No statistically significant changes between subgroups were found (Table 57).
TABLE 52 Participants performing hand/wrist exercises to help with RA at 4 and 12 months by arm
Are you currently doing any
hand/wrist exercises to help
with your RA?
4 months 12 months
Exercise programme,
n (%)
Usual care,
n (%)
Exercise programme,
n (%)
Usual care,
n (%)
No 26 (12.0) 75 (33.9) 61 (29.8) 88 (40.7)
Yes (total) 190 (88.0) 146 (66.1) 144 (70.2) 128 (59.3)
Daily 95 (44.0) 65 (29.4) 32 (15.6) 47 (21.8)
3–4 times a week 56 (25.9) 40 (18.1) 47 (22.9) 37 (17.1)
1–2 times a week 23 (10.6) 32 (14.5) 49 (23.9) 39 (18.1)
Other 14 (6.5) 9 (4.1) 16 (7.8) 5 (2.3)
Blank 2 (0.9) – – –
Total 216 221 205 216
TABLE 53 Prescribed medication at each time point by arm
DMARD intensity
Baseline 4 months 12 months
Exercise
programme,
n (%)
Usual care,
n (%)
Exercise
programme,
n (%)
Usual care,
n (%)
Exercise
programme,
n (%)
Usual care,
n (%)
No DMARD medication 19 (7.7) 19 (7.9) 16 (7.6) 23 (10.3) 23 (10.9) 19 (8.8)
Single non-biologic
DMARD
103 (41.9) 118 (48.8) 83 (39.2) 110 (49.3) 74 (35.1) 95 (44.0)
Comb non-biologic
DMARDs
72 (29.3) 53 (21.9) 57 (30.7) 65 (21.5) 65 (30.8) 54 (25.0)
Biologic DMARDa 52 (21.1) 52 (21.5) 48 (22.6) 42 (18.8) 49 (23.2) 48 (22.2)
Oral steroids 49 (19.9) 52 (21.5) 39 (18.4) 45 (20.2) 42 (19.9) 40 (18.5)
NSAIDs 106 (43.1) 100 (41.3) 85 (40.1) 90 (40.4) 92 (43.6) 85 (39.4)
Analgesics 89 (36.2) 84 (34.7) 69 (32.5) 77 (30.0) 72 (34.1) 68 (31.5)
a Five patients in each arm were on rituximab at the start of the study; six in exercise programme and four in usual care
started rituximab at 0–4 months; eight in exercise programme and seven in usual care started rituximab at 4–12 months.
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TABLE 54 ‘As required’ medication at each time point by arm
Medication
Baseline 4 months 12 months
Exercise
programme,
n (%)
Usual care,
n (%)
Exercise
programme,
n (%)
Usual care,
n (%)
Exercise
programme,
n (%)
Usual care,
n (%)
Extra NSAID 9 (3.7) 15 (6.2) 10 (4.7) 13 (5.8) 12 (5.7) 9 (4.2)
Steroid tablet 2 (0.8) 5 (2.1) 1 (0.5) 3 (1.3) 3 (1.4) 2 (0.9)
Steroid injection
into joint
1 (0.4) – 5 (2.4) 1 (0.4) 1 (0.5) 2 (0.9)
Steroid injection
into muscle
2 (0.8) 3 (1.2) 2 (0.9) 8 (3.6) 4 (1.9) 1 (0.5)
TABLE 55 Change from no DMARD to DMARD at 4 and 12 months by arm
Change
Baseline to 4 months Baseline to 12 months
Exercise programme,
n (%)
Usual care,
n (%)
Exercise programme,
n (%)
Usual care,
n (%)
From no DMARD to DMARD 1 (0.5) 4 (1.8) 2 (0.9) 3 (1.4)
From DMARD to no DMARD 2 (0.9) 9 (4.0) 11 (5.2) 5 (2.3)
No change (on DMARD) 195 (92.0) 196 (87.9) 186 (88.2) 194 (89.8)
No change (not on DMARD) 14 (6.6) 14 (6.3) 12 (5.7) 14 (6.5)
TABLE 56 Change from no biologic to biologic DMARD at 4 and 12 months by arm
Change
Baseline to 4 months Baseline to 12 months
Exercise programme,
n (%)
Usual care,
n (%)
Exercise programme,
n (%)
Usual care,
n (%)
From no biologic DMARD to
biologic DMARD
9 (4.2) 4 (1.8) 12 (5.7) 6 (2.8)
From biologic DMARD to no
biologic DMARD
4 (1.9) 6 (2.7) 6 (2.8) 4 (1.9)
No change (not on biologic
DMARD)
160 (75.5) 175 (78.5) 156 (73.9) 164 (75.9)
No change (on biologic DMARD) 39 (18.4) 38 (17.0) 37 (17.5) 42 (19.4)
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TABLE 57 Subgroup analyses
Subgroup
4 months 12 months
n (combined
groups)
Treatment effect
(95% CI)
p-value for
difference
between
subgroups n
Treatment effect
(95% CI)
p-value for
difference
between
subgroups
Time since diagnosis (years)
< 5 116 6.57 (1.25 to 11.90) 115 6.08 (0.22 to 11.94)
≥ 5 284 3.08 (–0.15 to 6.31) 0.2588 276 3.72 (0.21 to 7.22) 0.4822
< 10 200 4.17 (0.13 to 8.21) 193 3.79 (–0.61 to 8.19)
≥ 10 200 3.91 (0.09 to 7.73) 0.9264 198 4.58 (0.38 to 8.78) 0.7969
Baseline MHQ overall function
< 52.5 220 5.08 (1.57 to 8.59) 210 3.89 (–0.32 to 8.10)
≥ 52.5 229 4.09 (0.55 to 7.62) 0.6953 228 4.75 (0.97 to 8.53) 0.7632
Age (years)
< 60 147 3.86 (–1.23 to 8.95) 142 4.69 (–0.73 to 10.12)
≥ 60 302 5.25 (2.10 to 8.41) 0.6323 296 4.07 (0.65 to 7.50) 0.8443
Type of referral
Clinic referrals 363 5.51 (2.49 to 8.53) 353 4.15 (0.94 to 7.35)
Review list mail-out 86 1.19 (–4.63 to 7.00) 0.2120 85 5.14 (–1.63 to 11.92) 0.7884
Gender
Male 106 5.81 (–0.12 to 11.73) 102 5.24 (–1.94 to 11.43)
Female 343 4.36 (1.36 to 7.36) 0.6528 336 4.10 (0.82 to 7.38) 0.7428
Baseline ESR (mm/hour)
< 16 166 4.30 (–0.30 to 8.90) 166 6.04 (1.54 to 10.54)
≥ 16 174 5.18 (0.80 to 9.56) 0.7853 168 1.89 (–2.83 to 6.61) 0.2102
Baseline CRP (mg/l)
< 6 197 3.29 (–0.61 to 7.19) 192 4.37 (–0.06 to 8.79)
≥ 6 197 5.52 (1.30 to 9.74) 0.4437 190 4.90 (0.40 to 9.40) 0.8668
SF-12 PCS (points)
< 34 225 6.36 (2.48 to 10.23) 220 4.18 (0.13 to 8.24)
≥ 34 223 2.95 (–0.73 to 6.64) 0.2110 217 4.86 (0.74 to 8.98) 0.8179
SF-12 MCS (points)
< 50 225 5.51 (1.71 to 9.31) 217 4.98 (0.75 to 9.21)
≥ 50 224 3.79 (0.00 to 7.59) 0.5290 221 3.78 (–0.19 to 7.75) 0.6825
Baseline DMARD therapy summary
Biological 92 1.97 (–3.80 to 7.75) 92 4.70 (–1.12 to 10.52)
Combination
non-biological
116 8.44 (2.47 to 14.41) 114 6.20 (–0.09 to 12.49)
Single non-biological 205 2.82 (–0.94 to 6.58) 199 4.20 (0.10 to 8.50)
No DMARD 35 8.51 (–0.96 to 17.98) 0.2390 33 –1.84 (–12.04 to 8.37) 0.6261
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Examination of the effect of subgroups on treatment compliance in the exercise programme group found
that participants with increased age, disease activity (CRP) and SF-12 mental score were more likely to have
attended all six sessions (Table 58). Note that no group has less than 60% adherence and this was not a
pre-planned analysis.
Treatment preference
Analysis of participants’ baseline treatment preferences reveals that the primary treatment effect was
higher (non-significantly) in the group of participants who expressed a preference to receive the exercise
programme (Table 59).
Primary outcome by level of treatment compliance
The CACE estimates based on full attendance are slightly larger than the overall trial estimates at 4 and
12 months (Table 60). The CACE estimates based on the lower compliance threshold were close to the
overall trial effect.
Therapist effects
The main therapist was defined as the individual who was the therapist for the initial (assessment) session.
A therapist was identified for 469 participants; for 10 participants no treatment log was available,
five participants did not attend a session and for four participants no therapist was identified.
The primary outcome was modelled adjusting for baseline score, age, sex and centre. There was no
significant therapist effect at 4 or 12 months (intraclass correlation coefficient= 0.00, p= 0.3106 and
p= 0.4561 respectively).
Prospectively it was decided to try an alternative definition of the therapist, i.e. for the exercise programme
arm, using the therapist who took the second session (first exercise session). Fifty-one participants who had
a first exercise session had a different therapist from the one at assessment. The results of the analysis
were very similar to that of the main therapist.
Multiple imputation analysis
A multiple imputation analysis was conducted to investigate the effect of missing data on the overall
treatment effect for the primary outcome. The trial design allowed for a maximum of 25% missing primary
outcome at 12 months. The actual rates achieved were considerably better at 12.2% in the exercise
programme arm and 8.3% in the usual care arm. The 4% difference in these is small enough to make it
unlikely to have a marked effect on the results.
In this multiple imputation analysis, the following baseline variables were used to estimate the primary
outcome at 4 months and 12 months: age, SF-12 PCS, SF-12 MCS, troublesomeness of pain scale,
confidence scale, ESR, CRP, finger joint deformity score, ROM summary score, combined finger flexion
summary score, composite finger extension summary score, thumb opposition score, swollen joints score,
tender joints score, dexterity score, full-grip strength score, pinch-grip strength score and DMARD
intensity score.
As can be seen in Table 61, the analysis resulted in a slight reduction in the effect sizes at both 4 and
12 months as compared with the original analysis (treatment effect 4.6, 95% CI 2.22 to 6.97 and 4.35,
95% CI 1.60 to 7.10 respectively).
Repeated measures
To account for taking repeated measurements at various time points, a repeated measures analysis was
conducted and adjusted for hospital, age and sex. Compared with the original analysis at 4 and
12 months, the results indicate virtually no difference between the two analyses (Table 62).
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TABLE 58 Treatment compliance by subgroup (exercise programme group)
Subgroup
< 6 sessions 6 sessions
p-valuen (%) n (%)
Baseline MHQ
Baseline MHQ overall function < 52.5 (median) 34 (27.4) 90 (72.6)
Baseline MHQ overall function ≥ 52.5 (median) 28 (23.0) 94 (77.0) 0.42
Time since diagnosis
< 5 years 12 (19.7) 49 (80.3)
≥ 5 years 39 (24.8) 118 (75.2) 0.42
< 10 years 23 (21.1) 86 (78.9)
≥ 10 years 28 (25.7) 81 (74.3) 0.42
Age
< 60 years 31 (33.0) 63 (67.0)
≥ 60 years 31 (19.1) 131 (80.9) 0.03a
Gender
Female 47 (25.0) 141 (75.0)
Male 15 (25.9) 43 (74.1) 0.89
Disease activity
ESR < 16mm/hour (median) 25 (26.6) 70 (73.4)
ESR ≥ 16 mm/hour (median) 28 (30.1) 65 (69.9) 0.56
CRP< 6 mg/l (median) 21 (18.7) 91 (81.3)
CRP≥ 6mg/l (median) 33 (30.8) 74 (69.2) 0.04a
SF-12 PCS
< 34 (median) 35 (28.0) 90 (72.0)
≥ 34 (median) 27 (22.3) 94 (77.7) 0.30
SF-12 MCS
< 50 (median) 42 (32.6) 87 (67.4)
≥ 50 (median) 20 (17.1) 97 (82.9) 0.005a
Recruitment method
Clinic referral 53 (26.8) 145 (73.2)
Rheumatology or therapy review list mail-out 9 (18.7) 39 (81.3) 0.25
Medication
Biologic DMARD 15 (28.8) 37 (71.2)
Combination non-biologic DMARD 16 (22.2) 56 (77.8)
Single non-biologic DMARD 24 (23.3) 79 (76.7)
No DMARD 7 (36.8) 12 (63.2) 0.52
a Statistically significant (p< 0.05).
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TABLE 59 Primary outcome by treatment preference and group allocation
Preference
4 months 12 months
Exercise
programme
Usual
care
Mean
treatment
difference
(95% CI) p-value
Exercise
programme
Usual
care
Mean
treatment
difference
(95% CI) p-value
Usual care
or ‘do
not mind’
130 137 2.79
(0.50 to 6.08)
0.0974 125 136 2.39
(1.28 to 6.05)
0.2024
Exercise
programme
90 89 7.30
(4.01 to 10.60)
0.0001 89 85 7.25
(3.10 to 11.40)
0.0008
Interaction p-value for difference in treatment effect between preference groups 0.0913
TABLE 60 Exercise programme compliance compared with primary outcome (CACE analysis)
Threshold attendance
Treatment effect, points on MHQ overall hand function (95% CI)
4 months 12 months
≥ 3 sessions 5.06 (2.97 to 7.18) 4.59 (2.34 to 6.81)
≥ 6 sessions 5.84 (3.43 to 8.27) 5.23 (2.62 to 8.01)
TABLE 61 Multiple imputation analysis for primary outcome
4 months 12 months
Treatment effect (95% CI) p-value Treatment effect (95% CI) p-value
4.06 (1.36 to 6.76) 0.0032 4.09 (1.11 to 7.07) 0.0074
TABLE 62 Repeated measures analysis for primary outcome
4 months 12 months
Treatment effect (95% CI) p-value Treatment effect (95% CI) p-value
4.55 (1.90 to 7.19) 0.0008 4.32 (1.46 to 7.17) 0.0032
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Adverse events
During the recruitment and follow-up period, 103 SAEs were reported to the trial team (Table 63). SAEs
were classified through discussions with local principal investigators and the trial lead. As much information
as possible was requested from the participant when a potential adverse event was noted, particularly
with regard to likelihood of cause of trial treatment. No SAEs were deemed both unexpected and related
to the trial involvement and therefore were not communicated to the MREC. The categories of SAE,
likelihood of relatedness and reasons are summarised in Table 64.
TABLE 63 Summary of SAEs by trial arm
Relatedness of SAE Exercise programme, n (% of patients in arm) Usual care, n (% of patients in arm)
Unrelated 27 (11) 43 (17)
Unlikely 18 (7) 13 (5)
Possibly 0 (0) 2 (< 1)
Total 45 (18) 58 (24)
TABLE 64 Categories and reasons for SAEs by trial arm
Category
of SAE
Usual care Exercise programme
Likelihood of
relatednessa (n) Reasons for SAE (n)
Likelihood of
relatednessa (n) Reasons for SAE (n)
Death Unrelated (2) Cancer, Parkinson’s disease Unrelated (0) NA
Life-threatening
condition
Unrelated (1) Terminal illness Unrelated (2) Terminal illness (2)
Hospitalisation Unrelated (3) Stroke, fractured
wrist, mastectomy
Unrelated (7) Chest pain, foot surgery,
fractured elbow, fractured
wrist, septic knee replacement,
stress fracture calcaneum,
general body flare of RA
requiring infusion
Medical
intervention
Unrelated (1) Steroid injection for flare Unrelated (1) Steroid injection for flare
Disability Unrelated (20) Flare of RA affecting whole
body (18), flare of RA in
hands with associated
increased disease activity (2)
Unrelated (33) Flare of RA affecting whole
body (24), flare of RA in hands
with associated increased
disease activity (2), flare of RA
due to stopping or changing
medication (2), flare in RA in
hands due to weather (1), flare
in RA in hands due to stress (1),
flare of RA in hands due to
reaction to food (1), fractured
leg (1), gout (1)
Unlikely (18) Flare of RA affecting whole
body (2), flare of RA in
hands/wrists reason
unknown (16)
Unlikely (13) Flare of RA due to increase in
activity outside trial (1), flare of
RA in hands/wrists reason
unknown (12)
Possibly (0) NA Possibly (2) Cervical spine and arm
symptoms, flare of RA in hands
NA, not applicable.
a There were no SAEs recorded as definitely or probably related to trial involvement.
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Chapter 5 Qualitative study
Introduction
This qualitative study was carried out to gain insight into participants’ experiences of the SARAH
intervention with a group of individuals within the exercise programme arm of the main trial. We explored
their experiences of the intervention at 4 and 12 months post randomisation and in particular examined
how the trial intervention translated into daily life after they completed their therapy sessions. Our
objectives were to:
l explore the participants’ experience of taking part in the SARAH trial, including their satisfaction and
its acceptability
l explore how participants gauged the effectiveness of the SARAH intervention
l explore the use of strategies used to improve adherence and facilitators and barriers to the SARAH
exercise programme.
Methods
Sampling procedure
The interview study was carried out at four acute NHS trusts taking part in the SARAH trial; one trust
yielded no eligible interview candidates. Trial participants were approached to take part in the interviews
at their 4-month assessment. Willing participants were given an information sheet and verbal consent
obtained for the interview researcher to telephone them if they were eligible for interview. As the
assessors were blind to treatment allocation, all participants were informed about the interviews, but only
those receiving the trial intervention were eligible for interview. Purposive sampling was done using the
4-month questionnaire, aiming to interview up to 10 participants who rated themselves as having
benefited and up to 10 participants who had not benefited from the intervention in order to gain a range
of experiences. Recruitment continued for approximately 1 year. Those eligible for interview were
contacted by one of the researchers carrying out the interviews (EW and VN) and a convenient time and
venue booked. At the beginning of the interview visit the researcher answered any questions arising from
the information sheet and took written consent for the interview study (see Appendix 7).
Interviews
Five pilot interviews were carried out during the trial pilot study. These interviews informed the initial
interview schedule and are not included in the analysis. Some changes were made to the interview
schedule as the study progressed in response to the completed interviews, which is in line with an
interpretative phenomenological analysis (IPA) approach (see Appendix 8 for interview schedules). Two
researchers carried out the interviews, EW carried out the pilot and first six 4-month interviews and VN the
remainder of the 4-month and all the 12-month interviews. Researcher notes were written immediately
after the interviews to capture the researchers’ thoughts on the interviews and promote reflexivity across
cases. Interviewees were given a pseudonym for anonymity.
Analysis
Analysis was carried out using IPA,104 which has been recommended as a suitable approach to investigate
how an individual perceives a situation or to explore the meaning of particular events, experiences and
states for the individual.105 This approach has been used successfully to describe the experiences of patients
with musculoskeletal problems such as chronic low back pain.106 IPA does not require the testing of a
hypothesis but allows the researcher to carry out exploratory work, thus reflecting the aims of this study.105
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All interviews were recorded using an Olympus DM10 digital voice recorder (Olympus Corporation,
Shinjuku, Tokyo, Japan), transcribed verbatim, anonymised and checked by the interviewer. All transcripts
were entered into NVivo, a computer software tool for managing qualitative data (NVivo V9, QSR,
Portsmouth, UK).
The first six interviews by EW were used to explore passages of the data from which initial codes were
developed. Codes were given definitions which were refined and ‘sharpened’ as the study progressed.
EW and VN worked in collaboration to merge similar codes. Coding was also discussed with another
experienced qualitative researcher (FT). After six interviews were completed, the 4-month interview codes
were examined again by VN and FT and codes were grouped into four main headings. Subthemes and
emergent themes across codes were explored with participant number counts. Analysis also involved
cross-case comparisons to identify similarities and differences in the data.
Before each 12-month interview the 4-month transcripts and researcher notes were reread and additions
made to the 12-month schedules which were specific to the individual. Interesting or ambiguous ideas and
phrases were further explored in line with an IPA approach.
Results
Ten participants who had rated themselves as having benefited were identified (four males and six females)
but only four participants who had rated themselves as having no benefit (three females and one male)
were identified from the four NHS trusts (Figure 6).
Fourteen trial participants were interviewed after their 4-month follow-up appointment. Twelve were
interviewed at home and two at their workplace. Interviews followed a semistructured schedule and lasted
54 minutes on average. Thirteen interviews were carried out at 12 months (one trial participant declined
for personal reasons) and lasted 46 minutes on average. Eleven of these interviews were carried out at
home and two at their workplace.
Baseline characteristics of those interviewed were compared with those in the trial intervention arm
(n= 246) of the total 490 trial participants (Table 65). The educational level groups showed a similar
percentage of people with no qualifications. The interview study had a higher proportion of males to
females and a higher number in employment. The mean of the MHQ scores of the interviewees showed
slightly less disability although the standard deviation was similar.
The findings are presented in seven sections:
l acceptability and adherence to the SARAH intervention
l establishing a routine: the key to success
l the SARAH therapist: from teacher to facilitator
l barriers to the SARAH exercises
l gauging the personal effectiveness of the SARAH intervention
l everyone is different; reasons the SARAH intervention might be effective for some people and
not others
l suggested changes to the SARAH intervention.
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TABLE 65 Interviewee characteristics compared with intervention arm trial participants
Characteristic Trial participants Interview study participants
Age
Mean (SD), range (years) 61.3 (12.4), 27–94 61.4 (11.8), 44–82
Mean years since diagnosis
Mean (SD), range (years) 13.1 (10.7), 0–43 13.2 (11.9), 1–36
Gender, n (%)
Male 58 (23.6) 5 (35.7)
Female 188 (76.4) 9 (64.3)
Ethnicity, n (%)
White 238 (96.7) 14 (100.0)
Other 8 (3.3) 0 (0)
Marital status, n (%)
Single 24 (9.7) 1 (7.1)
Married 157 (63.8) 9 (64.3)
Separated 4 (1.6) 0 (0)
Divorced 19 (7.7) 1 (7.1)
Widowed 28 (11.4) 3 (21.4)
Cohabiting 14 (5.7) 0 (0)
Employment status, n (%)
Full-time employed 29 (11.8) 2 (14.3)
Part-time employed 26 (10.6) 2 (14.3)
Self-employed 11 (4.5) 1 (7.1)
Unpaid work 3 (1.2) 0 (0)
Unemployed 12 (4.9) 1 (7.1)
Looking after home 24 (9.8) 1 (7.1)
Retired/inactive 141 (57.3) 7 (50.0)
Educational level, n (%)
Higher degree 26 (10.9) 1 (7.1)
NVQ4/5/degree or equivalent 18 (7.5) 3 (21.4)
Higher education below degree 23 (9.6) 1 (7.1)
NVQ3/GCE A-level equivalent 18 (7.5) 1 (7.1)
NVQ2/GCE O-level equivalent 41 (17.2) 2 (14.3)
NVQ1/CSE other grade equivalent 24 (10.0) 1 (7.1)
Foreign/other 9 (3.8) 0 (0)
No qualification 80 (33.5) 5 (35.7)
Missing 7 (2.8) 0 (0)
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Acceptability and adherence to the Strengthening And stretching for
Rheumatoid Arthritis of the Hand intervention
Acceptability of the Strengthening And stretching for Rheumatoid Arthritis
of the Hand intervention
The SARAH intervention was well received, all 14 interviewees said they were satisfied with the
programme and that they would recommend it to others. Although acceptability of the intervention as a
whole was high, the interviewees did express preferences about the different elements of the programme
and some elements worked better than others for different individuals.
The exercises
Half of the interviewees spoke of how easy the exercises were to understand and perform and eight spoke
of the guidance and progression they had been given.
. . . so it was nice to start off at a level that you could cope with and then increase gradually as you
went along.
Samantha; 4 months
There were more comments given about the exercises with the trial equipment which consisted of a
selection of balls, putty and Theraband which provided different levels of resistance. The exercises involving
the equipment often made interviewees split their exercises into those with and without equipment:
The easier ones from a personal point of view are the stretching ones. They’re quite good and you can
do those when you’re . . . even in a meeting. They’re dead easy and after a bit you just . . . It becomes
part of the routine. The ones that are less easy to fit in all of the time are the strengthening ones,
which are the ones that I need to do more often I think because I want greater strength.
Kate; 4 months
The ball exercise was well received by twelve interviewees. Three of these spoke about changing the
progression of the exercises:
. . . because as you got better, as you see, you could move from one up to a harder one and like at
the weekend, I could go back onto the easier one you see, so it did help.
Harry; 4 months
TABLE 65 Interviewee characteristics compared with intervention arm trial participants (continued )
Characteristic Trial participants Interview study participants
Medication intensity group, n (%)
Biologic DMARD therapy, n (%) 52 (21.1) 3 (21.4)
Combination non-biologic DMARD, n (%) 72 (29.3) 2 (14.3)
Single non-biologic DMARD, n (%) 103 (41.9) 8 (57.1)
No DMARD, n (%) 19 (7.7) 1 (7.1)
Michigan Hand Questionnaire baseline score 0 (worst)–100 (best)
Mean (SD), range (points) 50.7 (16.3), 15–93 58.3 (16.8), 28–88
A-level, Advanced level; CSE, Certificate of Secondary Education; GCE, General Certificate of Education; NVQ1, National
Vocational Qualification – level 1; NVQ2, National Vocational Qualification – level 2; NVQ3, National Vocational
Qualification – level 3; NVQ4, National Vocational Qualification – level 4; NVQ5, National Vocational Qualification – level 5;
O-level, Ordinary level; SD, standard deviation.
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One interviewee spoke about the balls being therapeutic:
In fact, that was therapeutic so that was quite nice. That’s when you get your stress balls don’t you?
It’s a bit like that in a way.
Samantha; 4 months
Eleven interviewees commented on the putty exercises, which were well received by four individuals:
I think they [putty exercises] worked really well and they’re not too much. They’re not too complicated
and once you get into the pattern of them.
Lucy; 4 months
Six interviewees spoke about difficulties regarding these exercises, three in general terms, and two had
had to stop the putty exercises early on:
Well, I tried it for a couple of weeks but I couldn’t manage it, you know. It was just too difficult
for me.
Sally; 4 months
One interviewee said that the difficulty was more to do with time and location:
I guess the greatest difficulty for me is actually making sure I could fit it into my day and particularly
the ones where we were using the putty. Which actually do take longer to do and do require a slightly
different environment.
Sadler; 4 months
One individual spoke of their difficulty and dislike for the exercise:
. . . the one I really don’t like, but I do is this one. You have to squeeze between the knuckles sideways
like that and that is really quite . . . It’s not nice to do . . . It’s hard, it’s difficult.
Samantha; 4 months
One interviewee questioned the value of this exercise:
It was the only one that I found . . . You know, I couldn’t really see what it was actually doing for you,
that one.
Joe; 4 months
Twelve interviewees commented on the Theraband exercise. Seven encountered some difficulties but had
continued with them, sometimes at a lower repetition level. Some found the exercise harder to do than
the others or that it could cause discomfort:
It was just more difficult.
Emily; 4 months
Two individuals actively disliked doing them:
Well, I hate the band. I still hate it now . . . I find that really uncomfortable . . . Yes, the actual exercise.
I don’t like it at all and I still don’t. That’s the one . . . if I miss anything out, that’s the one I won’t do
because I don’t like it.
Kate; 4 months
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Two interviewees said it caused them pain:
It hurts and it doesn’t matter how we try it, it hurts . . . We just did very few. We just kept it really low
and it just felt difficult.
Alice; 4 months
However, five interviewees had no problems with these exercises and one talked of liking a the
progression of different bands:
It was a bit of a challenge, because I think I’ve now got a full range of everything because I’ve worked
my way through and it was almost like an unsaid thing in my mind . . . I think I’ve got about three
bands, four balls. I’ve got all of the stuff now because I gradually . . . and that was another positive in
terms of because I was progressing.
Sadler; 4 months
The exercise booklet
The SARAH exercise booklet was mentioned by nine interviewees. Eight said it was useful and helped
their technique:
I thought that was nicely presented. I thought it was very user friendly. It was done in such a way that
I’ve always been able to read it and access it and with the visual cues and the fact that you’re
shown . . . You can look at it as a picture and you can actually watch somebody in practice and I
thought it was good.
Kate; 4 months
One person did not use the booklet:
To be quite honest, I didn’t really use it because I went through the exercises with [SARAH therapist]
and then I went through them again the next week to make sure that I was doing them properly, so
to be quite honest I didn’t really use the book at all.
Sally; 4 months
Completing the personal exercise guide
The personal exercise guide (PEG) promoted discussion around joint goal setting, the time and place of
exercise and the participants’ confidence to do the exercises as set. When exercises were not completed,
possible barriers to doing the exercises were explored. Both therapist and participant signed the PEG as a
form of contract.
I think having that marker and actually trying to build it into your routine, which was a piece coming
out in terms of right, okay create that commitment in terms of the contract and saying right, when are
you going to do it, where are you going to do it, and actually building some of those key elements
definitely for me works . . .
Sadler; 4 months
Thirteen interviewees spoke about goal setting. Six did not find goal setting useful:
Now I’m more and more aware that everybody keeps saying ‘You’ve got to set goals that you feel
you’re achieving.’ No, I’m sorry. For me personally it’s not a big thing.
Lizzy; 4 months
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However, five found goal setting useful:
. . . think it was a good idea. You know, it’s something to strive for and you get a bit of feeling for life
and if you don’t have a goal to go for then I think it’s half the battle really isn’t it?
Joe; 4 months
Two were unsure:
I’m not sure really. I suppose it gives you something to focus on and at the time when I did it, she
asked me in the first session and then we wrote it down in the second session. So, whilst I was talking
to her I thought, ‘I don’t know.’ You know, ‘I don’t really know what I want to achieve.’ But when
you come home and you start doing things and then you realise what you can’t do and how you
would like to do things slightly better.
Sally; 4 months
Daily diary sheets
Daily diary sheets were considered helpful by 10 interviewees, especially in the early stages of establishing
the exercises. These were introduced in the PEG and were helpful in different ways, some interviewees
spoke of more than one of these. Nine of these 10 interviewees said the sheets were useful for keeping
track of their exercises and two said that it acted as a reminder:
[the diary sheets] made sure that you’d done them and you hadn’t forgotten, you know. I know now
exactly what I have to do, so I needn’t fill it in every time now.
Harry; 4 months
Two spoke of the sheets making them accountable to the therapist:
What it did give me the opportunity to do was record where I’d modified the exercises. Report back to
the therapist. Not for me.
Bert; 4 months
One interviewee said it helped to motivate them:
. . . it also gives you that motivation, because you can actually look at that and think hey, I actually
done pretty well this week.
Sadler; 4 months
Adherence to the Strengthening And stretching for Rheumatoid Arthritis of
the Hand intervention
Most interviewees managed to keep with their exercise programme, a majority at 4 months and just over
half at 12 months. Eleven of the interviewees were still doing their exercises at 4 months, the majority
because they had gained or were hoping to gain some benefit, and three interviewees said their exercises
had become a habit. Doing exercise was deemed to be proactive by some, and three were doing them in
part because they had committed themselves to the trial. Two main reasons for non-compliance emerged
from the narrative: first, when hand function was felt to be too good to benefit from the exercise and,
second, when an increase in symptoms prohibited exercise.
At 12 months, 7 of the 13 interviewees were still doing their exercises, although sometimes extensively
reduced or modified, with only Harry and Joe keeping to their full regime:
. . . what I actually put it down to is not having to go back to the hospital, and have that follow-up
and have the exercises reassessed, and tailored a little bit upwards or downwards, depending on how
it goes. So I haven’t almost got to complete my homework and hand it in, and obviously the impact
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of work. Those are the real two key factors in terms of trying to fit things in. So where on average I
would probably say I was doing my exercises four or five times a week, at around that . . . I would say
I was probably now down to three times every fortnight.
Sadler; 12 months
Of the six who were no longer exercising, four gave reasons similar to the first interviews; their hand
function being too good or their symptoms preventing them. Two had other medical comorbidities which
impacted on their symptoms and their ability to exercise e.g. gout and a thyroid operation. The three
interviewees who were not exercising at 4 months were still not exercising at 12 months for the
same reasons.
Establishing a routine: the key to success
It was very clear from the narratives that establishing a routine was the key to successfully carrying out the
SARAH exercises. Some interviewees found that establishing a routine was easier to do than others and
they employed different strategies or ways of doing this.
‘Fitting in’ exercise into life
Some found it easy to fit exercise into their lives and established a routine:
I always believe in getting things done early of a morning. I’ve always done that, so it was the best
way of doing it.
Joe; 4 months
Ten interviewees spoke of differing adaptations they had adopted in order to establish a routine. They
described changes in the exercise programme itself (n= 6), the timing of when they chose to exercise
(n= 7) or the location in which they did them (n= 2). Sometimes these modifications were in response to
their symptoms:
Sometimes it will be the quantity I have changed. Sometimes I’m not able to do as much and
other times I know I can do more and it may be for a week or 2 weeks that I can actually do more.
[. . .] What else have I changed? I don’t always do them in the same routine. I get bored of the routine
. . . I start off with the first two because the second one can be particularly painful, so I like to get that
one over and done with.
Lizzy; 4 months
Others spoke about the difficulty this sometimes presented:
Introducing it into the routine and being able to manage time was probably the key difficulty.
Lizzy; 4 months
Three spoke of strategies they employed to facilitate this change in routine, some combining them with
other activities such as back exercises and others of leaving reminders to prompt themselves:
It’s quiet. There’s nobody else there. It’s peaceful and I often whip through them and I do my spinal
exercises then as well.
Kate; 4 months
Of the 11 still doing the exercises at 4 months, four had continued with their original programme of
exercises at one sitting. Three had found it more convenient to split them into two daily sessions. The
other four had modified them by doing them throughout the day:
I was terribly, terribly organised at first and I would come in in the evening before I started cooking
supper and I would go through the whole lot of exercises, but then sometimes I was late getting in
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from work or I had to get the girls somewhere and actually, it started to become quite difficult and
you’d think 20 minutes out of a day isn’t that much, so that’s when we started to . . . and also I was
finding if I was stiff and sore and it was actually the occupational therapy [SARAH therapist] who said
you can break it down. You don’t have to do them all at once, so I took that to heart and actually it
did make it so much easier.
Alice; 4 months
At 12 months, only two had kept to their original set of exercises, but most had further modified their
exercises to fit them into their life in a more flexible way:
Now I have done the routine so much that I know what the sets are, so I tick the day that I have done
them and then I put a half tick if I have done some but haven’t had time to do all of them, because if
it’s for example, weekend and the routine changes . . . So you might only have half a set done on a
particular day, but then other days normally, say, especially in the week it is better for a routine, you
know you can go through and do the whole daily exercise list . . .
Samantha; 12 months
Exercise becoming a habit
Three spoke about their routine becoming a habit. A habit seemed to be different from a routine – it was
suggestive of behavioural change and the subconscious habituation of including exercises in their lives:
Introducing it into the routine and being able to manage time was probably the key difficulty, but
building that piece in terms of right, this is an activity that is now inbred within your general activity of
a day and it becoming a habit is then just something that now evolves through naturally, and I think
that’s a key difference for me.
Sadler; 4 months
The Strengthening And stretching for Rheumatoid Arthritis of the Hand
therapist: from teacher to facilitator
Interviewees were not directly asked about their relationship with the SARAH therapist. However, they
offered insights into their interactions and the therapist’s role in helping them to exercise. Eight
interviewees spoke about the therapist in the interviews. All their encounters were spoken about in a
positive context and suggested that a good rapport was attained. The SARAH therapist was integral to the
interviewees’ ability to establish their exercise routine. The therapist was portrayed as a collaborator who
helped participants to exercise in the right way, at a time and routine which was negotiated with
the individual:
I mean [the SARAH therapist] took a lot of time. I felt she spent a lot of time with me on each session
making sure that I understood and could do the exercises.
Sally: 4 months
Interviewees provided examples of how the therapist facilitated their adherence with the exercise
programme. Interviewees said that therapists were motivational and reassuring and provided feedback on
how they were doing:
Having that weekly contact is certainly a huge motivator and it tends to make it much more of a focus
in sort of the week and then when you’re sort of cut loose and you’re left to your own responsibilities
you have to be really, really motivated.
Alice; 4 months
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During the therapy sessions interviewees were encouraged to discuss their progress (or regression) and the
therapist tailored the programme, progressing them when able and giving follow-up advice as needed.
The therapist monitored exercises for accuracy and suitability:
The first time you’re shown them and the physiotherapist does them with you and shows you how to
do them and then the next time you go back she’s sitting there and we were doing them together
and then after that, it was down to see how well had I improved, or not improved and how perhaps
there was a technique I could use that would be a little bit different.
Lizzy; 4 months
Four interviewees spoke of the therapist tailor-making their exercises rather than a ‘one size fits all’, which
was appreciated:
She’s so lovely and she was so kind to me and the fact that they’re all sort of modified to suit. You
know, it wasn’t that you had this goal that if you didn’t achieve X amount of exercises you couldn’t
carry on. It was all how much I could do, so once I found out I was quite excited because I thought it
could only help me. It couldn’t do any harm.
Alice; 4 months
The therapist provided input throughout the course of the programme but the role of the therapist varied
at the different stages and in response to the needs of the patient. Initially exercises were taught but the
PEG introduced behavioural elements which the therapist and patient signed up to. The therapist’s role
changed from a teacher of exercise to a collaborator and facilitator through shared goal setting and
reviewing how the exercises had or had not been carried out. Barriers were explored, problems solved and
new goals were set if appropriate.
The type of exercise provision given was new to many interviewees as seeing a therapist for detailed
exercise advice was not a common experience. Five people said that they had had varied or sporadic advice
about exercising from different disciplines through the rheumatology clinic, however over half felt that
they had had no specific advice about exercise:
No one has really given me advice about exercise . . . No one has actually said to me beforehand, ‘You
need to do some exercise.’
Mark; 4 months
Barriers to the Strengthening And stretching for Rheumatoid Arthritis of the
Hand exercises
Alongside the interviewees’ descriptions of factors which helped them to carry out the SARAH programme,
barriers were also identified. The majority of interviewees described barriers to doing exercise with RA
in general, and many of these applied to the doing the SARAH programme. There were some barriers
that were specific to carrying out the SARAH programme. Barriers were classified as intrinsic and
extrinsic barriers.
Intrinsic barriers
Intrinsic barrier came from within the individual. The most important was physical symptoms such as pain,
stiffness, flare-ups, swelling or feeling unwell:
. . . but then they got more difficult to do to the stage where no, I can’t do anymore because my
hands hurt so much.
Susan; 4 months
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A negative mindset fostering poor motivation, procrastination and avoidance was also considered to be an
internal barrier to exercise. Two spoke of a reluctance to exercise because the exercises reminded them
of their RA:
Sometimes it’s attitude of mind, because there are definitely down days when things are not . . .
You just don’t want to have it anymore and you want to give it to somebody else and that would
certainly impact on whether or not . . . how well I did them. I know it did, because emotionally you
have to be quite secure and stable don’t you?
Kate; 4 months
There were also challenges staying with the programme over time:
And I’d settled down to quite a pattern with the exercises. When I was off the hook with [the SARAH
therapist] at occupational therapy, it became much more difficult to be disciplined about doing them
every day. And after a period of time, I have to confess, that I ended up doing them probably three
times a week, the whole programme, interspersed when I was sitting having a cup of coffee I would
be doing odd ones just to keep it moving.
Lucy; 12 months
In relation to general exercises for RA, participants expressed concerns or fear around exercising with RA
and the narratives were examined to see if this was a barrier to doing the SARAH programme. This did not
appear to be the case, and in fact there was a noticeable absence of caution or fear of doing the
SARAH exercises and five participants actually said that ‘no harm’ was associated with them:
Honestly, I can’t see that it can do any harm.
Lizzy; 12 months
Extrinsic barriers
Extrinsic factors were those surrounding the individual such as competing commitments on their time and
changes in their routine which stopped them from exercising.
Competing priorities was given as the main barrier to doing the SARAH exercises, especially being busy
with household and family commitments:
I was trying to catch up in the garden and do things in the garden and all of a sudden I was trying to
do things in the house I hadn’t done for a while and the exercises sort of got put by the wayside
and I thought well, at least I’m exercising doing things, so I didn’t worry too much.
Emily; 4 months
The time it took to fit the SARAH exercises into their day was an issue for some. Five interviewees spoke
about the difficulties of exercising when they were out of their normal routine. Examples given were going
on holiday, working away or visiting family. The trial equipment was also mentioned with this theme, as
when away they were unlikely to take the equipment. Samantha also considered it antisocial to do the
exercises when visiting family:
. . . we went down to my dad’s for a long weekend and so that was difficult because you’re doing
something out of your routine, so anything out of routine, you’ve got to think; well where can I fit
them in and that was tricky and sometimes it was antisocial as well, so where you should be joining in
with something you couldn’t be doing these exercises.
Sam; 4 months
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Gauging the personal effectiveness of the Strengthening And stretching for
Rheumatoid Arthritis of the Hand intervention
We hoped to gain an understanding of the impact the SARAH intervention had on patient symptoms and
how interviewees measured the personal effectiveness of the programme.
Ten interviewees felt that the SARAH exercise program had worked for them, although Emily and Lizzy
were not sure if it was their medication or a combination of the intervention and medication. All 10
interviewees described how they felt the intervention had worked for them with physical improvements
being the most prevalent. An improvement in function was most cited; functional gains were described by
some in terms of being able to: do more in the garden (Samantha), do household tasks such as ironing
and drying the dishes more easily (Harry), pick things up more easily (Lucy) and decrease their reliance on
splints (Alice). Physical improvements were most often in strength or grip and flexibility or increased ROM:
Using the secateurs and also just to pull the stubborn weeds out. You can probably grip those better
and pull them out easier and lifting certain things with my hands and so for example, the container off
the lawnmower. I could probably do that a bit easier and maybe shopping bags a bit better. What
else; maybe a couple of jars with the tin opener.
Samantha; 4 months
Some spoke of improvements in their symptoms with regard to their exercises. Joe stated that since doing
the exercises he had had no flare-ups, and Alice said that her hands felt better after exercising.
Psychological constructs were difficult to characterise; some felt the benefit was ‘feeling better’ without
further elucidation. Mark and Kate felt that the sessions had given them a focus, and Lizzy spoke of an
increased awareness of her hands:
At 12 months, nine respondents still spoke of physical improvements:
I knew there was so much more flexibility in my hands. So the flexibility and, I suppose to a certain
extent, the strength was quite significant.
Lucy; 12 months
However, they also spoke of a higher proportion of psychological improvements at 12 months when
compared to 4 months. The most notable being in confidence and increased awareness, suggesting it took
time for confidence in improved hand function to develop and translate into everyday function. Additional
psychological benefits were a sense of empowerment, a hope of slowing their disease progress or
maintaining their function.
Samantha, Alice and Lucy spoke of an increased confidence in their hand function:
It’s little things. I’m probably more confident with picking things up and I’m more confident with the
manual dexterity. I mean my handwriting is still pretty appalling at times, but I was quite anxious
about picking things up and dropping things and that’s less of an issue now.
Alice; 12 months
Alice and Sadler spoke of a confidence in the exercise programme itself, which had increased their
confidence to continue with the exercises. Kate thought that it had empowered her to be in control of her
RA, the SARAH intervention had given her hope that she could improve or control her symptoms:
Because emotionally and psychologically I feel more at ease with it and it’s about the power of
thought for me, whereas before when I was first diagnosed with it I didn’t have any control over it
whatsoever, whereas I’m actually doing something that’s practical that might help and ‘might’ is
enough. It doesn’t have to be ‘will.’ It might and therefore, if that is in my hands to make that change
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I can do that. If it’s not in my hands I’m helpless and therefore that’s actually quite a difficult place to
be, so the SARAH project for me I think has been really quite valuable because it’s empowered me.
Kate; 12 months
An increased awareness of their hands was spoken about by five interviewees. Participants had become
more aware of addressing their limitations (Lucy), the importance of keeping moving and looking after
their hands (Lizzy, Samantha) or that it gave them other ways of doing things (Alice):
Yes, they [the exercises] are valuable. Because they’ve made me realise how important it is to keep
moving, it would be so easy to say, ‘Well I can’t do that’.
Lizzy; 12 months
Alice, Sadler and Samantha were hopeful that the exercises may possibly slow the rate of progress of their
symptoms and talked about the exercises ‘maintaining what they had’:
And I don’t know if 5 years down the line I’m going to be so grateful I did this, and if this is going
to help to maintain function and strength then I’m the only one who’s going to benefit from that,
so if I don’t put it in I’m not gonna get it out. And it’s so little to ask to do.
Alice; 12 months
Four participants felt that the SARAH intervention had not worked for them: Jean because she hadn’t
done the exercises, Susan because of a longstanding flare-up which hadn’t responded to treatment,
Bert because he felt his hands were too good prior to randomisation (and he wasn’t expecting any
improvement) and Sally because she hadn’t had any noticeable change yet (but was still hoping for change
over the rest of the trial period).
Everyone is different: reasons the Strengthening And stretching for
Rheumatoid Arthritis of the Hand intervention might be effective for some
people and not others
There was recognition from interviewees that different things may work for different people and they were
able to offer reasons as to why the SARAH intervention might be effective for some people and not for
others. Almost all interviewees gave insights at 4 or 12 months giving rise to four main themes: (1) a
positive mindset, (2) the level of disease, (3) reasons to exercise and (4) incorporating exercise into lives:
So I guess it’s all going to be about individuals in terms of how they’re . . . what their mental state is,
what their total environment is, what else is going on, but ultimately, it’s that balance between
spending the time doing it, either finding the time to do it in my case, putting yourself through the
rigours of trying to do it and the potential discomfort that that may bring, versus the long-term benefit.
It’s that balance which is ultimately going to be the equation that’s going to make it successful or not.
Sadler; 12 months
A positive mindset is important
Interviewees spoke of a positive mindset and that being motivated, committed and willing to put in the
effort was desirable. Being self-disciplined and taking responsibility for your health were also considered to
be useful traits. Conversely, not having the motivation or commitment, viewing the exercise as tricky, an
effort or ‘easier not to do them’ could mean that it might not work. Being unrealistic about the amount of
effort needed or wanting instant results also would not be useful:
Some people won’t do it for one thing. You’ve got to be motivated. You’ve got to want to do it.
You’ve got to want to put the effort in, although this really is not a lot of effort. It’s actually quite
minimal and I think you probably get a lot of benefit out of it, but I don’t know if everybody would
see that
Kate; 4 months
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The level of the disease was considered to be a contributing factor
Interviewees thought that giving exercise early in the disease process or when it was not severe might help
the intervention to work. Many felt that it might not work if the disease was advanced, in a flare-up or
causing pain and stiffness:
I think the exercises will work for people that have got arthritis as long as they’re not in a flare-up.
I think if you were in a flare-up then no exercises are any good at all.
Susan; 4 months
People need reasons to exercise
Interviewees felt that people needed reasons to exercise, such as having a past experience of exercise
being useful, the hope of some benefit or being accountable to the study and that these might make the
intervention work. Conversely it might not work if they did not have a good enough reason to engage,
preferred solely to take drugs rather than take exercise or weren’t accountable in some way.
Well, some might not keep to it you see. They might not . . . they might do it for a few days and then
say, ‘Oh well that’s it’, or if they haven’t got a good enough reason to do it, you know?
Harry; 4 months
Beliefs such as ‘people may think they are irreparable’ may also stop them from engaging with an exercise
programme. One person spoke of individuals having to balance many factors, alluding once more to
competing priorities.
People need to incorporate exercise into their lives
Fitting the exercises into their lives and doing them regularly was thought to help make the intervention
work. Conversely, not doing the exercise, not having the time or being out of routine might make it not
work. One person said that people might need more encouragement, explanation, contact and some may
prefer a different setting such as groups, reiterating how individual this may be.
Suggested changes to the Strengthening And stretching for Rheumatoid
Arthritis of the Hand intervention
At 4 months, half the interviewees said that they would not change anything about the intervention. Three
areas of potential change were identified from the remaining seven interviewees, and these seem to be
mostly about practical administration of the intervention. Individual comments were given about the
intervention content and suggestions included that daily diary sheets could be put in a ring folder with
more space to write explanatory comments, the putty exercises could be further modified and the bag
catch would have been better with a hook and loop fastening (rather than a clip fastening). Suggestions
were given concerning the intervention format and setting. One interviewee suggested a group setting for
interaction and accountability, but another felt a group setting may not work. Another interviewee
suggested delivering the programme in a community setting for ease of parking.
At 12 months, however, suggestions given by six people all concerned ways in which people could be
helped to ‘stay with’ the programme, three advocating groups. Three areas of change emerged. Firstly,
more inventive ways were suggested to help to establish a routine and help incorporate the exercises into
their lifestyle:
To change habits is quite difficult. [. . .] So I think it would be very good to carefully sit down with
somebody and just honestly say where could you fit this in, in your routine, to help them maximise the
chance of completing the exercises and saying ‘that exercise is really going to take you that long to
do.’ This exercise, you’ve got to find that putty, where is it? . . . So if people haven’t got time to do
that, they are not going to do it. So to really help them, with putting in place a plan that would fit in
to their routine, and they’re are more likely to get it done.
Samantha; 12 months
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Secondly, an increase of initial support by health-care professionals may help to establish a routine and
then a ‘touching base’ after the end of the therapist input may be useful:
. . . but it needs to be fairly intense at the beginning just to guide the patient through it, what they are
doing, what they are achieving or even keep an eye on what they are not achieving.
Bert; 12 months
Thirdly, interviewees gave ideas of other support systems which could be useful such as groups, peer/
mentor support, text messages, email or ‘YouTube’ videos to help people stay engaged with the process:
It could have been done in a group but it was, because really you could all do the same exercises
together in a group. But it is nicer when you’re one to one with a person because you can talk about
other things as well.
Mark; 12 months
I don’t see why you couldn’t have half a dozen people at a table . . . and it might give . . . it might
contribute towards the commitment element. That it would bring people together.
Lucy; 12 months
I think it would be useful to know what type of activity people enjoy, some people like groups, some
people don’t. [. . .] I’d have hated it. But that’s just me. But other people would see it as a much more
social event and would perhaps find support from being with other people. Sometimes it would have
been nice to have another person who was on the trial to sort of say, ‘I’m really finding that one
difficult’ . . . so that you had people that (you) could contact . . . I know that might not be feasible,
but I do think actually that sort of mentor support is useful. Particularly if it’s such an ongoing
long-term programme . . .
Alice; 12 months
One thing that’s just going through my mind is the use of the new technology and the internet and is
there something, in terms of keeping in touch, that that could be factored in, because clearly it’s
not easy to have that time, both from the patients perspective and from a healthcare professional
perspective, people coming in, being on the road and coming in and meeting people. Could we use
the internet or email or whatever, to actually do that. Is there any, almost like ‘YouTube’ video place
that you could have access to, to remind you what you should be doing and things that . . .
Sadler; 12 months
Discussion
The SARAH programme is feasible and acceptable to patients with relatively stable RA symptoms. All
interviewees said they were satisfied with the programme and would recommend it to others and they
seemed confident in the delivery and continued use of the exercises. It has been reported that patients
with RA are cautious about exercising owing to concern such as doing harm or damage.107 However,
interviewees in this study did not express these concerns regarding the SARAH exercise programme,
providing further evidence that the programme was acceptable to patients.
The importance of establishing a routine was the major emergent theme throughout the interviews and
the key to successfully carrying out the exercise intervention. Being out of routine was suggested as a
barrier to doing the exercise programme. Establishing a routine was easy for some interviewees but others
required support and encouragement. Interviewees found some elements of the programme challenging,
for example the putty and Theraband exercises, which needed the most adaptation to the individual to
ensure they were completed. This study has highlighted the importance of the therapist in enabling
patients to establish a routine and incorporate the exercises into their lives and teaching patients to modify
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exercises if needed (e.g. if painful or during a flare-up). Competing priorities were highlighted as the
biggest barrier to doing the exercises regularly. Physical symptoms experienced by individuals were another
important barrier to exercising. The need for a reason to exercise was also emphasised. Individuals who
thought that their hand function was good, and hence that they did not need to do the exercises, were
also unlikely to carry out the programme.
Our study is in agreement with a previous interview study (n= 6) by Ronningen et al.,69 who explored the
effect of a hand exercise programme. This study found that those successful in maintaining a programme
had incorporated it into their daily routine, and stated the importance of tailoring programmes to the
individual allowing for changes in their symptoms or ability.
When asked about the effects of the intervention, the most striking difference between the two time
points was the mention at 12 months of more psychological improvements alongside the physical. One
possible mechanism for this may be that the physical improvements early on resulted in increased
confidence (self-efficacy) in participants’ own abilities to carry out exercises or activity in general. Greater
self-efficacy is often associated with better health outcomes and could potentially also mean that patients
were less fearful of exercise or activity. Swardh et al.108 (n= 18) explored patients with RA’s experiences of
exercise maintenance. They concluded that individuals have differing needs in terms of context and
support but advocated the importance of a self-efficacy approach to prepare someone for exercise
maintenance, helping the patient to adapt and problem solve, a similar ethos to the SARAH intervention.
Implications for clinical practice
We have demonstrated that the behavioural elements of the SARAH intervention were successfully
implemented and enhanced the more traditional exercise provision role of therapists. The use of
behavioural strategies such as completing the PEG may not be familiar to all therapists. However, they
were an important aspect of the SARAH exercise intervention so need to be delivered alongside the
exercises. The role of the SARAH therapist changed from teacher to facilitator, enabling the patient to gain
expertise and subsequently to exercise independently (Figure 7). Therapists who deliver the intervention
need to be trained in all elements of the programme but training is straightforward and could be
incorporated into current therapy departmental training programmes.
Further research
Several participants suggested the exercise programme could be delivered in a group setting, but this
needs to be evaluated before it could be recommended.
Different methods of providing on-going support for patients as a way of ensuring long term adherence of
the exercise programme were suggested. These ranged from ‘touching base’ visits to the therapist to the
use of on-line resources such as ‘YouTube’. Evaluating ways of providing support is another area of
further research.
Therapist’s role 
Initial two sessions
•   Assesses
•   Advises on joint care
•   Teaches exercises
•   Provides equipment
•   Introduces exercise
     contract; joint goal
     setting, when, where,
     explores possible barriers
               
Therapist and patient roles
Subsequent sessions
•   Establish a routine
•   Review; contract goals, 
     adherence to programme 
•   Discuss challenges
     and successes
•   Negotiate progression
•   Encourage and motivate
•   Build confidence 
  
Patient’s role
Post-therapy sessions
•   Exercises independently
     with confidence
•   Fits exercise into their lives  
•   Exercises habitually
•   Problem solves when,
     where and how to
     maintain their exercises
•   Seeks assistance if needed     
                 
FIGURE 7 Therapist and patient roles in the SARAH intervention.
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Chapter 6 Health economics
Introduction
The cost-effectiveness analysis of the SARAH exercise intervention compared with usual care is presented in this
chapter. Cost-effectiveness is estimated using a ‘within-trial’ analysis, based on health-care resource use and
utility data collected alongside the clinical data over the 12-month trial period. We considered developing a
model to predict longer-term impacts of the intervention, but concluded that in this case it would not help to
quantify or resolve uncertainty for decision makers. The prospects for modelling are discussed further below.
The cost-effectiveness analysis was guided by an analysis plan prepared before data were available, and follows
the NICE reference case109 and International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
recommendations on conducting economic evaluations alongside clinical trials.110 The economic analysis uses
an intention-to-treat approach. Effectiveness was measured using quality-adjusted life-years (QALYs), estimated
by the area-under-the curve method from patient-reported health status at baseline, 4 and 12 months using
the EQ-5D-3L questionnaire, with preference weights from a UK general population (the UK Social Tariff).111
For comparison, we also estimated QALYs using the Short Form questionnaire-6 Dimensions (SF-6D) utility
index.112 NHS perspective was used for the costing. Costs were estimated for each participant over 12 months
of follow-up, based on patient-reported use of a list of health services potentially influenced by hand function,
RA status or side effects of treatment. Unit costs were obtained from national sources, and the cost of the
intervention estimated from trial records. Given the 1-year time horizon, there was no need to discount costs or
QALYs for time preference.
Unit cost data
Intervention costs
Participants in both treatment groups attended physiotherapy or occupational therapy appointments
during the course of the trial. Assumptions used to cost the therapist time for these appointments are
shown in Table 66. For the usual care group (control), the trial protocol specified a maximum of one and a
half hours therapy spread over three sessions, although in practice some control patients attended more
TABLE 66 Assumptions for costing therapist time
Section costed Type of costing Amount Source
Training for exercise
programme
Total therapist hours spent on training (hours) 183 Trial records
Number of therapists 56 Trial records
Mean training time per therapist (hours) 3.3
Therapist cost per hour £35 PSSRU estimate (Curtis 2011)113
Total cost of training for trial £6405
Patients attending at least one session 473 Treatment logs
Cost per patient attending at least one session £13.54
Treatment sessions First session (minutes) 45–60 Estimate
Second session (minutes) 45 Estimate
Next three sessions (minutes) 30 Estimate
Final session (minutes) 45 Estimate
PSSRU, Personal Social Services Research Unit.
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sessions than this (n= 6 and often for splinting issues). Usual care therapy included JP education and
advice, simple mobility exercise for the hand and functional splinting.
Participants in the usual care and exercise group (experimental) received the usual care regimen
supplemented with additional sessions of an optimised exercise programme delivered by specially trained
physiotherapists and occupational therapists over a 12-week period. Participants were invited to attend six
30- to 45-minute sessions, given an individualised exercise programme to perform at home, and asked to
keep a record of their activities. Training time for therapists to provide the optimised exercise programme
ranged from 3 to 5 hours depending on site. In the base-case analysis we allocated the full cost of
physiotherapist time spent on training (183 hours at £35 per hour) across the trial participants who
attended at least one treatment session (n= 473) (see Table 66). This entails a conservative assumption
that the training has no residual value. In practice, there would be a one-off cost for training
physiotherapists new to the intervention, and then an on-going cost for training due to staff turnover and
possibly also ‘top up’ training for existing staff.
Participants in the exercise programme arm who attended at least one session were given additional
information and equipment for home exercises (Table 67). Each participant received an exercise booklet
with a description of all the exercises they were to perform at home and in clinic, an exercise diary at each
session (printed A4 sheet of paper), a PEG, a discharge advice information sheet and a spare exercise diary,
a cardboard folder to hold all the paperwork, and a blue bag to keep this and the exercise materials in.
Depending on whether or not there were any major changes to the participants’ goals or programme,
they may have received between one and five personal PEGs. Exercise materials included putty, balls and
TABLE 67 Cost of interventions
Resource item Unit
Cost per
unit (£)
Mean per participant
Baseline Worst case Best case
Quantity Cost (£) Quantity Cost (£) Quantity Cost (£)
Blue bag Item 1.7 1 1.7 1 1.7 1 1.7
Exercise booklet Item 1.43 1 1.43 1 1.43 1 1.43
Folder Item 1.85 1 1.85 1 1.85 1 1.85
Exercise diary Item 0.1 1 0.1 1 0.1 1 0.1
Discharge advice Page 0.02 1 0.02 1 0.02 1 0.02
Personal exercise guide Item 0.18 3 0.54 5 0.9 1 0.18
Putty 100 g 2.29 1.92 4.4 5 11.45 1 2.29
Ball Yellow/red/
green/blue
Item 15.97 1.98 31.62 4 63.88 1 15.97
Black Item 19.6 0 0 1 19.6 0 0
Subtotal 31.62 83.48 15.97
Theraband Beige 1m 1.21 1 1.21 1 1.21 1 1.21
Yellow 1m 1.3 0.42 0.55 1 1.3 0 0
Red 1m 1.41 0 0 1 1.41 0 0
Green 1m 1.49 0 0 1 1.49 0 0
Subtotal 1.76 5.41 1.21
Total cost of consumables 43.42 0 106.34 0 24.75
Source: recorded trial expenditure.
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Therabands. These were supplied according to each participant’s capabilities and may have changed as
they progressed through the programme. The quantity and colour of the material (which reflects resistance
level) that each participant received was individualised. In the cheapest case, a participant would have
received 100 g of putty, one ball and a 1m length of Theraband. In the most expensive case, materials
would have been changed at every exercise session: 500 g putty, five balls and 4m of Theraband.
The estimated costs of hand therapy by the number of sessions attended are shown in Table 68. Following
our base-case assumptions, the cost for a usual-care patient attending three sessions is £83, compared with
£186 for a patient in the intervention group attending all six recommended sessions. Intervention costs were
estimated at the individual patient level, based on the recorded number of session that they attended.
The cost of training therapists is allocated across 473, 237 and 0 intervention participants for the worst-case,
base-case and best-case scenarios respectively (473 patients attended at least one session in the trial). For
simplicity, the cost of consumables is allocated to all intervention patients who attend at least one session. We
conducted a simple one-way sensitivity analysis using the worst-case and best-case estimates (see Discussion).
Unit cost of medications
Information about prescribed medications was collected from participants in the baseline, 4-month and
12-month interviews. A list of all medications recorded was collated, and items related to RA were identified
for inclusion in the economic analysis (Table 69). This list included NSAIDs, biological and non-biological
disease-modifying drugs, analgesics and gastroprotective agents (possibly related to side effects of NSAID
treatment). NHS net prices per mg for these medications were obtained from the British National Formulary
(BNF).115 Costs for individual patients were estimated based on their reported dose and frequency if this
information was available, or otherwise on an assumed daily dose. This assumed dose was based on the
World Health Organization defined daily dose (WHO DDD),116 or on BNF recommended doses if no WHO DDD
was available. For the biologic disease-modifying drugs, doses were based on NICE recommended doses,
and the cost of injections and infusions was also included based on NICE guidance117 (Table 70).
TABLE 68 Cost of hand therapy sessions
Type of
costing Session type
Exercise programme (£) Usual care (£)
Base case Worst case Best case Base case Worst case Best case
Therapist
training
(If at least one
session attended)
6.77 13.54 0.00 0.00 0.00 0.00
Consumables 43.42 106.34 24.75 0.00 0.00 0.00
Therapist time Session 1 30.63 35.00 26.25 30.63 26.25 35.00
Session 2 26.25 26.25 26.25 26.25 26.25 26.25
Sessions 3–5 17.50 17.50 17.50 – – –
Session 6 26.25 26.25 26.25 – – –
Total cost by
number of
sessions
attended
0 sessions 0.00 0.00 0.00 0.00 0.00 0.00
1 session 80.82 154.88 51.00 30.63 26.25 35.00
2 sessions 107.07 181.13 77.25 56.88 52.50 61.25
3 sessions 124.57 198.63 94.75 83.13 78.75 87.50
4 sessions 142.07 216.13 112.25 109.38 – 113.75
5 sessions 159.57 233.63 129.75 135.63 – 140.00
6 sessions 185.82 259.88 156.00 161.88 – 166.25
7 sessions – – – 188.13 – 192.50
8 sessions – – – 214.38 – 218.75
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TABLE 69 Unit costs of drugs
Drug name Units
Cost/mg
(pence)
Dose/day
(mg)
Cost/day
(pence)
Source of
dose estimate
NSAIDs
Acemetacin Capsules 0.522 120 62.7 WHO DDD
Aspirin Tablet 0.003 1200 3.9 BNF
Celecoxib (Celebrex®, Pfizer) Capsules 0.359 200 71.8 BNF
Diclofenac Tablet 0.461 100 46.1 WHO DDD
Diclofenac/misoprostol (Arthrotec®, Pfizer) Tablet 0.399 100 39.9 BNF
Etodolac Capsules 0.045 400 18.1 WHO DDD
Etoricoxib Tablet 1.665 60 99.9 WHO DDD
Ibuprofen Tablet 0.009 1200 10.3 WHO DDD
Ibuprofen gel Gel 0.007 1500 10.5 Underwood et al.114
Indomethacin (indometacin) Capsules 0.321 100 32.1 WHO DDD
Meloxicam Tablet 0.293 15 4.4 WHO DDD
Mobic Tablet 4.133 15 62.0 BNF
Nabumetone Tablet 0.017 1000 17.0 WHO DDD
Naproxen Tablet 0.018 500 8.9 WHO DDD
Piroxicam Gel 0.004 20 0.1 WHO DDD
Biologic DMARDs
Adalimumab (Humira®, Abbott Laboratories) Injection 880.350 2.9 2515.3 BNF
Certolizumab Injection 178.75 14.3 2553.6 BNF
Etanercept (Enbrel®, Amgen) Injection 357.52 7.1 2553.7 BNF
Infliximab (Remicade®, Schering-Plough) Infusion 419.62 6.1 2547.7 BNF
Rituximab Infusion 174.63 17.9 3118.4 BNF
Tocilizumab Infusion 128.00 24 3108.6 BNF
Non-biologic DMARDs
Azathioprine Tablet 0.180 150 27.0 WHO DDD
Ciclosporin (Capsorin®, Novartis
Pharmaceuticals Ltd)
Tablet 1.748 250 437.0 WHO DDD
Gold (sodium aurothiomalate) Injection 22.460 7.1 160.4 BNF
Hydroxychloroquine Tablet 0.043 516 22.1 WHO DDD
Leflunomide Tablet 15.333 20 306.7 WHO DDD
Methotrexate (oral) Tablet 4.671 2.5 11.7 WHO DDD
Methotrexate (injection) Injection 197.067 1.1 211.1 BNF
Prednisolone Tablet 4.671 10 46.7 BNF
Sulfasalazine Tablet 0.026 2000 53 BNF
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TABLE 69 Unit costs of drugs (continued )
Drug name Units
Cost/mg
(pence)
Dose/day
(mg)
Cost/day
(pence)
Source of
dose estimate
Analgesics
Buprenorphine Tablet 50.300 0.2 10.1 BNF
Buprenophine (BuTrans Patches®, Purdue) Patch – – 112.1 Assume ‘10’ patch
Capsaicin (Zacin®, Teva) Cream 0.039 1500 59.0 Underwood et al.114
Co-codamol (30mg codeine,
500mg paracetamol)
Tablet 0.118 240 28.3 BNF
Codeine Tablet 0.099 1000 99.4 BNF
Co-dydramol Tablet 0.353 80 28.3 BNF
Dihydrocodeine Tablet 0.165 150 24.8 WHO DDD
Fentanyl patches Patch – – 91.3 Assume ‘12’ patch
Gabapentin Capsule 0.073 1800 132.1 WHO DDD
Morphine Sulphate [Minijet®, International
medication systems (UK) Ltd]
Injection 150.0 30 4500 WHO DDD
Morphine Sulphate (Sevredol®, Napp
Pharmaceuticals Ltd)
Tablet 0.945 100 94.5 WHO DDD
Oxycodone Tablet 12.543 75 940.7 WHO DDD
Paracetamol Tablet 0.002 3000 6.0 WHO DDD
Pregabalin Tablet 0.767 300 230.0 WHO DDD
Codeine phosphate (Solpadol®,
Sanofi-Synthelabo)
Caplet 0.225 240 53.9 BNF
Tramadol hydrocholoride and paracetamol
(Tramacet®, Grüenthak Ltd, UK)
Tablet 0.430 300 129.1 BNF
Tramadol Capsule 0.076 300 22.8 WHO DDD
Cocodamol (Tylex®, UBC Pharma Ltd) Capsule 0.257 240 61.6 BNF
Gastrointestinal
Lansoprazole Capsule 0.286 30 8.6 WHO DDD
Nizatidine Capsule 0.164 300 49.3 WHO DDD
Omeprazole Capsule 0.289 20 5.8 WHO DDD
Pantoprazole Tablet 0.179 40 7.2 WHO DDD
Ranitidine Tablet 0.016 300 4.9 WHO DDD
Robeprazole Sodium Tablet 3.491 20 69.8 BNF
BNF.115
WHO DDD.116
Source of unit cost data, BNF NHS net price. Costs for smallest appropriate pack size, non-proprietary (unless brand is
stated). Individual recorded doses were used where possible, otherwise average daily doses from this table were assumed.
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Unit costs of other health services
The 4- and 12-month patient questionnaires included questions about their use of a range of other NHS
services related to their hand arthritis (Table 71). Unit costs were collected for each of these items from
national published sources: Department of Health reference costs118 or Personal Social Services Research
Unit (PSSRU).113
TABLE 70 Estimated costs of administering injections and infusions
Medication
Injections Infusions Administration cost (£)
Per annum Per annum Per annum Per day
Adalimumab (Humira®, Abbott Laboratories) 26 111 0.30
Certolizumab 26 111 0.30
Etanercept (Enbrel®, Amgen) 104 442 1.21
Infliximab (Remicade®, Schering-Plough) 7 1078 2.95
Rituximab 3.78 582 1.59
Tocilizumab 13 2002 5.48
Cost per injection (£4.25) – assuming 5 minutes of primary care nurse time (at £51 per hour).113
Cost per infusion (£154) – based on NICE Technology Appraisal Committee considerations.117
TABLE 71 Unit costs of other NHS services
Resource item Unit
Mean cost
(£ per unit) Sources
Physiotherapist Session 38 Ref cost: 650A
Occupational therapist Session 56 Ref cost: 651A
General practitioner Session 31 PSSRU
Rheumatologist Session 138 Ref cost: 410
Orthopaedic surgeon Session 99 Ref cost: 110N
Other specialist Session 110 Ref cost: weighted mean of orthopaedic and rheumatology outpatient
Nurse Session 49 Ref cost: CN203AAF
Podiatrist/chiropodist Session 43 Ref cost: 653
Self-management group Session 5.8 PSSRU: assume 1-hour group of six patients led by an occupational
therapist
Occupational therapist Hour 35 PSSRU
Inpatient stay Episode 2676 Ref cost: elective and non-elective (long and short stay) HRG HB13Z,
HB14B, HB14C, HB23B, HB23C, HB32A, HB33D, HB33E, HB53Z,
HB54B, HB54C, HB62B, HB62C, HB72Z, HB91Z, HB99Z
Day case treatment Episode 1308 Ref cost: day case HRG HB13Z, HB14B, HB14C, HB23B, HB23C,
HB32A, HB33D, HB33E, HB53Z, HB54B, HB54C, HB62B, HB62C,
HB72Z, HB91Z, HB99Z
X-rays Test 5 Assumption
CT scan Test 93 Ref cost: RA08Z–RA10Z
MRI scan Test 167 Ref cost: RA01Z–RA03Z
Blood tests Test 3 Ref cost
CT, computerised tomography; HRG, health resource group code; MRI, magnetic resonance imaging.
Ref cost: Department of Health, NHS Reference Costs.118
PSSRU: Personal Social Services Research Unit, Unit Costs of Health and Social Care 2011.113
Where more than one code applies, costs are estimated weighted by activity.
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Resource use and costs
Prescribed medication usage was acquired at baseline, 4 months and 12 months. Participants were asked
to list the drugs that they were currently taking, and to report the dose and frequency of use. For the
included range of medications (as listed in Table 69 above), the mean daily doses between time points
were taken and assumed to be constant across the period, to give an estimate of daily dose (in mg) during
the two time periods 0–4 months and 4–12 months. Where information about an individual patient’s dose
or frequency of use was missing or difficult to interpret, we assumed an average daily dose as listed in
Table 69. The resulting estimates of daily dose for each drug were then multiplied by unit costs and where
relevant the costs of administering infusions and IV (see Table 70) were added. This yielded an estimate of
the cost of prescribed medications for each individual over the two time intervals (Table 72). The mean
cost per patient of prescribed medications over the 12 month trial period was similar for the treatment
groups: £1641 for the exercise group compared with £1721 for the usual care group.
Information about the use of other relevant NHS services was obtained by patient self-report at 4 and
12 months. Reported estimates of health care use over 0–4 months and 4–12 months are given in
Tables 73 and 74 respectively. These resource quantities were multiplied by the relevant unit costs
(see Table 71) to provide estimates of the mean costs per patient from 0–4 months (Table 75) and
TABLE 72 Prescribed drug costs
Time point
Number of patients Mean cost, £ (SE)
Mean treatment
difference (95% CI)a
Exercise
programme Usual care
Exercise
programme Usual care
Mean cost per day
Baseline 246 242 5.00 (0.63) 5.25 (0.65) –0.25 (–2.03 to 1.52)
4 months 212 223 5.34 (0.73) 5.07 (0.69) 0.27 (–1.70 to 2.24)
12 months 211 216 5.42 (0.74) 5.45 (0.74) –0.04 (–2.09 to 2.01)
Total cost
0–4 months 212 223 558.29 (74.53) 548.01 (71.94) 10.28 (–193.3 to 213.8)
4–12 months 198 207 1120.25 (155.67) 1161.02 (157.88) –40.77 (–477.0 to 395.5)
0–12 months 198 207 1641.16 (227.34) 1721.27 (230.75) –80.16 (–717.4 to 557.2)
SE, standard error.
a Negative value indicates reduced cost in favour of exercise programme.
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TABLE 73 Mean NHS service use: 0–4 months
Type of care
Number of patients Mean quantity (SE)
Mean treatment
difference (95% CI)a
Exercise
programme Usual care
Exercise
programme Usual care
Physiotherapist 223 228 0.78 (0.17) 0.36 (0.08) 0.42 (0.05 to 0.79)
Occupational therapist 223 227 0.52 (0.09) 0.37 (0.07) 0.14 (–0.09 to 0.37)
General practitioner 223 228 0.88 (0.10) 0.90 (0.12) –0.02 (–0.33 to 0.29)
Rheumatologist 223 228 0.86 (0.07) 0.69 (0.06) 0.16 (–0.02 to 0.34)
Orthopaedic surgeon 223 228 0.11 (0.03) 0.14 (0.03) –0.04 (–0.12 to 0.05)
Other specialist 222 227 0.15 (0.03) 0.20 (0.04) –0.05 (–0.15 to 0.05)
Nurse 223 228 0.59 (0.07) 0.64 (0.10) –0.06 (–0.30 to 0.19)
Podiatrist/chiropodist 223 228 0.26 (0.04) 0.38 (0.06) –0.12 (–0.27 to 0.03)
Self-management group 222 228 0.16 (0.13) 0.08 (0.07) 0.08 (–0.21 to 0.36)
Inpatient stay 223 227 0.02 (0.01) 0.04 (0.01) –0.02 (–0.05 to 0.01)
Day case treatment 222 227 0.12 (0.02) 0.10 (0.02) 0.02 (–0.03 to 0.08)
X-ray 223 228 0.29 (0.05) 0.22 (0.03) 0.07 (–0.05 to 0.18)
CT scan 223 228 0.03 (0.01) 0.04 (0.01) –0.01 (–0.04 to 0.03)
MRI scan 223 228 0.09 (0.03) 0.04 (0.01) 0.05 (–0.01 to 0.12)
Blood tests 222 228 2.21 (0.14) 2.05 (0.12) 0.16 (–0.20 to 0.52)
CT, computerised tomography; MRI, magnetic resonance imaging; SE, standard error.
a Negative value indicates reduced service use in favour of exercise programme.
TABLE 74 Mean NHS service use: 4–12 months
Type of care
Number of patients Mean quantity (SE)
Mean treatment
difference (95% CI)a
Exercise
programme Usual care
Exercise
programme Usual care
Physiotherapist 215 221 0.41 (0.12) 0.18 (0.04) 0.23 (–0.02 to 0.49)
Occupational therapist 215 221 0.10 (0.04) 0.09 (0.03) 0.01 (–0.08 to 0.10)
General practitioner 216 221 0.82 (0.10) 0.98 (0.16) –0.16 (–0.53 to 0.22)
Rheumatologist 215 221 0.83 (0.06) 0.89 (0.07) –0.06 (–0.23 to 0.12)
Orthopaedic surgeon 214 221 0.20 (0.05) 0.12 (0.03) 0.08 (–0.03 to 0.20)
Other specialist 213 221 0.13 (0.03) 0.25 (0.05) –0.12 (–0.24 to 0.00)
Nurse 215 221 0.63 (0.07) 0.78 (0.09) –0.15 (–0.37 to 0.07)
Podiatrist/chiropodist 214 221 0.39 (0.07) 0.46 (0.07) –0.07 (–0.27 to 0.12)
Self-management group 214 221 0.02 (0.02) 0.01 (0.01) 0.01 (–0.03 to 0.06)
Inpatient stay 215 221 0.03 (0.01) 0.02 (0.01) 0.01 (–0.02 to 0.04)
Day case treatment 213 219 0.14 (0.02) 0.13 (0.02) 0.02 (–0.05 to 0.08)
X-ray 215 220 0.23 (0.03) 0.26 (0.04) –0.04 (–0.14 to 0.07)
CT scan 215 220 0.03 (0.01) 0.04 (0.01) –0.01 (–0.04 to 0.02)
MRI scan 214 220 0.04 (0.01) 0.06 (0.02) –0.03 (–0.07 to 0.02)
Blood tests 214 218 2.19 (0.13) 2.24 (0.15) –0.05 (–0.43 to 0.34)
CT, computerised tomography; MRI, magnetic resonance imaging; SE, standard error.
a Negative value indicates reduced service use in favour of exercise programme.
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4–12 months (Table 76). Differences between the groups in the costs of health care use over these
periods were modest, with wide CIs.
A summary of all included costs over the trial period is given in Table 77. This shows a significant
difference between the groups in intervention costs – taking account of individually recorded attendance
at the intervention sessions. The mean cost per participant for the exercise programme group was £171,
compared with £44 for the usual care group: a difference of £127 (95% CI £122 to £131). Overall, taking
account of costs for the intervention, for prescribed medications and for other NHS services, the estimated
between-group difference in costs is £103 (95% CI –£622 to £828) per patient. This wide variation in
health-care costs is common, owing to large outliers as some patients incur very high costs. This can be
seen in the frequency distributions in Figure 8. The bimodal nature of these distributions is due to high
costs incurred by a subgroup of patients on expensive biological disease-modifying drugs.
TABLE 75 Mean NHS service costs: 0–4 months
Type of care
Number of patients Mean cost, £ (SE)
Mean treatment
difference (95% CI)a
Exercise
programme Usual care
Exercise
programme Usual care
Physiotherapist 223 228 29.82 (6.53) 13.83 (3.01) 15.99 (1.97 to 30.01)
Occupational therapist 223 227 28.88 (5.14) 20.97 (4.01) 7.91 (–4.88 to 20.70)
General practitioner 223 228 27.25 (3.18) 27.87 (3.70) –0.63 (–10.23 to 8.98)
Rheumatologist 223 228 118.20 (10.22) 95.63 (7.64) 22.57 (–2.43 to 47.56)
Orthopaedic surgeon 223 228 10.65 (2.86) 14.33 (3.02) –3.67 (–11.86 to 4.51)
Other specialist 222 227 16.35 (3.37) 21.81 (4.29) –5.45 (–16.21 to 5.30)
Nurse 223 228 28.78 (3.61) 31.59 (4.88) –2.81 (–14.78 to 9.16)
Podiatrist/chiropodist 223 228 10.99 (1.88) 16.22 (2.75) –5.23 (–11.80 to 1.34)
Self-management group 222 228 0.94 (0.74) 0.48 (0.41) 0.46 (–1.20 to 2.11)
Inpatient stay 223 227 48.00 (23.84) 94.31 (32.82) –46.31 (–126.3 to 33.64)
Day case treatment 222 227 159.08 (28.76) 126.77 (25.74) 32.31 (–43.45 to 108.1)
X-ray 223 228 1.43 (0.24) 1.10 (0.17) 0.34 (–0.24 to 0.91)
CT scan 223 228 2.50 (1.17) 3.26 (1.27) –0.76 (–4.16 to 2.64)
MRI scan 223 228 14.98 (4.99) 5.86 (2.04) 9.12 (–4.16 to 2.64)
Blood tests 222 228 6.64 (0.41) 6.16 (0.37) 0.48 (–0.61 to 1.56)
Total 223 228 502.74 (44.46) 478.55 (53.12) 24.19 (–112.3 to 160.7)
CT, computerised tomography; MRI, magnetic resonance imaging; SE, standard error.
a Negative value indicates reduced cost in favour of exercise programme.
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TABLE 77 Cost summary
Types of cost
Number of patients Mean cost, £ (SE)
Mean treatment
difference (95% CI)a
Exercise
programme Usual care
Exercise
programme Usual care
Intervention 238 235 171.19 (1.88) 44.29 (1.19) 126.89 (122.50 to 131.29)
NHS services 208 216 1021.52 (706.88) 975.42 (81.83) 46.1 (–174.96 to 267.12)
Prescriptions 198 207 1641.16 (227.34) 1721.27 (230.75) –80.12 (–717.44 to 557.21)
Total NHS cost 197 203 2812.28 (254.34) 2709.38 (266.62) 102.90 (–622.18 to 827.98)
SE, standard error.
a Negative value indicates reduced cost in favour of exercise programme.
TABLE 76 Mean NHS service costs (£): 4–12 months
Type of care
Number of patients Mean cost, £ (SE)
Mean treatment
difference (95% CI)a
Exercise
programme Usual care
Exercise
programme Usual care
Physiotherapist 215 221 15.73 (4.65) 6.88 (1.68) 8.85 (–0.77 to 18.47)
Occupational therapist 215 221 5.47 (2.04) 4.81 (1.59) 0.66 (–4.41 to 5.72)
General practitioner 216 221 25.55 (3.08) 30.44 (5.04) –4.89 (–16.56 to 6.78)
Rheumatologist 215 221 114.25 (8.15) 122.39 (9.24) –8.14 (–32.41 to 16.14)
Orthopaedic surgeon 214 221 19.89 (5.04) 11.65 (2.65) 8.25 (–2.86 to 19.35)
Other specialist 213 221 14.46 (3.60) 27.87 (5.46) –13.41 (–26.36 to –0.46)
Nurse 215 221 31.00 (3.65) 38.36 (4.17) –7.36 (–18.28 to 3.55)
Podiatrist/chiropodist 214 221 16.68 (3.20) 19.85 (2.81) –3.17 (–11.52 to 5.18)
Self-management group 214 221 0.14 (0.14) 0.05 (0.05) 0.08 (–0.20 to 0.37)
Inpatient stay 215 221 87.13 (32.47) 48.43 (24.05) 38.69 (–40.42 to 117.8)
Day case treatment 213 219 184.23 (31.25) 167.23 (29.58) 16.99 (–67.54 to 101.5)
X-ray 215 220 1.14 (0.16) 1.32 (0.22) –0.18 (–0.72 to 0.36)
CT scan 215 220 2.60 (1.05) 3.38 (1.18) –0.79 (–3.89 to 2.31)
MRI scan 214 220 6.24 (2.17) 10.63 (3.33) –4.38 (–12.24 to 3.47)
Blood tests 214 218 6.57 (0.38) 6.72 (0.45) –0.14 (–1.30 to 1.02)
Total 216 221 526.52 (52.56) 498.28 (51.69) 28.24 (–116.6 to 173.1)
CT, computerised tomography; MRI, magnetic resonance imaging; SE, standard error.
a Negative value indicates reduced cost in favour of Exercise programme.
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FIGURE 8 Frequency distribution of total cost over 12 months by study arm. (a) Exercise programme; and
(b) usual care.
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Utility and quality-adjusted life-years
Utility scores were estimated using validated EQ-5D-3L and SF-12 questionnaires completed by patients at
baseline, 4 months and 12 months.
The EQ-5D-3L questionnaire consists of five dimensions: mobility, self-care, usual activities, pain/discomfort
and anxiety/depression. For each dimension, the patient indicates the level of problems experienced on a
3-level scale: no problems, some problems or extreme problems. These responses were converted into
utility scores using the UK social tariff.111 EQ-5D-3L scores at baseline, 4 and 12 months for the exercise
and usual care groups are shown in Table 78. Estimated by the simple area-under-the-curve method, mean
QALYs attained over the trial period were slightly higher for the exercise group than for the usual care
group: 0.01 (95% CI –0.03 to 0.05). However, this does not take account of the initial differences
between the groups (Figure 9).
The SF-12 consists of 12 items addressing eight domains of health: physical functioning, role-physical,
bodily pain, general health, vitality, social functioning, role-emotional and mental health. Patients indicate
a level of problem on 3- or 5-level scales. The SF-12 was converted into a SF-6D utility score.112 SF-6D
results are shown in Table 79 and Figure 10. This yields a slightly higher and statistically different estimate
of the QALY difference between the groups: 0.02 (95% CI 0.01 to 0.04).
TABLE 78 Utility and QALY estimates: EQ-5D-3L scores
Time point
Number of patients Mean quantity (SE)
Mean treatment
difference (95% CI)
Exercise
programme Usual care
Exercise
programme Usual care
Baseline 244 240 0.57 (0.02) 0.59 (0.02) –0.03 (–0.07 to 0.02)
4 months 224 228 0.62 (0.02) 0.60 (0.02) 0.01 (–0.04 to 0.06)
12 months 215 221 0.62 (0.02) 0.62 (0.02) 0.00 (–0.05 to 0.05)
Change 0–12 months 214 220 0.03 (0.01) 0.02 (0.02) 0.01 (–0.04 to 0.05)
QALYs 207 215 0.62 (0.01) 0.61 (0.02) 0.01 (–0.03 to 0.05)
SE, standard error.
QALYs estimated by the area under the curve for individual patients.
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FIGURE 9 European Quality of Life-5 Dimensions scores over 12 months’ follow-up.
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For comparison, we also show results based on the EQ-5D-3L VAS, which provides us with a value for
the participant’s self-rated health at the time of survey completion on a scale of 0–100 (see Table 80
and Figure 11).
The EQ-5D-3L and SF-6D questionnaires give very different distributions of utility scores (Figures 12 and
13). The spread of scores is much wider with the EQ-5D-3L, with a small number of patients having
negative scores (‘worse than death’) and others with a score just under 1 (‘perfect health’). In contrast,
the SF-6D gives a much narrower range of scores.
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FIGURE 10 Short-Form questionnaire-6 Dimensions scores over 12 months’ follow-up.
TABLE 79 Utility and QALY estimates: SF-6D scores
Time point
Number of patients Mean quantity (SE)
Mean treatment
difference (95% CI)
Exercise
programme Usual care
Exercise
programme Usual care
Baseline 245 238 0.64 (0.01) 0.64 (0.01) 0.00 (–0.02 to 0.02)
4 months 214 221 0.67 (0.01) 0.66 (0.01) 0.01 (–0.01 to 0.03)
12 months 203 216 0.67 (0.01) 0.65 (0.01) 0.02 (0.00 to 0.05)
Change 0–12 months 203 212 0.02 (0.01) 0.01 (0.01) 0.02 (0.00 to 0.04)
QALYs 193 201 0.67 (0.01) 0.66 (0.01) 0.02 (0.01 to 0.04)
SE, standard error.
QALYs estimated by the area under the curve for individual patients.
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FIGURE 11 Visual analogue scale scores over 12 months’ follow-up.
TABLE 80 Utility and QALY estimates: VAS scores
Time point
Number of patients Mean quantity (SE)
Mean treatment
difference (95% CI)
Exercise
programme Usual care
Exercise
programme Usual care
Baseline 246 242 66.11 (1.24) 67.31 (1.16) –1.20 (–4.54 to 2.14)
4 months 224 228 69.50 (1.30) 67.72 (1.23) 1.78 (–1.73 to 5.28)
12 months 214 220 69.54 (1.22) 66.54 (1.33) 2.99 (–0.56 to 6.55)
Change 0–12 months 207 215 0.02 (0.01) 0.00 (0.01) 0.02 (0.00 to 0.05)
QALYs 207 215 0.70 (0.01) 0.68 (0.01) 0.02 (–0.01 to 0.07)
SE, standard error.
QALYs estimated by the area under the curve for individual patients.
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FIGURE 12 Frequency distribution of QALYs (EQ-5D-3L) by study arm. (a) Exercise programme; and (b) usual care.
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FIGURE 13 Frequency distribution of QALYs (SF-6D) by study arm. Cost-effectiveness plane (EQ-5D-3L) 1000
bootstrap samples. (a) Exercise programme; and (b) usual care.
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Cost-effectiveness analysis methods
The incremental cost-effectiveness of the exercise intervention compared with the usual care control was
estimated by five methods (see Table 81). These analyses differed in assumptions about the distributions of
costs and QALYs, whether or not correlations between costs and QALYs were accounted for, adjustment
for baseline utility values and the handling of missing data. Analysis E is our preferred analysis, as it
accounts for a range of potential biases and sources of uncertainty, as recommended in guidelines for
economic analyses based on trials.110 The other analyses provide supplementary information about the
relative impact of these factors.
The five analyses were repeated using QALY estimates derived from EQ-5D-3L and SF-6D observations.
Our primary analysis is that based on EQ-5D-3L data, as this is the utility measure currently recommended
by NICE for the evaluation of cost-effectiveness of interventions in the NHS.109
The first four analyses (A–D) included only patients for whom full data on costs and QALYs over the
12-month study period were available. For the analysis based on EQ-5D-3L data, complete economic data were
available for 396 patients (195 in the exercise group and 201 in the usual care group). And for the SF-6D
analysis, complete data were available for 374 patients (186 in the exercise group and 188 in the usual care
group). The final analysis (E) used multiple imputation to include all 488 randomised patients.119
Analysis A used simple, large sample methods to estimate differences in mean costs and in mean QALYs
between the groups, with no adjustment for baseline utility. Analysis B used a regression approach to
better reflect the nature of the data.120 It is apparent that the distributions of costs are highly skewed
(see Figure 8), such that ordinary least squares (OLS) assumptions of normality might not be appropriate;
hence a generalised linear model was fitted for costs using a gamma distribution and identity link function.
QALYs were estimated using an OLS regression with baseline utility (EQ-5D-3L or SF-6D scores) as a
covariate, to adjust for any difference between groups. This method of adjusting for baseline utility
differences is more efficient than estimation of QALYs using the ‘change from baseline’ method.121
Because QALYs are not normally distributed (see Figure 12) we also attempted to apply a gamma and
log-normal distribution for 1 QALY as the response, but this did not improve the fit.
The third analysis (C) also allowed for the likely correlation of costs and QALYs, which is potentially
important for efficient estimation.122 This used a seemingly unrelated regression (SUR) approach to
estimate the costs and QALYs simultaneously.123 Again, baseline utility was included as a covariate for
QALYS. Analysis D repeated the SUR regression analysis, but using non-parametric bootstrapping of
residuals to avoid the assumption that they were normally distributed. The results presented below are
based on 10,000 bootstrap samples, which was sufficient to provide stable estimates of costs and effects.
TABLE 81 Methods of analysis for within trial economic evaluation
Analysis
Treatment of
missing data Covariates
Assumed distribution
for costs/effects
Correlation between
costs and effects
A. t-test Patients with full data None Normal/normal No
B. GLM Patients with full data Baseline utility Normal/gamma No
C. SUR Patients with full data Baseline utility Normal/normal Yes
D. Bootstrap SUR Patients with full data Baseline utility Non-parametric Yes
E. Bootstrap SUR
with imputation
Multiple imputation Baseline utility Non-parametric Yes
GLM, generalised linear model; SUR, seemingly unrelated regression.
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The final analysis (E) combined the bootstrap SUR method with multiple imputation of missing cost and
QALY data.110 For each of 10,000 iterations: one set of missing values was imputed for utilities and costs;
the SUR analysis was run on the imputed data set; non-parametric bootstrap samples were drawn from
the SUR residuals for the two treatment groups; predicted values of costs and QALYs were calculated
using the bootstrapped residuals; and mean costs and QALYs were estimated for the two treatment
groups and saved. This procedure provided an empirical estimate of the sampling distribution for
mean costs and effects from the two groups, which was used to estimate uncertainty around the
cost-effectiveness statistics of interest. The multiple imputation procedure was conducted using the Stata
version 9 ado file ‘ice’ (Stata Corp LP, College Station, TX, USA), and estimated missing values of
EQ-5D-3L/SF-6D, drug costs and other health-care costs from the baseline, 4-month and 12-month
assessments, adjusting for age and baseline values of MHQ overall scale, troublesomeness of pain scale
and confidence scale.
Results for the various analyses are presented as incremental cost-effectiveness ratio (ICER) statistics – the
‘cost per QALY’. This is the estimated difference in mean costs between the exercise and usual care arms
(the incremental cost), divided by the difference in mean QALYs between the arms (incremental effect).
The ICERs can be compared against the benchmark thresholds for cost-effectiveness in the NHS context of
£20,000 to £30,000 per QALY gained, as applied by NICE.124 If the ICER is below £20,000 per QALY, this
suggests that the intervention is a cost-effective alternative to usual care. Above £30,000 per QALY, the
ICER suggests that the intervention is not cost-effective and, in between these figures, the result is
indeterminate. We also present the results using incremental net benefit (INB) statistics, calculated by
multiplying the incremental effects by an assumed monetary value of a QALY (the ‘cost-effectiveness
threshold’) and subtracting the incremental cost. We calculate INB statistics based on the two cost per
QALY thresholds of £20,000 and £30,000 per QALY. A positive INB suggests that the intervention is
cost-effective compared with usual care at the defined threshold.
Uncertainty over the cost-effectiveness of the intervention is reflected in an estimated probability that
the INB is positive. If this figure is greater than 0.5, it indicates that the intervention is more likely to be
cost-effective than not. Finally, we present an expected value of perfect information (EVPI) statistic, which
integrates the likelihood of making the wrong decision based on the mean INB statistic with the expected
loss if the wrong decision is made. This provides an estimate of the maximum that it would be worth
paying to obtain information to fully resolve uncertainty about the cost-effectiveness of the intervention.
Cost-effectiveness results
The results of an incremental cost-effectiveness analysis of the SARAH exercise programme compared with
usual care are presented in Tables 82 and 83, based on the EQ-5D-3L and SF-6D outcomes respectively.
The estimated mean health-care cost with the intervention was approximately £200 higher than the mean
cost under usual care based on our preferred analysis (method E using EQ-5D-3L data), but there was a
wide CI around this estimate (95% CI –£495 to £908). The results were more favourable when estimated
by the other methods of analyses (A to D) and for the EQ-5D-3L and SF-6D complete case data sets.
The estimated difference in mean QALYs accrued over the 12-month period was approximately 0.01
greater in the intervention group than in the usual care group (analysis E using EQ-5D-3L data), with a CI
of –0.02 to 0.04. The magnitude of QALY gain was similar across the different methods of estimation, and
with the EQ-5D-3L and SF-6D.
These results suggest that the hand exercise programme costs around £17,941 more per additional QALY
gained than the usual care control. This figure was rather more favourable under the other methods of
analysis based on complete case data set.
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Patients excluded from the economic complete case analyses were different from those included. Overall,
92 patients (41 control and 51 intervention) could not be included in the EQ-5D-3L based analysis because
one or more cost or utility observations were missing. At baseline, the excluded patients tended to be
younger (mean age 59 vs. 63, p< 0.001), with worse hand function (mean MHQ score 47 vs. 52 points,
p< 0.01), more troublesome pain (52 vs. 46, p< 0.01), poorer confidence in self-efficacy (64 vs. 69,
p< 0.05), lower EQ-5D-3L scores (0.48 vs. 0.60, p< 0.001) and higher daily drug costs (£4.64 vs. £7.21,
p< 0.05). Similar differences were found between the patients included/excluded from the SF-6D complete
case economic analysis.
Given the wide CIs for the incremental cost and QALY estimates, it is not surprising that a high level of
uncertainty over cost-effectiveness was observed. Figure 14 shows the results for 10,000 bootstrap
samples based on EQ-5D-3L analysis with imputation, where there is a 52% chance that the intervention is
cost-effective at a threshold of £20,000 per QALY and 59% chance at a threshold of £30,000 per QALY.
This uncertainty is also shown in the cost-effectiveness acceptability curve (CEAC) in Figure 15.
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FIGURE 14 Bootstrap samples using SUR and imputation of missing data (analysis E): CEAC (EQ-5D-3L). Controlling
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FIGURE 15 Cost-effectiveness acceptability curve based on analysis E (bootstrap SUR with imputation).
DOI: 10.3310/hta19190 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 19
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
103
Analysis of the SF-6D data yields a rather lower estimated probability that the intervention is cost-effective:
47% at £20,000 per QALY and 56% at £30,000 per QALY. Finally, the EVPI estimates indicate a maximum
value of further research in the region of £200 per patient.
Discussion
Analysis of the costs and effects of the hand exercise programme over the 12-month trial period indicates,
on balance, this is likely to be a cost-effective use of NHS resources. At £17,941 per QALY gained based
on EQ-5D-3L scores at 0, 4 and 12 months, the estimated ICER is within NICE’s lower cost-effective
thresholds of £20,000. Using the SF-6D method for quantifying HRQoL, the estimated ICER was slightly
less attractive, but still within the upper £30,000 per QALY threshold. There is, however, a high degree of
uncertainty over these estimates, owing to the small magnitude of QALY gain observed and the very wide
variation in the costs of rheumatoid-related health-care for individual patients.
Missing data might also have introduced a bias into the health economic results. Although overall rates of
data completion in the trial were very good, the complete resource use and utility data across all time
points that are needed to estimate QALYs and total costs for the year of follow-up were available for
fewer patients: 92 (19%) patients could not be included in the EQ-5D-3L based economic analysis, and
114 (23%) could not be included in the SF-6D analysis. Furthermore, the patients with missing data did
appear to be different from those with complete data: at baseline the former tended to be younger, with
worse hand function, pain, self-efficacy and quality of life, and higher drug costs. These differences may
explain the rather less attractive estimates of cost-effectiveness obtained when multiple imputation was
introduced to investigate the effect of missing data (analysis E, bootstrap SUR with imputation), compared
with our complete case analyses (analyses A–D). The probabilistic results for analysis E incorporate an
estimate of uncertainty related to the imputation procedure. However, there is a further element of
structural uncertainty related to the choice of the imputation model that is not quantified in the
above estimates.
The analysis was limited to a 12-month time horizon. There was an observed difference in reported quality
of life at this end point – not statistically significant for the EQ-5D-3L, but it was significant for the SF-6D,
and for the primary trial outcome of MHQ score. It is likely that this difference would have persisted for
some time after 12 months. This, coupled with the lack of evidence for any difference in health-care costs
other than the initial cost of delivering the intervention, suggests that the cost-effectiveness would be
better in the longer-term than that estimated. We therefore considered using modelling to extrapolate the
trial results, and to obtain a better long-run estimate of cost-effectiveness and of the uncertainty over this
figure. However, there is no reliable means for estimating the likely persistence of the quality-of-life gap
beyond 12 months. We therefore did not believe that modelling would help to resolve or further quantify
uncertainty in this case. Furthermore, any extrapolation would only be likely to reduce the estimated ICERs,
and would therefore not change the conclusion that the exercise programme is likely to be cost-effective.
Another potential bias that might have led to an underestimation of cost-effectiveness is double-counting
of the costs of the therapy sessions. Patients were asked about their use of a range of NHS services,
including physiotherapy and occupational therapy, at the 4-month and 12-month assessments. They were
asked not to include services that were part of the exercise programme intervention, as these were to be
costed separately based on attendance records at the exercise sessions. However, it is possible that some
patients might not have understood the difference between intervention and other routine therapy
sessions. The intervention group did report more frequent use of physiotherapy and occupational therapy
than the control group (see Tables 73 and 74), which translated to a mean additional cost of £33 per
patient. If we assumed that all of the difference in therapy costs was down to double counting, the correct
ICERs would be somewhat lower than the above estimates (£15,825 per QALY based on EQ-5D-3L
estimates, analysis E).
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Our conservative assumption regarding the training costs of physiotherapists and occupational therapists
may have also led to underestimation of cost-effectiveness. A simple sensitivity analysis shows that if the
ongoing training costs were half those incurred within the trial (£6.77 per patient), the ICER would fall
to £17,395. Using the best-case scenario for the cost of consumables (£24.75) reduced the ICER to
£16,361 and using the worst-case scenario (£106.34) increased the ICER to £23,453. The high degree of
uncertainty around the cost-effectiveness estimates suggests that further research that would reduce
this uncertainty might be worthwhile.
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Chapter 7 Extended follow-up study
Introduction
Having confirmed that the SARAH exercise programme improved hand function at 4 and 12 months
compared with usual care alone, a decision was made to carry out an extended follow-up. The aim of the
extended follow-up was to study the effects of the SARAH exercise programme beyond 12 months. We
had successfully completed a similar extended follow-up for another Health Technology Assessment (HTA)
funded study, the Back Skills Training Trial125 and we used similar follow-up procedures.
Methods
Data collection
Data collection was by postal questionnaire. The questionnaires were sent to participants at the same time
(between September 2012 and January 2013) regardless of when they were randomised, so that the time
to extended follow-up varied. Participants were sent a questionnaire and a response form so that they
could indicate whether or not they wish to participate in the extended follow-up. On the response form,
there was also an option for participants to request to complete the questionnaire over the telephone. We
designed a shortened version of the questionnaire containing only ‘core’ outcome measures, to be asked
and answered verbally, via telephone, by participants who had indicated they wish to do so. A reminder
letter encouraging participants to return the questionnaire was sent after 2 weeks to those who have not
yet returned their questionnaire.
To reduce the burden on participants, the number of outcome measures collected was reduced compared
with the earlier time points, and included the outcomes where significant differences between the two
groups were observed at earlier time points. The following outcomes were collected:
l MHQ – overall hand function subscale (primary outcome)
l MHQ – ADLs subscale
l MHQ – work subscale
l rating of troublesomeness
l participant-rated improvement
l Arthritis Self-efficacy Scale
l current hand exercise performance
l HRQoL (SF-12 and EQ-5D-3L)
l health-related resource use
l time off work.
Analysis of extended follow-up
We used the same data analysis methods for the extended follow-up as approved by DMEC for the main
trial. The analysis was intention to treat. We investigated differences in baseline characteristics of
participants completing and not completing the extended follow-up to assess selection bias.
The outcome measures based on scores from extended follow-up were analysed as a single time point as
for the earlier follow-up. The estimates were added to a reduced version of the previous outcome table.
For the MHQ overall hand function score, the inclusion of a time covariate was investigated. The repeated
measures and multiple imputation estimates for MHQ overall hand function were also calculated for the
extended follow-up time point.
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Ethical approval and monitoring
The Oxford C Multicentre Research Ethics Committee approved the extended follow-up study as a
substantial amendment in September 2012. The research and development departments of each
participating centre gave approval to implement the amendment.
The extended follow-up was supported by the DMEC and the TSC.
Results
Follow-up
There were 25 withdrawals and two unrelated deaths following the main study (one death occurred
between the 12-month follow-up and extended follow-up) so 461 participants were eligible to be
approached to take part in the extended follow-up. In total, 328 (67% of the original cohort) participants
provided data for the extended follow-up analysis (Table 84).
The time from randomisation to when the participant completed the extended follow-up is reported in
Table 85.
TABLE 84 Response to extended follow-up
Response category Exercise programme, n (%) Usual care, n (%)
Allocation 246 (100) 244 (100)
Withdrew 17 (7) 10 (2)
Died 0 (0) 2 (1)
Eligible for extended follow-up 229 (93) 232 (95)
Unable to contact (no current contact
details available)
3 (1) 2 (< 1)
Sent extended follow-up questionnaire 226 (92) 231 (95)
Provided extended follow-up data 155 (63) 173 (71)
Full questionnaire 153 (62) 172 (70)
Core questionnaire (phone) 2 (< 1) 1 (< 1)
Declined to participate 18 (7) 11 (5)
Unable to contact 6 (3) 3 (1)
Died 2 (< 1) 0 (0)
Did not respond 48 (20) 45 (19)
TABLE 85 Median time (in months) from randomisation to completion of extended follow-up
Time Exercise programme, median (IQR) Usual care, median (IQR)
Time in months to extended follow-up 25.8 (22.0–30.8) 26.0 (22.2–29.9)
IQR, interquartile range.
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Comparisons of those retained versus lost to follow-up
Baseline characteristics of participants who did and did not complete the extended follow-up questionnaire
are provided in Table 86. The groups were broadly similar based on age, gender, duration of disease and
EQ-5D-3L scores. Those who were lost to follow-up had worse hand function at baseline (approximately
6 points lower on the MHQ) than those retained in the study. They also had slightly lower SF-12 scores.
Missing data
The number of missing data on the returned questionnaires was minimal (Table 87).
TABLE 86 Characteristics of participants completing and not completing the extended follow-up by arm
Characteristic by arm
Participants completing
the extended follow-up
Participants not completing
the extended follow-up
Exercise programme
Age (years) at randomisation, mean (SD) 62.9 (11.0) 58.6 (14.0)
Sex, percentage female 77.4 74.7
Disease duration (years), mean (SD) 12.4 (10.8) 14.4 (10.4)
Baseline MHQ hand function, mean (SD) 53.9 (15.1) 48.9 (14.8)
SF-12 PCS, mean (SD) 35.4 (9.7) 31.1 (9.4)
SF-12 MCS, mean (SD) 49.7 (10.5) 45.5 (10.7)
EQ-5D-3L health state, mean (SD) 0.6 (0.3) 0.5 (0.3)
Change in MHQ hand function baseline to 12 months,
mean (SD)
7.2 (13.6) 9.8 (16.8)
Change in SF-12 PCS baseline to 12 months, mean (SD) 0.8 (7.2) 2.3 (6.3)
Change in SF-12 MCS baseline to 12 months, mean (SD) 2.1 (9.9) 2.4 (12.4)
Change in EQ-5D-3L health state baseline to 12 months,
mean (SD)
0.0 (0.2) 0.0 (0.2)
Usual care
Age (years), mean (SD) 64.3 (10.8) 61.5 (12.1)
Sex, percentage female 74.0 81.2
Disease duration (years), mean (SD) 14.7 (12.5) 12.3 (10.7)
Baseline MHQ hand function, mean (SD) 54.1 (15.6) 47.0 (17.4)
SF-12 PCS, mean (SD) 35.4 (9.7) 32.1 (8.5)
SF-12 MCS, mean (SD) 50.4 (10.4) 45.1 (11.7)
EQ-5D-3L health state, mean (SD) 0.6 (0.2) 0.5 (0.3)
Change in MHQ hand function baseline to 12 months,
mean (SD)
3.2 (16.0) 4.8 (16.3)
Change in SF-12 PCS baseline to 12 months, mean (SD) –0.1 (7.6) 0.5 (6.7)
Change in SF-12 MCS baseline to 12 months, mean (SD) 0.2 (9.5) 1.1 (10.8)
Change in EQ-5D-3L health state baseline to 12 months,
mean (SD)
0.0 (0.2) 0.0 (0.3)
continued
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TABLE 86 Characteristics of participants completing and not completing the extended follow-up
by arm (continued )
Characteristic by arm
Participants completing
the extended follow-up
Participants not completing
the extended follow-up
Combined
Age (years), mean (SD) 63.6 (10.9) 59.8 (13.2)
Sex, percentage female 75.5 77.8
Disease duration (years), mean (SD) 13.7 (11.8) 13.5 (10.6)
Baseline MHQ hand function, mean (SD) 54.0 (15.4) 48.1 (15.9)
SF-12 PCS, mean (SD) 35.4 (9.7) 31.5 (9.0)
SF-12 MCS, mean (SD) 50.1 (10.4) 45.3 (11.1)
EQ-5D-3L health state, mean (SD) 0.6 (0.3) 0.5 (0.3)
Change in MHQ hand function baseline to 12 months,
mean (SD)
5.1 (15.0) 7.5 (16.7)
Change in SF-12 PCS baseline to 12 months, mean (SD) 0.3 (7.5) 1.5 (6.5)
Change in SF-12 MCS baseline to 12 months, mean (SD) 1.1 (9.7) 1.8 (11.7)
Change in EQ-5D-3L health state baseline to 12 months,
mean (SD)
0.0 (0.2) 0.0 (0.3)
SD, standard deviation.
TABLE 87 Missing items/scales from questionnaires
Missing items/scales questionnaires
Extended follow-up
Exercise programme (n= 155) Usual care (n= 173)
MHQ
MHQ: overall hand function both 1 –
MHQ: ADLs 2 1
MHQ: work 8 4
Secondary outcomes
Pain troublesomeness: any missing 2 –
Arthritis self-efficacy scale: any missing 4 1
Participant-rated benefit 2 1
EQ-5D-3L any items 2 –
SF-12 any missing items – –
Health resource use sections
GP visits because of RA 5 2
Nights in NHS hospital (RA) 3 –
Work
Days off work 3 1
Current exercises 2 –
GP, general practitioner.
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Outcomes and estimation
Primary outcome: hand function
Both groups continued to report improved hand function compared with baseline at the extended
follow-up with greater benefit observed in the exercise group. The difference between the two groups was
no longer statistically significant (Figure 16 and Table 88).
In the adjusted analysis of the primary outcome, the time from randomisation to receipt of follow-up in
months was included as a covariate. As shown in Table 88 this resulted in a small change to the estimated
treatment effect from 1.74 to 1.93. A test to determine whether there was a difference in the follow-up
effect between treatments was not significant (p= 0.2607).
Repeated measures analysis of overall hand function
As with the main trial analysis, the repeated measures estimate uses the overall hand function scores at all
time points and is adjusted for hospital, age and sex. The treatment difference estimated from baseline
to the extended follow-up is 1.49 (95% CI –1.68 to 4.65; p= 0.3585).
TABLE 88 Michigan Hand Outcome Questionnaire overall hand function subscale scores at extended follow-up
MHQ overall
hand function
(both hands)
Number of
patients analysed Mean change score (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
Extended
follow-up
154 173 3.76
(1.50 to 6.02)
1.97
(–0.45 to 4.39)
1.74
(–1.46 to 4.95)
0.2875 0.11
(–10.00 to 0.32)
Adjusted for centre, sex and age 1.72
(–1.53 to 4.96)
0.3007
Adjusted for centre, sex, age and time of follow-up 1.93
(–1.33 to 5.19)
0.2469
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FIGURE 16 Michigan Hand Outcome Questionnaire overall hand function subscale scores over time.
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Multiple imputation estimate for overall hand function
To take some account of the effects of the data being incomplete, the same method of multiple
imputation analysis was used here as in the main trial analysis with the addition of the extra time point.
The estimate of treatment difference from baseline to extended follow-up is 1.31 (95% CI –2.08 to
4.71; p= 0.4404).
Complier average causal effect
The CACE estimates based on full attendance and for the lower compliance threshold are slightly larger
than the overall trial estimates for the extended follow-up but they remain non-significant.
Complier average causal effect estimates for 0–24 months with bootstrap 95% CI:
Threshold (complier = 6þ sessions) = 2:04 (95% CI −0:68 to 5:97) (1)
Threshold (complier = 3þ sessions) = 1:92 (95% CI −0:84 to 4:37) (2)
Other outcomes
Michigan Hand Outcome Questionnaire activities of daily living and
work subscales
Both groups had higher MHQ ADLs scores and MHQ work at the extended follow-up than at baseline.
Greater improvement from baseline was observable in the exercise arm but the difference between
the two groups was no longer significant (Table 89).
Health-related quality of Life (Short Form questionnaire-12 items and
European Quality of Life-5 Dimensions)
There was no difference between the two treatments as measured by the SF-12. The majority of SF-12
subscales were similar to the baseline scores at the extended follow-up in both groups. The exceptions
were the social functioning subscale, with both groups demonstrating a reduction in social functioning
compared with baseline, although there was no difference between the groups. Both groups also reported
a reduction in their general health compared with baseline, but there was no difference between the
two groups.
There was no difference between the two treatments as measured by the EQ-5D-3L (Tables 90 and 91).
TABLE 89 Michigan Hand Outcome Questionnaire ADLs and work subscales
MHQ
Number of patients Mean change score (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
MHQ ADLs (both hands)
Extended
follow-up
152 172 3.15
(0.30 to 6.01)
2.34
(0.03 to 4.66)
0.85
(–2.71 to 4.42)
0.6401 0.03
(–0.12 to 0.18)
MHQ work
Extended
Follow-up
147 168 7.76
(4.67 to 10.84)
5.81
(2.97 to 8.65)
1.84
(–2.22 to 5.90)
0.3745 0.09
(–0.10 to 0.28)
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TABLE 90 Short Form questionnaire-12 items scores
SF-12
Number of patients Mean change score (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
SF-12 aggregate physical scale (PCS)
Extended
follow-up
153 173 0.19
(–1.16 to 1.54)
0.51
(–1.66 to 0.64)
0.69
(–1.01 to 2.40)
0.4271 0.07
(–0.11 to 0.26)
SF-12 aggregate mental scale (MCS)
Extended
follow-up
153 173 0.27
(–1.25 to 1.78)
0.21
(–1.23 to 1.66)
–0.22
(–2.11 to 1.67)
0.8215 0.00
(–0.19 to 0.20)
SF-12 physical functioning
Extended
follow-up
150 167 1.33
(–2.78 to 5.45)
–2.25
(–6.03 to 1.54)
3.21
(–2.12 to 8.54)
0.2388 0.12
(–0.07 to 0.30)
SF-12 role-physical
Extended
follow-up
149 169 2.18
(–1.38 to 5.74)
1.11
(–2.23 to 4.45)
1.11
(–3.47 to 5.69)
0.6362 0.04
(–0.15 to 0.23)
SF-12 bodily pain
Extended
follow-up
153 172 2.12
(–1.99 to 6.24)
2.76
(–0.84 to 6.36)
–0.53
(–5.40 to 4.35)
0.8322 –0.02
(–0.23 to 0.19)
SF-12 general health
Extended
follow-up
152 173 –3.09
(–6.48 to 0.30)
–4.13
(–7.41 to –0.86)
0.65
(–3.58 to 4.87)
0.7648 0.04
(–0.14 to 0.22)
SF-12 vitality
Extended
follow-up
150 173 2.00
(–1.67 to 5.67)
0.14
(–3.08 to 3.37)
1.81
(–2.60 to 6.22)
0.4227 0.07
(–0.12 to 0.27)
SF-12 social functioning
Extended
follow-up
153 173 –4.41
(–8.86 to –0.15)
–3.18
(–6.90 to 0.54)
–1.38
(–6.39 to 3.62)
0.5887 –0.04
(–0.25 to 0.16)
SF-12 role-emotional
Extended
follow-up
150 171 4.08
(–0.15 to 8.32)
1.46
(–2.35 to 5.27)
1.15
(–3.80 to 6.10)
0.6500 0.09
(–0.10 to 0.28)
SF-12 mental health
Extended
follow-up
150 168 –0.33
(–3.67 to 3.00)
0.97
(–2.03 to 3.96)
–1.44
(–5.45 to 2.58)
0.4842 –0.06
(–0.27 to 0.15)
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Pain troublesomeness and self-efficacy
At the previous follow-up point, both groups had reported less pain than at baseline, and this continued in
the control group at extended follow-up. The pain scores reported in the exercise arm were similar to
baseline scores. The difference between the two groups was not significant (Table 92). Self-efficacy scores
remained slightly higher in the exercise arm than in the control arm, but the difference was not significant
(Table 93).
Participant rated improvement
There was no difference between the two groups as measured by the participant-rated improvement
(Table 94).
Current hand exercise performance
There was no difference in current exercise performance between the two groups (Table 95).
TABLE 92 Pain troublesomeness
Pain
troublesomeness
overall scorea
Number of patients Mean change score (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
Extended follow-up 153 173 0.20
(–2.98 to 3.38)
–3.79
(–6.93 to –0.64)
2.68
(–1.41 to 6.77)
0.2002 0.18
(–0.02 to 0.39)
a Higher score= pain more troublesome.
TABLE 93 Self-efficacy
Confidence in
performing tasks
overall score
Number of patients Mean change score (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
Extended follow-up 151 172 2.96
(0.03 to 5.90)
0.22
(–2.34 to 2.78)
2.11
(–1.37 to 5.59)
0.2347 0.14
(–0.06 to 0.34)
TABLE 91 European Quality of Life-5 Dimensions scores
EQ-5D-3L
Number of patients Mean change score (95% CI) Mean
treatment
difference
(95% CI) p-value
Standardised
mean
difference
(95% CI)
Exercise
programme
Usual
care
Exercise
programme Usual care
EQ-5D-3L health statea
Extended follow-up 152 172 –0.01
(–0.05 to 0.03)
–0.01
(–0.05 to 0.02)
–0.01
(–0.06 to 0.04)
0.6511 0.01
(–0.18 to 0.20)
EQ-5D-3L VAS (your health today)
Extended follow-up 151 171 –1.42
(–4.23 to 1.38)
–1.91
(–4.49 to 0.68)
–0.03
(–3.20 to 3.80)
0.8667 0.03
(–0.18 to 0.23)
a Full health= 1.0.
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Health resource use
Four participants in the exercise intervention arm and six participants in the usual care arm reported
spending at least one night in a NHS hospital because of their RA within the previous 4 months. The mean
number of nights is not reported since four of the six participants in the usual care arm did not report how
many nights and one participant in the intervention arm reported spending 28 nights in hospital. There
was no difference in visits to their general practitioner or NHS therapists because of RA between the two
groups (Table 96).
Time off work
Of those participants working, 3/41 in the exercise intervention arm and 7/47 in the usual care arm
reported taking time off work during the previous 4 months because of their RA. The number of days off
work is not presented as this was dominated by two participants in the usual care arm losing 16 weeks
and 8 weeks. Changes to work hours owing to RA are reported in Table 97. There was no difference
between the two groups.
TABLE 95 Participants performing hand/wrist exercises to help with RA by arm
Are you currently doing any hand/wrist
exercises to help with your RA?
Extended follow-up
Exercise programme, n (%) Usual care, n (%)
No 57 (37.3) 74 (42.8)
Yes, total 96 (62.7) 99 (57.2)
Yes, daily 20 (13.2) 38 (22.1)
Yes, 3–4 times a week 28 (18.5) 22 (12.8)
Yes, 1–2 times a week 42 (27.8) 35 (20.3)
Yes, other 6 (4.0) 3 (1.7)
Yes, blank – 1 (0.6)
Total 151 172
Chi-squared test for currently performing exercises or not (p= 0.3104).
TABLE 94 Self-rated improvement by arm
Response
Extended follow-up
Exercise programme, n (%) Usual care, n (%)
Completely recovered – 1 (0.6)
Much improved 25 (16.3) 22 (12.8)
Slightly improved 24 (15.7) 17 (9.9)
No change 58 (37.9) 75 (43.6)
Slightly worsened 35 (22.9) 41 (23.8)
Much worsened 7 (4.6) 15 (8.7)
Vastly worsened 4 (2.6) 1 (0.6)
Total 153 172
Mantel–Haenszel chi-squared test for linear association (p= 0.2729).
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Discussion
Improvements in the primary outcome compared with baseline were still observable in both groups more
than 2 years after randomisation. MHQ overall hand function scores at the extended follow-up remained
higher than baseline scores despite a reduction over time compared with earlier follow-up points.
Greater benefit persisted in the exercise group although this was no longer significantly different between
groups. A similar pattern was observable in the MHQ ADLs and work subscale scores. We demonstrated
at earlier time points that the exercise programme did not result in increased pain and this was still true at
the extended follow-up.
The majority of subscales in the HRQoL measures were similar to baseline scores at the extended follow-up
and there were no differences between the two groups. Some improvement was observed in aspects
of HRQoL at earlier time points, but it is not surprising that this effect diminished over time as the
intervention was specifically focused to the hand. An interesting finding was that both groups reported
reduced general health ratings and social interaction scores measured by the SF-12 compared with
baseline. This may reflect the impact of RA as a systemic disease on general health and subsequently social
functioning as individuals with RA often have comorbidities such as cardiovascular problems.126
The mean follow-up time point was approximately 26 months post randomisation. Participants who were
allocated to the exercise intervention had completed treatment with the therapist approximately 3 months
post randomisation and so for some participants it had been 2 years since they had attended an
appointment with a therapist. Therefore, it is unsurprising that the added benefit from attending the
therapy sessions had reduced over time. The qualitative study demonstrated that the encouragement and
support provided by the therapists was integral to them successfully carrying out their exercise programme
regularly. The data suggest that by the extended follow-up many of the participants who were allocated to
the exercise arm were no longer doing the exercises they were given as part of the study. At 4 months,
88% of participants reported doing hand/wrist exercises for their RA, and this fell to 70% at 12 months’
follow-up. There was a further reduction to 63% at the extended follow-up. Specifically, the number of
TABLE 97 Changes to employment owing to RA in the last 4 months
Changes to hours of employment owing to RA
Extended follow-up
Exercise programme Usual care
No, stayed the same 33 34
Yes, increased – 1
Yes, decreased 2 3
Not applicable 117 134
TABLE 96 Mean NHS service use within the last 4 months
Type of care
Number of patients Mean quantity (SE)
Mean treatment
difference (95% CI)
Exercise
programme Usual care
Exercise
programme Usual care
General practitioner
visits due to RA
51/150 61/171 0.678 (0.110) 0.564 (0.074) 0.117 (–0.143 to 0.377)
NHS therapist visits
due to RA
29/152 27/172 0.467 (0.131) 0.394 (0.109) 0.073 (–0.261 to 0.407)
SE, standard error.
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participants who reported doing daily hand/wrist exercises (as per the exercise intervention protocol) had
fallen from 44% at 4 months follow-up to only 13% at the extended follow-up. Reported exercise
behaviour was very similar in the two arms of the study at the extended follow-up time point. RA is a
progressive disease so regular exercise of sufficient intensity is needed to maintain muscle strength and
flexibility. It is likely that participants in the exercise intervention arm were no longer achieving a sufficient
level of exercise intensity to maintain the functional improvements they achieved earlier on in the study
compared with the control group.
It was proposed that another mechanism by which the intervention improved function was bolstering
self-efficacy and the participants’ ability to self-manage their condition. This effect had also diminished
over time and the difference between the groups was no longer evident. This may be because it had been
such a long time since receiving encouragement and support from the therapist.
The response rate for extended follow-up was lower than for the main study. This was not unexpected as
it was a postal questionnaire rather than the face-to-face appointment used for the earlier follow-up
assessments. Also, as this was not planned at the outset of the study and participants had not been made
aware of the extended follow-up, we limited the contact with participants to reminders by post so as not
to place undue pressure on participants to respond. We only phoned those who requested to complete
the questionnaire by phone. In total, 67% of participants provided follow-up data, which means the
analysis is slightly underpowered to detect a difference in the primary outcome. Loss to follow-up could
introduce bias and there were some differences in baseline characteristics of those who responded and
those who did not. Most notably, those who did not return the questionnaire had poorer hand function
at baseline compared with those who did return the questionnaire. The difference was approximately
6 points on the MHQ. Multiple imputation techniques were used to estimate the effect of missing data
and the results were largely similar, indicating that the missing data did not overly influence the findings.
Overall, we are confident that the participants providing data were a good representation of the
total cohort.
These results show that an exercise programme delivered over 12 weeks benefited participants for
12 months, but after this time point a reduction in benefit was observed. These findings raise important
questions regarding how patients might be encouraged to carry out exercise programmes long term in the
hope that improvements will be maintained. In the qualitative study, interviewees did suggest that ongoing
contact with the therapist would help them to continue with their exercises. Further research needs to
evaluate methods of providing support for patients to assist them to continue with long-term
exercise programmes.
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Chapter 8 Discussion
This discussion provides an overview of findings, issues surrounding internal and external validity of thestudy and its analyses and provides interpretation for clinical and policy arenas. Recommendations
for further research are also provided.
Aims and overview of the trial findings
Hand and wrist dysfunction are a significant and common concern for people with RA. Clinical guidelines
recommend treatments targeted specifically at hands to improve impairments and resulting disabilities.
Prior to the SARAH trial, no high-quality evidence existed regarding the clinical effectiveness of exercise
specifically for RA hands, although findings from small-scale studies were promising. Also, no evidence
existed of cost related to exercise interventions of hand therapy for RA and subsequent cost-effectiveness
analyses. Therefore, the aim of the study was to estimate the clinical effectiveness and cost-effectiveness
of adding an optimised exercise programme to best practice usual care. The addition of an embedded
qualitative study provided the participants’ perspective and assists with explaining and interpreting
the findings.
For the primary outcome of overall hand function, an optimised programme of stretching and
strengthening exercises provided significant improvements in both the short and long term (4 and
12 months) when added to best practice usual care. Maintenance of an effect at 12 months is
impressive considering the intervention was delivered in the first 4 months and then relied on patients to
self-manage. The finding from the primary outcome is supported by findings from some, but not all,
secondary outcome measures: participants reported greater ratings of global improvement, greater benefit
from treatment and greater treatment satisfaction at both time points. As well as improving hand function,
the exercise programme resulted in significant improvement in self-efficacy. Physical and psychological
benefits from the exercise programme were reported by participants of the qualitative study. The pattern
of changes are consistent with an intervention that effects hand function but not the broader effects of RA
such as impaired mobility (although swollen and tender joints in the hands and wrists were significantly
improved in the short term). The findings from the extended follow-up study that there was no benefit of
the exercise programme over usual care alone at approximately 2 years after randomisation and treatment
is at odds with the original study time points but not unexpected considering the lack of therapist support
and reduction in proportion of patients continuing to perform specific exercises.
With regard to impairment measures, there were improvements in strength, ROM and dexterity in both
groups. The exercise programme group had greater gains in power grip strength at 4 months and pinch
grip strength at 12 months. Improvements in dexterity, measured by the nine-hole peg test, were
sustained in the exercise programme. Whether or not further sessions or longer treatment duration
would have resulted in greater changes in impairment measures is a matter of conjecture, although
previous studies have not reported consistent links between improved function and changes in
impairment measures.
The intervention is likely to be cost-effective, although there is considerable uncertainty owing to
difficulties in estimating costs and the small magnitude of the observed between-group difference in
EQ-5D-3L scores (there is a 59–66% likelihood that it is cost-effective at an upper NICE threshold of
£30,000 per additional QALY gained for the base-case analysis). Results suggest that the hand exercise
programme costs between £6000 and £23,000 more per additional QALY gained over a 12-month time
horizon, compared with usual care and depending on the measure and methods of analysis used. These
figures are within current willingness-to-pay levels applied by NICE. The exercise programme is also a
cheap intervention, costing around one-tenth of the cost of average medications for the patients in this
study over 12 months.
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This trial also proved that the addition of an optimised exercise programme was safe. There was, on
average, no increase in pain or disease activity, no adverse events attributable to treatments and a
short-term reduction in joint tenderness and swelling.
Internal validity and methodological limitations
According to the sample size calculation, data from a minimum of 352 participants were required to show
a moderate mean effect size difference of 0.3 at 12 months. We recruited 490 participants and had a
lower than estimated loss to follow-up rate of 10%, producing 438 participants with primary outcome
data at 12 months, which provided ample statistical power to detect the difference originally specified.
Randomisation resulted in two well-matched groups. Demographic data, self-report functional measures,
clinical impairment measures and disease stability and duration were all very similar. The small difference
between arms in proportions of participants taking single or combination DMARDs is very unlikely to be a
significant imbalance. Randomisation was stratified by site and used variable block length, minimising the
chances of research staff anticipating and allocating treatments for certain participants.
It was intended that outcome assessors (research clinicians) would remain blind to allocation throughout
the trial. It was not possible to blind participants and therapists because of the nature of the interventions
tested. We asked the participants not to disclose the treatments they received within the trial; however,
with face-to-face assessments (as opposed to postal questionnaires) there is a risk that unblinding can
occur, and it appears that outcome assessors were unblinded in approximately one-quarter of cases. The
rate indicates the difficulty in maintaining blinding in pragmatic rehabilitation trials of this nature. Post-hoc
sensitivity analysis indicated that this does not have a significant impact on findings. It is also to be noted
that the primary outcome measure was participant self-report and, therefore, unlikely to have been
influenced by unblinding of the outcome assessor anyway.
The interventions in both arms were well received by participants according to the results of the satisfaction
with treatment question and qualitative study, and well delivered by the therapists as determined by quality
assurance checks. Attendance rates were above those normally expected for NHS out-patient therapy
(10% non-attendance according to the Audit Commission)127 and adherence to the treatment protocols
was good, with 75% of participants in the exercise programme arm completing all six sessions of treatment.
Progression of exercises was regarded as key in order to achieve the physiological changes required for
strengthening and stretching of hands and wrists. The treatment logs provided evidence that approximately
80% of participants in the experimental arm progressed between their first and last sessions as intended.
We found no significant therapist effects at either time point, implying a well-standardised intervention.
A small proportion of participants (5%) withdrew, and these were generally distributed evenly across the
two trial arms. There was a trend for a higher proportion of loss to follow-up among participants in the
exercise programme and mostly at their time of treatment, potentially because of the greater number of
sessions and demands on their time, but this was within the realms of chance. There were no significant
baseline differences between those retained and those lost to follow-up although there was a slight trend
for lost participants to be younger and male – a common finding in pragmatic clinical trials. Where
participants were unable to attend face-to-face clinic assessments, collecting core data by postal
questionnaire or telephone proved successful in retaining an extra 10–15% of original participants. Overall,
our estimates of treatment effectiveness appear insensitive to missing data.
Medication can have a far greater influence on symptoms and disability than an exercise programme for
RA so we investigated this as part of the trial. There were no significant differences in medication type,
usage and changes at the follow-up time points, suggesting that the changes found in hand function were
due to the addition of the exercise programme.
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External validity and generalisability of the findings
Overall, we believe the generalisability of the findings of the trial is good. Originally we had planned to
recruit from 10 NHS trusts; however, a suboptimal recruitment rate meant that we involved a further seven
NHS trusts. The advantage of this was a greater range of centres in terms of geography and size. We
recruited from large university teaching hospitals as well as small district general hospitals. The training
provided to the staff in these centres was brief, with most NHS therapy staff already having sufficient
expertise to deliver the exercise programme intervention. As a result we believe the implementation of this
intervention into the NHS would be straightforward and involve relatively small cost.
We consider the population recruited into this trial to be representative of patients who would be referred
from NHS rheumatology clinics to hand therapy for treatment of hand and wrist problems. The majority of
study participants were female (76%), which reflects the estimates that prevalence in women is three
times that of men.1 The average age of participants was 63 years, which is consistent with the estimate
of 70+ years as the peak age of prevalent RA.128 A previous RCT reported a cohort of very similar
characteristics.23 There exists the possibility that those recruited into the study form only a proportion of
RA patients who typically present to rheumatology clinics, with some suggestions that newly diagnosed
patients (i.e. younger with shorter disease duration) and those suffering from greater instability or
‘flare-ups’ form a significant percentage of the caseload.
There were few recently diagnosed patients in this study. The inclusion criteria for the study stipulated that
patients needed to be on stable medications for at least 3 months. This may have resulted in a higher
proportion of patients with longer disease duration being included in the study as patients are less likely to
be on stable medication regimes when newly diagnosed. Our qualitative study found that one of the main
barriers to regular exercise was flare-ups or increased symptoms. This suggests that stable symptoms are
an important aspect of selecting patients for this intervention as uncontrolled symptoms make
exercising difficult.
The participants in this study had relatively low inflammatory disease activity, as shown by the low ESR and
CRP in both treatment groups at baseline. This would be in keeping with the idea that they represent a
group who have been established and stabilised on a successful treatment regime, and thus very few
patients required changes in DMARD treatment during the course of the study. It is important to note,
however, that this does not mean that these were patients whose RA had burnt out. On the contrary,
approximately half the participants were being treated with either biologic DMARDs or combination
non-biologic DMARDs, which are the two most intensive forms of drug therapy for RA. About one-fifth of
participants were being treated with biologic DMARDs, which signifies that in the relatively recent past
their arthritis was so active that they fulfilled the NICE guidelines for starting these new and expensive
agents. Thus, the results of the study suggest that, when active disease has been brought under control
using an appropriate DMARD regime, the addition of a relatively inexpensive exercise programme can
maximise the beneficial effect to the patient. The qualitative study also suggests that it would be better to
introduce exercise once active joint inflammation has been controlled, since pain or flaring in joints was
identified as a disincentive to carrying out exercises.
Our cohort had a slightly higher proportion of participants of white ethnicity compared with the British
population as a whole (97% vs. 91% respectively),129 but the prevalence of RA in ethnic minorities is not
well known or understood so it is difficult to infer what influence this may have on the generalisability of
our results. It is not unusual to have difficulty recruiting ethnic minority patients with RA into trials and we
would echo calls for further research in this area.
The source of recruitment for the study (i.e. approached while attending rheumatology clinic or from
mail-out to patients on rheumatology or therapy review lists) was equal in the two groups and did not
appear to have any effect on treatment outcomes. Other subgroup analyses examining baseline disease
DOI: 10.3310/hta19190 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 19
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
121
duration, age, sex, disease activity, medication, hand function (MHQ) and HRQoL (SF-12) indicate that
these factors also did not affect the primary outcome measure.
Interpretation and implications for clinical practice and policy
Although a statistically significant difference in hand function at 12 months was found between the two
groups, it is difficult to state the degree of clinical benefit provided by the exercise programme over and
above the usual care intervention. The difference in scores between the groups was between 4–5 points
on the MHQ overall hand function scale in favour of the exercise group. Although the responsiveness to
change of the MHQ has been reported elsewhere,41 the minimum clinically important difference for the
MHQ has not been established in a conservatively treated RA population. Previous work has investigated
this property of the MHQ following MCP joint arthroplasty with the minimum clinically important
difference of the hand function subscale reported at 13 points.130 These findings suggest that the change
in hand function in this study did not reach clinical relevance as it was less than half of the change that
would be required for the participant to describe an improvement in satisfaction with hand function.
An alternative explanation is that a conservative intervention, such as the exercise programme used in this
study, resulted in a clinical change almost half of that previously described for joint surgery, a procedure
vastly more invasive and costly that would be expected to result in a far greater difference between
pre- and post-intervention assessments. Viewed from this perspective, the change score recorded as part
of this study is good. The extended follow-up demonstrated that the benefit of the exercise programme
was reduced but not completely diminished at a mean follow-up time of 26 months post randomisation.
This is an encouraging finding as the participants received the intervention in the 4 first months post
randomisation but the benefit was observed for a considerable time beyond this period. As RA is a chronic
disease it is most likely that patients need to continue with regular exercise at an adequate level to
maintain improvements for longer time periods. The participants in this study did not receive any further
support to continue their exercises beyond the duration of their appointments with the therapists when
they were left to exercise independently. Finding cost-effective ways to support patients to continue with a
regular independent exercise programme at a sufficient dose could potentially extend the benefits already
demonstrated by this study.
For the purposes of the trial, the control intervention was standardised across all sites in accordance with
what would be considered ‘best practice’ usual care, with the quality of this care being high. Prior to the
trial, considerable variation in normal practice existed across the centres, with some offering little or no
treatment. Therefore, involvement of these ‘no treatment’ centres in the trial resulted in additional care for
their patients irrespective of which arm they were allocated to. The subsequent improvement described
for those in the control intervention may include the effect of the greater than normal treatment at some
sites, suggesting that the mean treatment difference between the groups may be underestimated for some
NHS trusts currently.
From the 12-month interviews it was apparent that, in addition to functional improvement, interviewees
reported psychological benefits, primarily in their confidence levels. This reported benefit was also mirrored
in the main trial findings, with those receiving the exercise intervention reporting higher levels of
self-efficacy to manage their arthritis. Improvement in confidence may go some way to explain why
the exercise intervention improved function despite no impact on participants’ pain or symptoms.
One of the pleasing aspects of the study was the high number of participants who completed the exercise
programme in full with its associated procedures (74%). This in part can be explained by the motivation of
the participants, but is also due to the design of the intervention, which made every effort to include
measures to increase adherence. The importance of maximising adherence is highlighted by the results of
the CACE analysis, which, despite being limited to some extent by the small number of participants that
did not attend all six sessions, revealed a greater treatment effect for those who completed treatment
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in full. This may be an important factor for therapists to consider when providing information to patients
regarding how to gain maximum benefit from an exercise programme. It also suggests that a minimum
number of sessions or duration of treatment is required in order to effect the necessary changes,
physiological or otherwise, that result in improved hand function.
Participants in the interview study were advocates of exercise, which is perhaps unsurprising as they had
agreed to participate in a research project involving exercise. Patients seen in normal clinical practice may
not hold such beliefs about the benefit of exercise, which could potentially impact on their adherence.
The interview study identified several factors that are important for future implementation of the SARAH
intervention into clinical practice. The key to adherence was the ability to ‘establish a routine’. Interviewees
reported the importance of being able to integrate the programme into their daily routine as being
essential to regular completion of the exercise programme. The behavioural strategies (daily exercise diary
and PEG) used in the study were reported to be helpful tools to assist in establishing a routine; thus, this
would be an essential component to delivering the exercise programme in clinical practice. The therapists
also had a pivotal role in teaching, supporting and motivating patients to carry out the exercises at home.
It was also suggested that interviewees need to be motivated to do this and, if motivational factors are
lacking, then adherence to the exercise programme is unlikely. Demotivating factors were often linked to
the symptoms experienced by patients. For example, if they perceived their symptoms to be too mild then
they were unlikely to be motivated to exercise because of a lack of potential benefit. However, severe
symptoms such as those experienced during a flare-up were also potential barriers to carrying out the
programme. Other potential barriers spoken about were competing priorities, lack of time and having a
negative mindset. These are important factors for therapists to consider when trying delivering the SARAH
intervention in clinical practice.
Other literature
Only one relevant RCT has been published since the SARAH trial began. Cima et al.131 randomised
20 women with deformed RA hands to receive an intensive strengthening and co-ordination exercise
programme or no treatment. The results showed that function and grip strength were significantly
improved in patients in the exercise arm but were only for short-term measurement (follow-up 10 weeks).
This reinforces the importance of the SARAH trial findings in terms of their definitive nature and long-term
follow-up.
We also await the imminent publication of another UK-based RCT evaluating exercise for the upper limb in
early RA patients [the Education, Self-management and Upper limb Exercise training in People with
Rheumatoid arthritis (EXTRA) study, n= 108].132 This study found short-term improvements in function and
self-efficacy and reduction in impairment when compared to usual care, but these were not maintained in
the longer term (9 months). An important message from this study is that a similar exercise programme to
that used in SARAH was found to be effective and safe in RA patients with average disease duration of
20 months.
Further research
With the findings of the extended follow-up indicating that participants found it hard to maintain the
exercise programme beyond 1 year, it would be beneficial to explore the effects of different motivational
techniques, such as top-up contacts, on adherence to the programme. Investigation of effectiveness of the
SARAH exercise programme in a population with shorter disease duration also appears to be warranted.
The individualised exercise intervention has been shown to be likely to be cost-effective over a 12-month
period, but some participants of the interview study felt that it could be implemented in a group setting.
This could potentially make it even more cost-effective and time-efficient. Interviewees suggested that
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benefits such as peer support and improved commitment could be gained from undertaking the exercise
programme along with others with a similar condition. Delivering the exercise programme in a group
setting would provide different challenges in design and would obviously need further evaluation before it
could be recommended. Further study of implementation could include evaluation of how therapists are
able to prioritise the SARAH exercise programme within time and resource constraints of current clinical
practice and existing modes of hand exercise prescription.
Current NICE guidance recommends an annual review for all patients with RA.13 Evaluation of whether or
not this should include a therapist review to reinforce the importance of hand exercise and JP is warranted.
Core elements of the exercise programme (e.g. the behavioural activation approach) could be tested in
other areas of the body for RA or for other musculoskeletal conditions.
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information carefully and discuss it with friends, relatives and your GP if 
you wish. Ask us if there is anything that is not clear or if you would like 
more information.  
Thank you for reading this.
1. What is the purpose of the study?
The SARAH trial is looking at two approaches to treatment for 
Rheumatoid Arthritis (RA), affecting the hands. We are comparing the 
provision of joint protection advice with joint protection advice in addition 
to an exercise programme for the hands and arms. All people who enter 
the trial will receive joint protection advice, with half of all people in the 
study also undertaking the additional exercise programme.
2. Why have I been invited?
You have been chosen because you are an adult with RA affecting your 
hands. We wish to recruit 480 people with RA affecting their hands, 
across the country. 
3. Do I have to take part?
It is up to you to decide whether or not to take part. If you decide not to 
take part, the care you receive from the hospital or GP will not be 
affected. You are free to withdraw from the study at any time.
4. What will happen if I do take part?
People will be allocated to one of two treatment programmes and then 
the effects of these treatments will be compared. The reason we need 
to do this is that sometimes we do not know the best way to treat 
patients for certain conditions and we need to compare the different 
treatments that are available. A computer is used to decide randomly 
which treatment programme you would receive, similar to tossing a 
coin. In this trial you have an equal chance of receiving either of the two 
treatments. This is called a randomised controlled trial.
You will be offered one of the following options:
· Advice session(s), covering methods to protect your joints during 
every day function. You will attend for a maximum of one and a 
half hours with a specially trained physiotherapist or occupational 
therapist, who will advise and discuss how best to protect your 
hand joints from day to day.
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· Advice session(s) on joint protection, identical to the above, 
followed by a further five sessions of supervised exercise. These 
sessions will be spread over 12 weeks and will encourage you to 
strengthen and stretch your hands and arms. A specially trained 
physiotherapist or occupational therapist will provide treatments, 
and advise on how best to manage your condition. The exercise 
sessions will last 30-45 minutes and be on a one to one basis 
with the therapist.
5. Expenses and Payments
So that you will not be out of pocket by participating in this research, we 
will pay for your transport costs (taxi / public transport) to attend for the 
research assessments. Transport costs will be reimbursed on the 
submission of your travel receipts.
6. What do I have to do?
As well as attending your allocated treatment, you will be asked to 
attend three assessments and asked to fill in some questionnaires 
about your condition and how it has affected you. We will arrange for 
you to attend an assessment of your hand and arm function before you 
receive either treatment and again at four and twelve months after you 
have joined the study. These assessments will enable us to measure 
your hand and arm strength, flexibility and dexterity. If you do not 
participate, this will not affect the standard of care you receive from the 
hospital or GP.
7. What is the procedure that is being tested?
We are testing the effectiveness of gently stretching the hand joints and 
strengthening the hand muscles on the painful and disabling effects of 
RA. Whilst all participants will be advised on how to protect their joints 
in every day life, we are investigating whether it is possible to make the 
hand stronger and more mobile.
8. What are the alternative treatments?
The alternative to exercise is often to rest the hands, although we do 
not know if this is the correct advice. Traditionally, the treatment of RA 
of the hands has either involved encouraging exercise or not 
DOI: 10.3310/hta19190 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 19
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
139
encouraging it. Whilst there is some evidence that exercise might be 
beneficial, not all people with RA of the hands are encouraged to 
exercise. 
9. What are the possible disadvantages of taking part?
Occasionally people experience a short-term increase in pain after 
beginning an exercise programme. This is a normal response to 
treatment and is not usually long lasting.
10. What are the possible side-effects of the treatment, when taking part?
There are very few risks associated with exercising with RA. Exercise 
has not been shown to be detrimental to RA and is likely to be of 
benefit. We are not testing drugs or surgery and will not change your 
current medication.
11. What are the possible benefits of taking part?
We hope that the treatments will help you. However, this cannot be 
guaranteed. The information we get from this study may help us to treat 
future patients with RA of the hands. 
12. What happens when the research project stops?
After you have completed your allocated treatment as part of the trial, 
your hospital will continue to treat you, if necessary, or, when 
appropriate, will refer you on to other health professionals.
10. What if there is a problem?
It is unlikely that you will be caused problems by taking part in this 
study. If you are concerned about the treatment you should contact your 
hospital straight away.  If you are harmed by taking part in this study, 
there are no special compensation arrangements.  If you are harmed 
due to someone’s negligence, then you may have grounds for a legal 
action, but you may have to pay for it.  Regardless of this, if you wish to 
complain, or have any concerns about any aspect of the way you have 
been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms are available to you.
11. Will my taking part in this project be kept confidential?
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All information that is collected about you during the course of the 
research will be kept strictly confidential. This information will be kept in 
a secure place and only people involved in the study will have access to 
it. Any information which leaves the hospital will have your name and 
address removed so you cannot be recognised from it.
12. What if relevant new information becomes available?
Sometimes, during the course of a research study, new information 
becomes available about the treatment that is being studied. If this 
happens, the hospital or researchers will tell you about it and discuss 
with you whether you want to continue in the study. If you decide to 
withdraw from the research they will make arrangements for your care 
to continue. If you decide to continue in the study you will be asked to 
sign an updated consent form. Also, on receiving new information the 
hospital or researchers might consider it to be in your best interests to 
withdraw you from the study.  He/she will explain the reasons and 
arrange for your care to continue.
13. What will happen if I don’t want to carry on with the study?
You can withdraw your participation in the study at any point. If you 
withdraw it will have no bearing on any further treatment you would 
receive at your hospital or with your GP.
14. Will my GP be informed of my decision to participate in the study? 
If you consent, your GP will, with your permission, be notified of your 
participation in the study. We will write to your GP, to inform them that 
you have agreed to participate in the trial. We have asked them to 
contact us if they have concerns about your participation in the study.
15. What will happen to the results of the research study?
The data collected will be analysed and the results will be used to write 
a research report and journal articles for doctors and other health 
professionals. In any report or publication we will not use your real 
name, and will not give any details that could identify you. We will post a 
regular report of the trial progress on our web-site:
www.warwick.ac.uk/go/sarahtrial
16. Who is organising and funding the research?
The person responsible for the research is Professor Sallie Lamb from 
the University of Warwick. It is being paid for by the National Health 
Service’s Health Technology Assessment Programme. The study has 
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received a favourable ethical opinion by Oxfordshire Multi-Centre 
Research Ethics Committee.
17. Who is being paid for this research?
The researchers involved in this study will not be paid for including you 
in the study. No participants will receive a payment for inclusion either.
18. Who has reviewed this Study?
This study was reviewed by independent experts involved in the 
awarding of the funding for the study. Independent scientists and 
doctors working on behalf of the NHS Health Technology Assessment 
Agency reviewed this study and agreed that it was an important clinical 
question to investigate.
19. What if I have any concerns?
If you have any concerns or other questions about this study or the way 
it is being carried out, you should contact:
Mr Mark Williams
SARAH Trial Lead 
Tel:
Fax: 
E-Mail: 
Or you may contact the hospital complaints department.
Thank you for taking the time to read this leaflet.
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Appendix 2 Consent form
Centre number: ________ 
Trial Number:  ________ 
CONSENT FORM 
 
Please initial box 
 
1. I confirm that I have read and understand the information leaflet 
dated  version  for the above study. I have had the  
opportunity to consider the information, ask questions and have  
had these answered satisfactorily. 
 
2. I understand that my participation is voluntary and that I am   
free to withdraw at any time, without giving any reason, 
without my medical care or legal rights being affected. 
 
 
3. I understand that relevant sections of the data collected during the  
study may be looked at by individuals involved in the study, or from  
regulatory authorities or from the NHS trust, where it is relevant to my  
taking part in this research. I give permission for these individuals  
where it is relevant to have access to my records.  
 
 
4. I agree to my GP being informed of my participation in the study.  
 
 
 
5. I am aware that the results of the study may be presented in
research reports, scientific conferences and/or journals. However,  
the information I provide for the study will remain confidential.   
 
 
6. I am aware that the research team will contact me again at 4 and 12  
months.  
 
 
7. I agree to take part in the above study  
 
 
 
 
_______________________                   _________    _____________________ 
Name of Participant (BLOCK CAPITALS)      Date                              Signature 
 
 
 
 
_____________________________                     ____________               __________________________ 
Name of person taking consent                    Date                              Signature 
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Appendix 4 Impairment measures scoring
Metacarpophalangeal joint deformity score (degrees, four finger measurements for each hand).Summarised as a single score for both hands representing the average of left and right. This will be
calculated if all finger scores are available as the average of the individual finger scores. For each patient
the number of missing finger scores will also be counted.
Active wrist flexion (degrees, two measurements) and active wrist extension (degrees, two measurements).
Summarised as a single score for both hands representing the average of left and right. This will be
calculated if both scores are present as the sum of flexion and extension.
Combined finger flexion (mm, four measurements for each hand). Summarised as a single score for both
hands representing the average of left and right. This will be calculated if all finger flexion scores are
present as the average of the individual finger scores. For each patient the number of missing finger scores
will also be counted.
Composite finger extension method A or method B (mm, two measurements for each hand). Summarised
as a single score for both hands representing the average of left and right. This will be calculated if all the
finger extension scores are available as the average of the individual finger scores, method A being
counted as positive, method B as negative. For each patient the number of missing finger scores
is counted.
Kapandji thumb opposition score (a count for each hand).
Swollen joint count (overall count for both hands combined).
Tender joint count (overall count for both hands combined).
Dexterity: observation of timed nine-hole peg test (seconds, one measurement for each hand).
Full-hand grip (newtons, three measurements for each hand). The maximum will be used for each hand.
Tripod pinch strength (newtons, three measurements for each hand). The maximum will be used for
each hand.
DOI: 10.3310/hta19190 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 19
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Williams et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
211

Appendix 5 Example of exercise diary
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Appendix 6 Personal exercise guide sheet
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Appendix 7 Qualitative study consent form
Participant ID number: ___________
CONSENT FORM
Strengthening and Stretching for Rheumatoid Arthritis of the Hands 
(SARAH) 
Interview Study
1. I confirm that I have read and understand the information leaflet dated 11/2/2010 for 
the above study. I have had the opportunity to consider the information, ask 
questions and have had these answered satisfactorily. 
2. I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being 
affected.
3. I agree to the interviews being recorded so that they can be read by individuals 
involved in the study.
4. I give permission for information collected during the interviews to be used in 
publications related to the trial including quotations from the interviews.  I understand 
that all efforts will be made to remove any information that would identify me. 
5. I agree to take part in the interviews as part of the SARAH Trial. 
Please give one copy to the participant, one copy for the SARAH trial site file and one for the medical notes
Please initial each box
____________________________ _________  __________________________
Name of participant Date Signature
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Appendix 8 Qualitative study interview schedules
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